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“There is a theory which states that if ever anyone discovers exactly what the 
Universe is for and why it is here, it will instantly disappear and be replaced by 
something even more bizarre and inexplicable. 
 
There is another theory which states that this has already happened.” 
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ABSTRACT 
 The haloalkanoate dehalogenase (HAD) and monotopic 
phosphoglycosyl transferase (monoPGT) superfamilies were used to study 
structure/function relationships and protein evolution. Phosphomannomutases 
(PMM), members of the HAD superfamily, catalyze the transformation of mannose 
6-phosphate to mannose 1-phosphate, an essential reaction in eukaryotic N-linked 
glycosylation. In mammals, there are two isozymes of PMM which share high 
sequence identity (67% for human isozymes). PMM2 is ubiquitously expressed, 
and mutations to this gene cause congenital diseases of glycosylation (CDGs), 
resulting in depleted levels of glycoconjugate products (hypoglycosylation). In 
contrast, PMM1 is expressed in the brain, lungs, and kidneys, and no measurable 
phenotype is detected in mouse knockout models. In vitro characterization of 
PMM isozymes provide a proposed link of isozyme specificity to disease-related 
phenotypes. Clinically, galactosemia patients exhibit buildup of galactose 1-
phosphate (Gal1P) and phenotypes similar to those seen in CDGs including 
 
 xi 
hypoglycosylation. In this work we showed that in vitro, Gal1P inhibits PMM2 at 
physiological concentrations. However, Gal1P does not inhibit PPM1, even at 
saturating concentrations.  
The X-ray crystal structure of PMM1 in complex with vanadate reveals 
distinct preference for binding to the distal phosphoryl sub-site. Combined with in 
vitro inhibition analysis of PMM1 by vanadate, the structures support a “catch and 
close” mechanism of substrate binding, rather than an induced fit model.  
A superfamily approach yielded insight into protein evolution and substrate 
specificity in the monoPGT superfamily. MonoPGTs catalyze coupling of a soluble 
nucleotide-activated sugar to a membrane-resident polyprenol phosphate (PrenP), 
the first membrane-committed step in glycoconjugate biosynthetic pathways. The 
diversity of the family is revealed by the generation and analysis of a sequence-
similarity network (SSN), with fusion of monoPGTs with other pathway members 
being the most frequent and extensive elaboration. The fusion domains fall into 
three subclasses: sugar-modifying enzymes, glycosyl transferases, and regulatory 
domains. The occurrence of protein fusions in the glycoconjugate biosynthetic 
pathways provides support for protein-protein interactions that could increase 
pathway throughput. Analyses of the re-entrant membrane helix (RMH) motif of 
monoPGTs via generation of hidden Markov models (HMM) describes sequence 
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1.1 Phosphoryl and phosphoglycosyl transfer reactions 
Phosphoryl chemistry is essential to numerous cellular events, including 
cell signaling, regulation, energy, and metabolism. The main classifications of 
enzymes catalyzing phosphoryl transfer chemistry include: kinases (catalyze 
phosphorylation), phosphatases (catalyze dephosphorylation), and 
phosphomutases (catalyzing phosphoryl-transfer within a molecule). A fourth and 
less common example is phosphoglycosyl-transfer, which are reactions specific to 
glycoconjugate biosynthesis. Most enzymes catalyzing reactions at phosphorus 
have evolved to use a divalent metal (usually magnesium or manganese ion) to aid 
in coordination and shielding of negative charges of the phosphoryl group and 
nucleophile.(1)  
Kinases catalyze the phosphorylation of their substrate, either a small 
molecule or a protein (Figure 1.1). Often in the case of phosphoregulation, kinases 
have autophosphorylation activity in the presence of ATP, and relay that 
phosphoryl group to their protein substrate.(2) Kinases will not be addressed in 
detail in this dissertation, but regulatory mechanisms of protein kinases are 
described in Chapter 4.  
Non-enzymatic hydrolysis of a phosphate ester occurs at a rate of 2 x 10-20 
s-1.(3) However, most phosphatases exhibit catalytic rates on the order of 1 s-1 to 
15,000 s-1 and therefore, have evolved their catalytic machinery to overcome the 
steep energy barrier.(3) Phosphatases act on a wide range of substrates including 
phospholipids, phosphorylated proteins, phospho-glycans, nucleotides, and 
 
 3 
phosphorylated metabolites. There are 20 superfamilies of phosphatase enzymes, 
which all follow one of three catalytic mechanisms: covalent catalysis followed by 
hydrolysis, activation of water nucleophile by metal-ion cofactor, and activation of 
water nucleophile by a general base residue.(1) A general phosphatase reaction is 
shown in Figure 1.1 (yellow). 
Phosphomutase enzymes, such as phosphoglycerate mutase or 
phosphoglucomutase, catalyze the interconversion of two phosphorylated isomers. 
For example, β-phosphoglucomutase (PGM) facilitates the isomerization of 
glucose 1-phosphate (Glc1P) and glucose 6-phosphate (Glc6P). There are three 
superfamilies of phospho-sugar mutases: the haloalkanoate dehalogenase (HAD) 
superfamily (β-PGM and phosphomannomutase (PMM))(4–6), the α-D-
phosphohexomutase superfamily(7), and the histidine phosphatase 
superfamily(8) (phosphoglyceromutase). Phosphomutases often belong to a 
phosphatase superfamily and evolve the architecture and chemistries for 
phosphoryl transfer, rather than phosphate hydrolysis (Figure 1.1, green). In 
the HAD, α-D-phosphohexomutase, and histidine phosphate phosphatase 
superfamilies, phosphomutase activity has evolved from phosphatase activity, 
wherein the sugar acts as a nucleophile, attacking the phosphorous center of a 
phosphoenzyme intermediate rather than a water molecule in phosphatase 
enzymes.  
Phosphoglycosyl transferase (PGT) enzymes catalyze the transfer of a 
phosphoglycosyl moiety from a nucleotide diphosphosugar onto a lipid carrier 
4 
located in the membrane. This reaction constitutes the first membrane-committed 
step of glycoconjugate biosynthetic pathways in prokaryotes, meaning it combines 
a soluble sugar and a PrenP carrier, linking the sugar to the membrane. There are 
two non-homologous isofunctional superfamilies of enzymes that catalyze 
phosphoglycosyl-transfer. The polytopic PGTs proceed through a ternary complex 
and have direct transfer of the phosphoglycosyl moiety to the lipid carrier. (9, 10) 
In contrast, the monotopic PGTs employ a ping-pong mechanism.(11) A general 
reaction scheme is shown in Figure 1.1 (blue). Although isofunctional, the 
monotopic PGT (monoPGT) and polytopic PGT (polyPGT) superfamilies have 














































































































































































































































































































1.1.2 Comparison of the HAD and monoPGT superfamilies 
Members of the HAD superfamily are predominately phosphatases and 
phosphomutases (Chapter 3, Appendix 1, Appendix 3, Appendix 4) and monoPGT 
(Chapters 4, Chapter 5) superfamilies are highlighted throughout this dissertation. 
Although they catalyze different reactions, HAD and monoPGT enzymes both use 
a nucleophilic aspartyl residue and activate the electrophilic phosphoryl group 
through coordination by magnesium ion.(12, 13) The HAD superfamily has been 
extensively studied over the past 20 years, and work in the Allen Lab has elucidated 
mechanisms of catalysis and means of evolving substrate specificity in this diverse 
superfamily. All enzymes in this superfamily proceed through a covalent, 
phosphoaspartyl intermediate.  
In contrast to the HAD superfamily, the mechanistic and structural 
characteristics of the monoPGT superfamily have only recently been 
elucidated.(11, 12) Characterized members of the monoPGT superfamily exhibit bi-
bi ping-pong kinetics in which an NDP activated sugar binds first, allowing for 
transfer of a phosphoglycosyl moiety to the nucleophilic aspartate, followed by 
liberation of NMP and subsequent transfer of the phosphoglycosyl moiety to the 
lipid carrier (Figure 1.1 (blue)).(11) In both the HAD and monoPGT 
superfamilies, a covalent intermediate is formed, either a phosphoaspartyl residue 
(HAD) or a phosphoglycosyl-aspartatyl residue (monoPGT). The phosphoryl 
moiety is then transferred either to water (HAD phosphatase) or to the lipid carrier 
substrate (monoPGT).(11, 13) In both superfamilies, the magnesium ion cofactor 
is essential for catalysis. It shields the charges of the nucleophile and 
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phosphorylated substrate, and positions both the substrate and the nucleophile in 
the active site.(12–14)  
1.2 Glycan biosynthetic pathways and their roles in biology  
The second theme throughout this dissertation is the role of selected 
enzymes in glycoconjugate biosynthetic pathways. Chapter 3 aims to elucidate 
structural and mechanistic features of two isozymes of PMM, members of the HAD 
superfamily. PMM2 catalyzes the conversion of mannose 6-phosphate (Man6P) to 
mannose 1-phosphate (Man1P). This reaction is one of the initial steps in 
eukaryotic N-linked glycosylation in the endoplasmic reticulum (ER).(15) 
Enzymes in the monoPGT superfamily catalyze the first membrane committed step 
in prokaryotic glycoconjugate biosynthetic pathways. They are predominately 
bacterial(14), however we identified a small subset of enzymes which are archaeal 
(vide infra, Chapter 4). Eukaryotic glycosylation pathways use enzymes from the 
analogous PGT superfamily, the polytopic PGT (polyPGT) superfamily to catalyze 
the first membrane committed step.(16) Glycoconjugate pathways and glycan 
products will be discussed in the following section. 
1.2.1 Glycoconjugate classification and biosynthesis 
Glycoconjugates impart structural integrity for individual cells, are 
necessary for proper folding of many proteins and allow for cell-cell interactions 
either intra-species or inter-species (or tissue) recognition or interaction.(17) 
Generally, all domains of life synthesize glycoproteins (N- or O- linked) and 
glycolipids; however, the structure and function of these glycoconjugates vary 
substantially between domains of life and between species. Glycoconjugates 
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common to both Gram-positive and Gram-negative bacteria include glycoproteins 
(N- and O- linked), capsular polysaccharides (CPS), exopolysaccharide (EPS), 
peptidoglycan (PG), and glycosylated flagella and pili (Figure 1.1). Further, 
Gram-positive bacteria also synthesize wall teichoic acids (WTA) and lipoteichoic 
acids (LTA) and Gram-negative bacteria synthesize lipopolysaccharides (LPS) and 
lipooligosaccharides (LOS).(18) Several of these bacterial glycoconjugates, 
including N- and O- linked glycoproteins, CPS, EPS, and LPS, impart a recognition 
motif on the cell surface for either evasion or recognition by glycan binding 




















































































































































































































































































































































Archaeal glycoconjugates and their biosynthesis most closely resembles 
bacterial systems. Additionally, both archaea and bacteria use diverse 
monosaccharide sugars (>100 unique sugars), whereas eukaryotes, specifically 
mammals, typically use up to ten different monosaccharides in glycoconjugates 
biosynthesis.(18, 20) In addition to glycoproteins linked to long oligosaccharide 
chains, eukaryotic systems also commonly glycosylate proteins with a single O-
GlcNAc modification, used for regulation of function and protein localization.(21) 
The common prokaryotic and eukaryotic glycoconjugates are depicted in Figure 
1.1.  
Glycosylation can occur via one of two different mechanisms, sequential or 
en bloc transfer. Sequential glycosylation occurs in the cytoplasm, where there is 
direct glycosylation of the growing substrate onto the target (ie lipid or protein) by 
glycosyl transferases (GTs) typically producing simple glycoconjugate products. In 
contrast, en bloc mechanisms build a glycan onto a polyprenol phosphate (PrenP) 
carrier systematically. Building of the glycan is initiated on the cytoplasmic face of 
the membrane by a PGT which transfers a phosphoglycosyl moiety from a 
nucleotide donor to the PrenP, followed by GTs, adding additional glycosyl 
moieties. The synthesized oligosaccharide is translocated to the periplasmic space 
by a flippase and then delivered to target molecule by oligosaccharyl transferases 
(OTases).(18) Genes that encode en bloc biosynthetic enzymes are localized to the 
same operon. Metabolic channeling of the intermediates is predicted, and 
substantiated by lack of intermediate formation in the bacterial N-linked 
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glycosylation (Pgl) pathway.(22) Eukaryotic N-linked glycosylation pathway 
proceeds in an en bloc manner, like bacterial glycosylation. However, in eukaryotic 
organisms, glycan synthesis occurs in the ER membrane, rather than the cell 
membrane. Additionally, all eukaryotic N-linked glycans bear a GlcNAc moiety on 
the reducing end, whereas in bacterial species there is substantial variation in the 
reducing-end sugar moiety in glycoprotein production.(23) 
1.2.2 Physiological roles of glycosylation in eukaryotic and bacterial systems 
In mammals, glycosylation is essential for immune modulation(24), cancer 
pathologies(25), and pathogenesis of bacteria. Furthermore, enveloped viruses 
such as human immunodeficiency virus (HIV) and hepatitis B virus (HBV) can be 
glycosylated via host machinery, allowing for evasion from the immune 
 
Figure 1.3. Bacterial N-linked glycosylation pathway. 
This depiction illustrates the en bloc building of the glycan in the cytosol followed by 
translocation to the periplasm and delivery to target by PglK and PglB, respectively. In 
this scheme the yellow pentagon refers to nucleotide diphosphate, the navy and gray 
hexagons, denote generic hexose sugars, the orange sphere denotes a phosphoryl 




system.(24) Advances in the fields of microbiology, including the human 
microbiome project, have begun to reveal the intricacies of bacterial-mammalian 
cell interactions and their influences on host health.(26)  
Mucus contains specialized glycoproteins called mucins, which line the 
mucosal surfaces in mammalian species, serving as a lubricant to protect against 
physical, as well as biological factors such as infection. Mucins can also assist in 
mediating interactions between cells via recognition of glycan-binding proteins, 
allowing for interactions between commensal bacterial species, or pathogenic 
species.(19) In mammalian species, α1–2 fucosyltransferase (Fut2) adds a terminal 
fucose moiety onto mucins, and thus decorates the end, which interacts with 
bacterial cells. Kashyap et al. created a Fuc2- mouse model which exhibited a 
unique glycan profile on mucins, as they lack the terminal fucose. Notably, this 
change altered the overall microbiome of the mouse models in a diet-dependent 
manner, and caused changes in metabolic pathway expression.(27)  
Furthermore, as mucins provide epitopes for bacterial biding, bacterial 
glycoconjugates also provide epitopes for binding to eukaryotic host cell receptors. 
However, in this case, the bacterial glycoconjugates play roles critical for virulence, 
including host-cell adhesion and evasion of the immune system.(18) First 
confirmed in Campylobacter jejuni, N-linked glycoproteins bind to human 
macrophage galactose-type lectin and adhere to dendritic cells. This allows for 
immune modulation by C. jejuni.(28) N-glycosylation can also protect 
glycoproteins from proteolysis via host proteases.(29)  
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O-glycosylation products include pillin and flagellar glycoconjugates in 
bacterial organisms. In Acinetobacter baumannii, O-glycosylation is required for 
biofilm formation and pathogenicity.(30) Recently, the role of pilin or flagellar O-
glycosylation in host-microbe interaction for both pathogenic and commensal 
bacterial species has been investigated. In the case of Lactobacillus rhamnosus 
GG, a beneficial gut bacteria, the mannosylation and fucosylation of pili allow for 
their recognition by human dendritic cells via a lectin receptor which leads to 
adhesion and  immune modulation.(31) Pathogenic bacteria such as Neisseria 
gonorrhoeae also use pilin glycosylation for host adhesion. In this case, N. 
gonorrhoeae pilin glycosylation is essential for adhesion to cervical tissue which 
underlies its pathogenesis. Flagellar glycosylation has been connected with 
virulence of various bacterial species, including C. jejuni.(32)  
In addition to using glycosylation for cell adhesion and immune 
modulation, there is evidence that toxin secretion by certain pathogens relies on 
the action of glycosyl transferases. In Clostridioides difficile, a TcdB/TcdA toxin 
system is used to promote pathogenesis. In this system, TcdA, a glycosyl 
transferase, is shuttled into the host cell via TcdB internalization by cell surface 
receptors. Once in the cytosol, TcdA, can glycosylate the  host cell’s Rho-dependent 
GTPases, resulting in disruption and inhibition of  cell signaling. Other similar 
systems are observed in Legionella pneumophila, the causative agent of 
Legionnaires’ disease, and Escherichia coli, the predominant cause of infant 
diarrhea.(30) In these cases, bacterial secretion systems are used to secrete effector 
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proteins into the host’s cell, which include glycosyl transferase that can modify 
elongation factor eEIF1A inhibiting translation (L. pneumophilia)(33) or 
glyceraldehyde 3-phosphate dehydrogenase, preventing interaction with TNF-
receptor-associated factor 2, which is required for TNF-α-mediated NF-κB 
activation (E. coli).(34)  
Together, these examples of the roles of glycoconjugates in host-pathogen 
responses exhibit potential targets for therapeutic development.  In many of these 
cases, glycoconjugates interact directly with either microbial or host cells, which 
allows for immune modulation or alteration of host-cell biochemistry.  
1.2.3 Mammalian glycan biosynthesis as it pertains to cancer and genetic 
diseases 
Due to the large percentage of the eukaryotic proteome which is 
glycosylated and the important roles these modifications have for protein folding 
and stability.(35) Glycoprotein overexpression is a common marker used in clinical 
testing for malignant cells.(36) There are distinct glycan epitopes present on the 
cell surface that can differentiate malignant cells from healthy cells. One 
mechanism of O-glycan truncation is a result of increased pH in the Golgi of 
cancerous cells.(25) A secondary means for malignant cells to produce truncated 
O-glycoconjugates is a result of mutations to and altered expression levels of the 
glycosylation machinery.(37) The resulting truncated O-glycans allow for immune 
modulation and increased cell invasion as shown recently in glioblastoma and 
gastric cancers, respectively.(38, 39) In N-linked glycosylation,  rather than 
synthesis of truncated glycoconjugates, glycosylation pattern and branching in 
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cancerous cells is variable as a result of the overexpression of different glycosyl 
transferases.(40, 41)  
In eukaryotic N-linked glycosylation pathways, mutations to glycan 
biosynthetic genes cause also a group of genetic diseases referred to as congenital 
disorders of glycosylation (CDG) presenting as hypoglycosylation.(15) CDGs are 
broken into four groups based on the pathway(s) affected: CDG-I (N-linked 
glycosylation), CDG-II (O-linked glycosylation), CDG-III (N- and O-linked 
glycosylation), and CDG-IV (glycosylphosphatidylinositol (GPI) biosynthesis). The 
most common CDG is PMM2-CDG, (also referred to as CDG-Ia), an autosomal 
recessive disease.(42) PMM2 catalyzes the conversion of Man6P to Man1P, an 
initial step in N-linked glycosylation. Mutation of PMM2 results in 
hypoglycosylation. Phenotypically, CDG-PMM2 presents early in development 
with developmental delays and neurological disease, and dysmorphic features. 
After infancy, the disease can progress leading to endocrine abnormalities, 
cerebellar ataxia, and hypogonadism. Treatment for PMM2-CDG consists 
primarily of symptom management.(42)  
1.2.4 Bacterial glycan biosynthesis: ideal target for antibacterial therapeutic 
development 
As infections by antibiotic resistant bacteria increases, there is a growing 
need to identify novel targets for therapeutic intervention. The prevalence of 
glycoconjugates in virulance functions suggests that targeting these pathways 
could decrease the pathogenicity of bacteria without affecting cell viability. 
Because the bacterial N-linked glycosylation pathway is best characterized  in C. 
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jejuni, target validation studies have focused on the necessity of enzymes in this 
pathway for virulence and viability of the bacteria. There have been numerous 
studies connecting inhibition of or knocking out Pgl pathway and decreased 
pathogenicity.  A study identified mutations in sugar modifying enzymes PglF, 
PglE, and PglD which catalyze the transform UDP-GlcNAc into UDP-linked N'N-
diacetyl bacillosamine (diNacBac), used for the first addition to the PrenP carrier, 
exhibit a 100 to 1000-fold decrease in colonization of chicks.(43)  Generating 
mutations in one of the downstream glycosyl transferase genes, pglH, causes an 
inability to produce glycoproteins in C. jejuni. Further, the pglH mutant strain 
exhibits a substantially reduced ability to invade human epithelial cells, and is 
unable to colonize chicks. Therefore, the lack of glycoprotein production directly 
affects the ability of C. jejuni to invade and colonize its host, yet the organism is 
still viable.(44) Suppressor mutations in GT and oligosaccharyl transferase genes 
actually affect cell viability rather than virulence, most likely due to the inability to 
release the lipid carrier for use in other essential glycan pathways. There is also 
evidence that suppressor mutations of the PGT gene in Staphylococcus 
pneumoniae CPS biosynthesis, CpsE, causes severe reduction in CPS on the outer 
membrane. (45, 46) A primary function for these polysaccharides is to shield the 
bacterium from recognition by the eukaryotic host machinery, allowing it to evade 
the immune system. Therefore, therapeutic development targeting bacterial 
oligosaccharyl biosynthetic pathways is advantageous as these mutations confer 
decreased virulence, and, in some cases, decreased viability.  
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A class of antibiotic inhibitors that target glycosylation pathways are the 
natural product nucleoside inhibitors, tunicamycins. However, tunicamycin also 
inhibits human N-acetylglucosamine-phosphotransferase (DPAGT1), the PGT 
functioning in N-linked glycosylation.(9) Due to this cross reactivity and 
eukaryotic cell toxicity, tunicamycin cannot be used as an antibiotic. The X-ray 
crystal structures of MraY and DPAGT1 in complex with tunicamycins allowing for 
rational design of tunicamycin derivatives to improve the selectivity and potency 
towards bacterial polyPGTs.(9, 47) Notably, tunicamycin does not inhibit 
monoPGT enzymes.(48) The lack of inhibition is most likely a result of the 
divergence of chemical mechanisms between polyPGTs and monoPGT enzymes, 
that is, ternary complex versus ping-pong mechanism. The structure of 
tunicamycin includes moieties mimicking polyprenol-phosphate, nucleotide 
phosphate, and sugar (Figure 1.4). Because  the NDP-sugar and PrenP substrates 
do not reside in the active site at the same time, it is likely that tunicamycin cannot 
bind to monoPGTs.  
 
Figure 1.4. Tunicamycin structure. The chemical structure of tunicamycin has 
three general substrate-based motifs: PrenP analog (gray), sugar analog (blue), and 




The PGT reaction serves as an ideal target for therapeutic development. 
Studies summarized above predict the PGT step as a key step for regulating 
pathway throughput and conserving the lipid carrier. MonoPGTs in particular are 
ideal therapeutic targets because there are no eukaryotic members of the 
superfamily (Chapter 4 and 5), and therefore, there is no concern for off-target 
effects on host glycosylation.  
1.3 Overview of dissertation 
This dissertation work encompasses mechanistic and structural analyses of 
two superfamilies of enzymes, the HAD and monoPGT superfamilies. Chapter 2 
describes structural experiments to provide mechanistic insight into phosphoryl 
transfer and substrate specificity within the HAD superfamily. This work was 
published as a chapter in Methods in Enzymology volume 607, Phosphatases. 
Chapter 3 includes the mechanistic and structural studies of human PMM 
isozymes, specifically working to elucidate physiological differences and 
interconnection of glycosylation and metabolic pathways. Further, we propose that 
in galactosemia patients, patients harboring mutations in the galactose 1-
phosphate uridylyltransferase (GALT) gene, elevated levels of galactose 1-
phosphate inhibit PMM2 leading to the phenotypic observance of CDG like 
symptoms (i.e. hypoglycosylation, developmental delay). Chapters 4 and 5 aim to 
characterize the monoPGT superfamily of enzymes using bioinformatic 
techniques. Through generation of a sequence similarity network, I identified three 
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distinct bifunctional monoPGT subclasses resulting from gene fusion with either 
sugar-modifying, glycosyl transferase, or regulatory domains (Chapter 4). Chapter 
5 analyzes the re-entrant membrane helix (RMH) as a possible motif for 
recruitment of the lipophilic substrate, undecaprenol phosphate. Additionally, 
Chapter 5 analyzes the evolution and conservation of the large monoPGT family of 
enzymes and pseudoenzymes. Together, this dissertation seeks to find the 
mechanistic and evolutionary underpinnings of enzymes of phosphoryl and 
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Phosphotransferases catalyze reactions on chemically diverse molecules in 
organisms from all domains of life. The haloalkanoate dehalogenase superfamily 
(HADSF) is a model system for phosphoryl transfer enzymes as members catalyze 
phosphoester hydrolase, phosphonate hydrolase, and phosphomutase reactions 
from sugars, lipids, nucleotides and peptides. Because these reactions are 
fundamental to essential metabolic transformations, understanding the 
mechanism and determinants of substrate specificity in the HADSF is critical.  
Structure/function relationships in the superfamily have also been 
leveraged in the development of methodologies for the assignment of enzyme 
function. Enzyme complexes with substrate, product, and analogs of the ground 
state or intermediate/transition state can be studied via high-resolution 
macromolecular crystallography to provide insight to the relative location of 
residues and ligands, as well as associated enzyme conformational states. This 
knowledge can provide insight for inhibitor design of phosphohydrolase reactions 
and target-specific therapeutics. Here we describe experimental approaches to 
capture liganded X-ray crystallographic structures of HADSF members. A number 
of these methods can be employed generally, including other families of 





Phosphohydrolases are vital to the cellular processes of signal transduction, 
regulation, and primary and secondary metabolism. Hence, the enzymes that 
catalyze phosphohydrolase reactions are ubiquitous and catalyze phosphoryl 
transfer from chemically varied molecules including proteins, nucleotides, 
carbohydrates and lipids.(1) The necessity for Nature to have evolved such 
catalysts is underscored by the extraordinarily slow rate of uncatalyzed phosphate 
monoester hydrolysis at 2 x 10-20 s-1.(3) Therefore, understanding the catalytic and 
chemical mechanisms of phosphoryl transfer is of significant interest. To lend 
mechanistic insight, a primary approach is the use of X-ray crystallography to 
visualize the Michaelis complex or its analogs (including product complexes) to 
provide the active-site residue positions relative to bound substrate. Insights from 
such “ground-state” complexes are often extended by obtaining 
intermediate/transition-state analog complexes to visualize interactions integral 
to catalysis. Using these approaches together with evaluation of steady-state 
kinetic constants and site-directed mutagenesis provides significant insight into 
the contribution of enzyme residues to chemical steps, to substrate binding, and to 
stabilization of the transition state. Additionally, identifying substrate specificity 
determinants can aid inhibitor design for therapeutics. Herein, we discuss the 
design and technical aspects of experiments to determine the liganded structures 
of phosphatases with substrate, substrate mimics, intermediate and transition-
state analogs, products, and inhibitors.  
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Throughout this chapter, the haloalkanoate dehalogenase superfamily 
(HADSF) will be used as a model system for phosphohydrolases. The HADSF is the 
largest family of phosphatases consisting of ~120,000 members from all domains 
of life and is comprised mostly of enzymes that perform reactions at phosphorus 
(99% of annotated members).(13, 49) The many liganded structures deposited in 
the Protein Data Bank (PDB) (>114 unique liganded structures at the time of this 
writing) make it an ideal superfamily for describing a variety of methods for 
obtaining enzyme-ligand complexes via crystallography. HADSF members are 
comprised of a Rossmann-fold containing core domain and an accessory cap 
domain, which closes onto the core, completing the solvent excluded active site at 
the interface between cap and core (Figure 2.1A).(49) The major cap types (C0, 
C1, C2a/C2b) are named by the location of the cap insertion into the Rossmann 
core domain and by the size and secondary structure topology of the domain. 
Irrespective of cap type, the active site is found at the interface of the core and cap 
domain. The cap domain and its dynamics with respect to the core typically 




Figure 2.1. Structural characteristics of HAD superfamily members. A. 
Ribbon diagram of the structure of trehalose phosphate phosphatase in the unliganded, 
open conformation (light gray, PDB ID: 6UPB) and in the substrate-bound, closed 
conformation (dark gray). Magnesium ion is shown as a pink sphere and substrate 
shown as ball and stick. The active site loops 1-4 are colored as in panel b. The common 
active site of HADSF members. Note that the substrate specificity loop 5 is a 
simplification to denote one or more secondary structural elements that provide 
residues to bind the substrate leaving group.  
The mechanism of catalysis in the HADSF involves a divalent magnesium 
ion cofactor, nucleophilic aspartate (Dn), and a general acid/base aspartate located 
two residues toward the C-terminus in the primary structure (Dn+2) (Figure 
2.1B). The reaction scheme, shown in Figure 2, proceeds through a trigonal 
bipyramidal phospho-enzyme intermediate/transition state.(52–54) The 
substrate undergoes a nucleophilic attack by aspartate, Dn, cleavage of the bond to 
the substrate leaving group, and subsequent formation of the phosphoaspartyl 
intermediate. The second half reaction comprises hydrolysis of the 
phosphoenzyme and regeneration of the nucleophilic aspartate, releasing 
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inorganic phosphate as a second product.(55) Each step along the reaction 
coordinate (or its mimic) can be analyzed structurally via well-designed 
crystallographic studies. In this chapter, we describe methods to determine the 
structure of enzyme complexes revealing the ground-state and transition-state 
geometries using substrates, substrate analogs, products, phosphoryl mimics, and 
inhibitors. 
 
Figure 2.2. General mechanism of HADSF members. Asp+2 designates the 
general acid/base residue (Dn+2) 
Ligands can be introduced to proteins prior to crystal formation, via 
endogenous ligands carried through purification or exogenously introduced by co-
crystallization. Alternatively, ligand addition after protein crystals have formed is 
accomplished via soaking. It is important to consider the benefits and drawbacks 
of each method for every protein system as the approaches vary depending on the 
HADSF member. Co-crystallization is advantageous when the protein requires a 
significant conformational change for productive ligand binding, which is common 
among HADSF members. Ligand binding with induced fit often leads to protein 
stabilization, which has the added benefit of promoting crystallization; however, 
co-crystallization often requires extensive optimization for each ligand. As soaking 
requires a pre-formed crystal, the crystal contacts must allow the protein to adopt 
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a conformer amenable to ligand binding, and the ligand size (usually < 500 
Daltons) must allow diffusion through the solvent channels to the binding site. In 
general, soaking is enabled by the high solvent content in protein crystals (at 
present 86% of protein X-ray crystallographic structures in the PDB are 35-65% 
solvent). Thus, if the crystal lattice can adopt a productive conformer, and if 
ligands are small and soluble, then protein-ligand complexes can be determined 
via soaking without laborious optimization of the crystallization condition. The 
soaking method can lead to rapidly obtaining structures of numerous enzyme-
ligand complexes.   
In both soaking and co-crystallization methods, the concentration of the 
ligand must be optimized to have > 90% of the protein molecules bound as 
crystallographic electron density is obtained from averaging all molecules exposed 
to the X-ray source. We suggest a protein:ligand ratio of 1:1.2 to supply excess 
ligand while preventing non-specific ligand binding. Non-specific binding can 
cause heterogeneity, disrupt crystal contacts and prevent crystallization, or 
degrade crystal quality and lead to a decrease in resolution. Additionally, 
considerations for the binding affinity should be made to ensure homogeneity; the 
ligand concentration should ideally be 5-10 times greater than the dissociation 
constant (KD). Practically, the Michaelis constant (KM), inhibition constant (KI), 
and the half-maximal inhibitory concentration (IC50) can be used as estimates for 
KD. Both soaking and co-crystallization approaches have proven successful for 
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members of the HADSF. Considerations for experimental design, reagents, and 
methods are described in this Chapter.  
2.2 Substrate and Product Complexes 
2.2.1 Substrate Soaking 
Optimally, a crystal structure of the enzyme-substrate complex in the 
catalytically competent conformation with the residues aligned for catalysis (ie. the 
Michaelis complex) is desired. Unfortunately, using standard single-crystal 
macromolecular X-ray crystallographic approaches, data collection is not rapid 
enough to capture this complex prior to catalysis. Therefore, catalysis occurs and 
the product(s) either diffuse out of the active site, leading to an unliganded 
structure, or remain bound resulting in determination of the enzyme-product 
complex. However, based on the equilibrium between substrate and product(s), 
the enzyme conformation, and the rate of turnover in crystallo, catalysis may not 
occur or occur on a time scale slow enough to trap a Michaelis-like complex. Hence, 
we suggest attempting to soak crystals with the substrate. The resulting data must 
be closely analyzed to determine which species is bound: the substrate, the 
product(s), buffers, salts, or precipitants from the crystallization milieu, solvent, 
or any combination thereof. The population of any one bound species must be 
greater than 10-20% of the ensemble (depending on the resolution and ligand 
motion), otherwise the corresponding electron density may be weak or 
unobservable.(56) Notably, the occupancies and B-factors of solvent/ligands are 
correlated at the resolutions commonly observed for protein complexes (< 2.5 
Å).(57) If multiple species are bound, all ligands should be modeled and B-factors 
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and occupancies refined for appropriate interpretation of the data (for an example 
of refinement of multiple species see Stiers and Beamer(58)).  
Alternative to the soaking with substrate alone, shifting the equilibrium 
towards substrate by the addition of products can prevent catalysis. This approach 
was applied in determining the complex of D-glycero-D-manno-heptose-1,7-
bisphosphate phosphatase (GmhB) from Escherichia coli (Ec) with D-glycero-D-
manno-heptose 1,7-bisphosphate (PDB ID: 3L8G). The crystals were soaked with 
a 1:1 ratio of substrate to product, shifting the equilibrium towards bound 
substrate.(59)  
An additional aspect in substrate soaking exists in that flexible enzymes may 
crystallize in a conformation that is not catalytically competent. In the HADSF, the 
cap domain must close over the core, providing a solvent exclusive environment 
and maintaining electrostatic control of the active site to promote catalysis.(60–
63) Thus, if the enzyme crystallizes in the cap open conformer, soaked substrate 
may bind to either the core or cap domain alone precluding identification of all 
binding and catalytic determinants, as is the case for Mycobacterium tuberculosis 
(Mt) trehalose-6-phosphate phosphatase (T6PP)(64)  and Homo sapiens (Hs) 
phosphomannomutase 1 (PMM1) (PDB ID: 2FUE).(5) As the MtT6PP structure 
shows interactions of the substrate with only the core domain, interaction with 
catalytic residues (Dn and Dn+2) and a subset of substrate-binding determinants 
(for the most part those involved in binding the phosphoryl group) can be 
identified. In contrast, D-mannose 1-phosphate is bound solely by residues of the 
 
 29 
cap domain of HsPMM1, and therefore, only interactions with the substrate leaving 
group are identified.  
In these two examples, the large conformational change necessary for 
turnover is precluded by crystal contacts. However, it is possible that even in a 
domain-domain closed conformation, small, but necessary, changes to reach the 
transition state are prevented by decreased mobility in the crystalline form, 
causing the catalytic rate of the enzyme to be lower than that of free enzyme. For 
example, the turnover rate (kcat) of aldolase is two times slower in crystallo than in 
solution.(65) Thus, a short soak (1 - 5 minutes) prior to flash freezing could yield a 
substrate-bound structure for an enzyme that is slow (kcat < 1 s-1) with a natural 
substrate or a poor substrate (kcat/KM < 103 M-1s-1). The success of a quick soak 
depends on three characteristics of the crystalline enzyme: the viscosity of the 
mother liquor, the crystal morphology, and the kcat of the enzyme. The viscosity of 
the mother liquor determines the diffusion rate of the ligand. For example, a 
system with a viscous mother liquor or soaking solution and a larger ligand will 
have a slower diffusion rate. The crystal morphology also determines the rate at 
which a ligand fully diffuses into a crystal. Small, thin crystals (plates, 
microcrystals, etc.) with high surface to volume ratios equilibrate with the 
substrate faster than large, thick crystals (cubic, pyramidal, etc.). This rate has 
been estimated in our laboratory empirically by measuring the time for a 
Coomassie-based or other dye (eg. Izit Dye (Hampton Research)) to color the 
crystal. Alternatively, the time for diffusion into the crystal can be calculated using 
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the binding affinity of the ligand for the enzyme and physical and chemical 
properties of the protein crystal and ligand.(66) Once the crystal is cryo-cooled, it 
is assumed that the catalytic reaction is terminated. Experimental trial and error 
is necessary to optimize the amount of time the substrate is soaked with the crystal. 
A structure of the Michaelis-like complex may be obtained by simply 
soaking a pre-formed crystal with substrate. But, one must consider the species 
present at equilibrium, the conformation of enzyme in crystallo and soaking time. 
Section 2.2.2 provides experimental procedures for ligand soaking. 
2.2.2 Ligand Soaking Experiments 
2.2.2.1 Equipment 
• Crystal trays (i.e. 24 well Hampton Research VDX plate) 
• Siliconized cover slips (Hampton Research) 
• Stereo-Microscope (eg: Olympus SZX12) 
• CryoLoopsTM (Hampton Research) 
2.2.2.2 Buffers and reagents 
• Pre-grown crystals (>0.7 mm on a side tend to be more fragile than smaller 
crystals) 
• Components of crystallization solution 
• Ligand stock solution (as concentrated as allowed by solubility) 
• Cryo-protectant 
2.2.2.3 Procedure 
1. Select crystals for soaking. 
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2. Create a soaking solution of mother liquor with at least a 5-20% increase in 
precipitant (i.e. polyethylene glycol (PEG), ammonium sulfate, etc.) and 
ligand of interest at a concentration such that a final molar ratio of 1.2:1 
ligand: protein (using the total concentration of protein in the drop) or 10 x 
KD is reached (whichever is larger). 
3. Carefully transfer crystals from original drop to soaking drop using a loop 
large enough to allow for collection of multiple crystals (if applicable), seal 
the well, observe under a microscope for any immediate crystal 
cracking/decay. Visible signs of crystal decay include crystal dissolution, 
precipitation, phase separation, and crystal cracking. Occasionally, crystals 
will appear solid, but upon disturbance, they crack and dissolve. 
Additionally, crystals may lose diffraction upon soaking. 
4. Allow for crystal to equilibrate (soak) in ligand-containing drop prior to 
cryoprotection and cryocooling for data collection. 
2.2.2.4 Notes and examples 
• The soaking drop size can vary between 2-20 µL and is generally larger than 
the crystallization drop. We prefer a 5 µL soaking drop (increased with 
respect to a typical 2 µL crystallization drop). One advantage to a larger drop 
is that it will not dry out as quickly under the microscope during 
manipulation for crystal mounting. 
• The suggested concentration of ligand for soaking is a minimum and greater 
concentrations may be necessary and should be empirically determined. 
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• Initial soak time is typically determined as described in section 2.1 then 
optimized via trial and error depending on resulting diffraction quality and 
achievement of the desired bound complex. 
• If possible, it is best to introduce the cryo-protectant in the soaking solution 
to decrease the number of crystal transfers and damage to the crystal. This 
can be accomplished by adding glycerol, ethylene glycol, or other cryo-
protectants to the mother liqueur solution.(67) 
• To shift the equilibrium towards bound substrate Nguyen and colleagues 
added product to a soaking solution (e.g. the GmhB structure (see section 
2.1)).(59) In this case the crystal was transferred to a drop of well solution 
containing an additional 5% PEG3350 and equal concentrations of 
substrate and product (30 µM). 
2.2.3 Mutation of the catalytic residue(s) 
Point mutations are utilized in crystallography to decrease surface entropy, 
add crystal contacts, and introduce residues necessary for experimental 
phasing.(68–70) Mutating an amino acid essential to enzyme catalysis but not to 
affinity oblates activity but generates a substrate-binding protein. In the HADSF, 
the Dn is often mutated to obtain substrate-bound crystal structures.(62, 71–73) 
Point mutations have varying effects on the production, stability and 
crystallization of the resulting protein. Mutating residues on the solvent-exposed 
surface of the protein may disrupt or promote crystal contacts, while changing 
amino acids on the protein interior can affect the structural stability. It has been 
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shown that replacing a polar residue with a non-polar equivalent in the enzyme 
active site can stabilize the protein(74) and consequently lead to higher quality 
crystals and enhanced resolution. As the active site of the HADSF is at the cap-core 
interface, the residues can be either solvent exposed or solvent excluded. 
Therefore, mutations at the active site can shift the equilibrium between the open 
and closed conformers. 
Taking into account these considerations, conservative mutation at the 
active site is recommended; for instance, a mutation of the nucleophilic Asp (Dn) 
to Asn has most commonly resulted in stabilization of the Michaelis complex for 
HADSF members.(62, 71, 72) Even with this conservative approach, results from 
mutation of the active site can vary. For instance, in the structure determination of 
Mus musculus (Mm) cytosolic 5¢(3¢)-deoxyribonucleosidase (cdN), the 
nucleophilic Asp (Dn) to Asn mutation had little effect on the stability of the 
enzyme (PDB IDs: 2JAR, 2JAO).(72) Variant protein was expressed, purified, and 
crystallized under the same conditions as wild type, and then simply soaked with 
substrate. However, co-crystallization of the Dn11N variant of 
Methanocaldococcus jannaschii (Mj) phosphoserine phosphatase (PSP) with 
phosphoserine (PDB ID: 1L7P) required optimization of the crystal conditions.(62) 
After success determining the structure of wild-type Candida albicans (Ca) T6PP 
bound to a substrate analog (PDB ID: 5DXI), co-crystallization of the Dn559N 
variant with substrate yielded no crystals. A structure with substrate bound was 
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instead determined for the Dn704N variant of T6PP from Cryptococcus 
neoformans (Cn) (PDB ID: 5DX9.(71) 
Although Asp (Dn) to Asn mutation has proven successful for HADSF 
enzymes, a different tactic was taken in the case of Bacillus cereus (Bc) 
phosphonatase, where the nucleophilic Asp was mutated to Ala. Whereas the wild-
type structure was determined to 3.0 Å resolution (PDB ID: 1FEZ),(75) this 
mutation afforded an unliganded structure with increased resolution (2.3 Å) (PDB 
ID: 1SWV), as well as a substrate-bound (phosphonoacetaldehyde) structure 
refined to a resolution of 2.55 Å (PDB ID: 1SWW).(73) It should be noted that the 
absence of the Dn side chain in this position caused the substrate phosphoryl group 
to move into the position usually occupied by the aspartyl carboxylate. 
2.2.4 Exchange metals 
In phosphoryl transfer reactions the magnesium ion acts to stabilize both 
the leaving group of the substrate and the oxygens of the phosphoryl group in the 
transition state(76)  and indeed, HADSF members that catalyze phosphoryl 
transfer have an absolute requirement for a divalent magnesium ion cofactor. 
Thus, when magnesium ion is replaced with another divalent metal, activity is 
either abolished as is the case with calcium ion or significantly decreased as is the 
case for cobalt ion and some other period 4 elements.(77) In systems with metal 
dependent catalysis, it is possible to exchange the metal to prevent turn-over and 
capture substrate-bound structures. Furthermore, in the HADSF, the catalytic 
magnesium ion is not typically essential for proper folding and stability, so it may 
be removed altogether. 
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One method to allow for calcium or cobalt ion binding in place of magnesium ion 
is simply to increase the concentration of the divalent metal chloride in the mother 
liquor solution, as is the case in HsPSP (PDB ID: 1NNL).(77) Similarly, a structure 
of Haemophilus influenza (Hi) 3-deoxy-D-manno-octusonate 8-phosphate 
phosphatase (KDO8PP) was determined with cobalt ion in place of magnesium ion 
by omitting magnesium from the crystallization buffer and adding 10 mM cobalt 
(II) chloride to the drop solution (PDB ID: 1K1E).(78) Although these metal swaps 
were not performed to obtain substrate-bound structures, the procedures show a 
valid means of replacing the catalytic magnesium with an alternative divalent 
metal. Moreover, the Ca2+-substituted structure of human PSP provides evidence 
that the loss of activity with calcium ion is due to the differing coordinate bonds 
between the calcium and magnesium ions. The calcium ion prevents the placement 
of phosphoserine in a catalytically competent orientation(77). 
Furthermore, substrate-bound structures may be determined by removing 
the magnesium from the active site by chelation via soaking of the crystal in 
ethylenediaminetetraacetic acid (EDTA) and substrate. This is exemplified by the 
structure of Synechocystis sp PCC 6803 (Ss) sucrose phosphatase (SPP), wherein 
the substrate, sucrose 6-phosphate (Suc6P), was bound (PDB ID: 1U2T) in an 
orientation that is consistent with a Michaelis-like complex but electron density 
consistent with that of a water molecule was observed in the binding site for the 
magnesium cofactor. Thus, in the absence of magnesium, it is expected that water 
binds in the metal-binding site, affording hydrogen bonds in place of coordinate 
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bonds to the phosphoryl group of the substrate. Notably, SsSPP crystals grown 
under the same condition and soaked in a solution containing Suc-6-P (no EDTA), 
allows for turnover in crystallo of substrate and produces a structure of SPP with 
sucrose and phosphate bound (PDB ID: 1TJ5).(79) This confirms that removal of 
magnesium via chelation by EDTA in crystallo may not destroy the crystal but can 
prohibit turnover, enabling comparison of substrate and product complexes using 
the same crystal form. 
The affinity of the enzyme for its metal cofactor should be considered as it 
varies substantially in the HADSF. In some members, such as Bc phosphonatase, 
the protein is destabilized and unfolds upon magnesium removal.(73) In contrast, 
Salmonella typhimurium (St) T6PP has a low affinity for magnesium; soaking with 
50 mM magnesium chloride prior to cryo-cooling does not provide full occupancy 
of the magnesium ion in the active site (unpublished observation). Lastly, 
magnesium salts prevent the crystallization of Mm magnesium-dependent 
phosphatase-1 (MDP-1). Even soaking crystals in magnesium alone did not allow 
for cofactor binding. However, MmMDP-1 crystals grown in the absence of 
magnesium and then soaked in a solution containing both sodium tungstate (as a 
phosphate analog) and magnesium resulted in full occupancy of the magnesium- 
and phosphate- binding sites (PDB ID: 1U7P).(80) The tungstate itself, provides 
one coordinate bond to aid in completion of the magnesium ion coordination 
sphere, synergizing tungstate and magnesium-ion binding. 
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The metal cofactor of the HADSF may be removed or replaced by another 
divalent metal before or after crystallization to generate a non-catalytic enzyme. 
As the affinity for the magnesium ion is different for each member of the 
superfamily, perturbation of the ion will have varied effects. 
2.2.5 Phosphate Binding 
The location, coordination state, and geometry of phosphate in the active 
site of phosphatases act as a bridge between substrate-bound and product-bound 
complexes. Oftentimes, these structures are a result of in-crystal hydrolysis of 
soaked substrate. In the case of Bordetelia bronchiseptica (Bb) GmhB and 
EcGmhB, the alternate substrates imidodiphosphate and fructose-1,6-
bisphosphate were soaked in crystals for five minutes prior to cryo-cooling. The 
ligand density in both structures clearly shows only phosphate bound in the 
phosphoryl transfer site of the active site (PDB IDs: 3L8F & 3L8H, 
respectively).(59) 
As phosphate is such a common precipitant in crystallization buffers, it is 
possible for phosphate to co-crystallize with the enzyme. This is observed in the 
structure of MjPSP (PDB ID: 1L7M) with phosphate bound(62). In this case, 
phosphate was not added to the protein or soaked into the crystal but the 
crystallization conditions included 0.5 M sodium phosphate dihydrate. These 
phosphate-bound structures corroborate the phosphoryl binding site and provide 
coordinate bonds to magnesium allowing for identification of the active site. The 
position of phosphate can also act as a valuable “anchor” for computational 
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positioning of substrates and phosphoryl- or phosphoryl mimic- bearing ligands 
via superposition. 
2.3 Ground-state, intermediate, and transition-state mimic complexes 
Using structural information of the binding to the Michaelis complex, 
transition state mimics, and intermediates, the overall mechanism of catalysis and 
determinants of ligand binding can be better understood to guide efforts in rational 
inhibitor design as therapeutics and as probes in chemical biology. 
 
 
Figure 2.3. Transition state and ground state geometries as represented by 
4HGO (A), 1J97 (B), 2RB5 (C) and 2RAV (D).  
A. The trigonal bipyramidal transition state mimic. The apical positions are occupied by 
the oxygens of KDN and Dn. B. BeF3 forming a coordinate bond with Dn acts as a mimic 
of the phosphoaspartyl intermediate. C. A trigonal bipyramidal geometry formed with 
tungstate with the apical position occupied by Dn and a water molecule illustrating the 
second half reaction, hydrolysis of the phosphoaspartyl intermediate. D. Tungstate 
bound structure in a tetrahedral geometry. Dn is not coordinated to the tungstate, 
showing the product bound complex. Magnesium ion is shown as pink sphere, and water 
molecules as red spheres. Dn+210A denotes a point mutation of aspartate to alanine.  
 In phosphatases, this is typically accomplished using phosphate 
analogs to mimic either the ground state (tetrahedral geometry) or transition state 
(trigonal bipyramidal geometry) (Figure 2.3). Vanadate and tungstate, the most 
commonly used phosphate analogs, may adopt either the tetrahedral or trigonal 
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bipyramidal geometries, because they are more flexible in the number of 
coordinate bonds in which they participate.(81) Orthovanadate (VO43-) and 
orthotungstate (WO42-) are tetrahedral and mimic the ground state geometry. In 
HADSF members, the ground state can be considered a substrate-bound, product-
bound or phospho-enzyme complex. We include the phospho-enzyme as ground 
state because of the relative stability, varying between family members but 
exemplified by the fact that the phospho-enzyme can be isolated.(82) 
Metavanadate (VO3-), in the absence of additional coordinate bonds from the 
enzyme or waters is trigonal planar. Pentacoordinate forms of tungstate and 
vanadate exhibit trigonal bipyramidal geometries, mimicking the transition state 
and include coordinate bonds donated by substrate, water and/or oxygen from the 
nucleophilic aspartate, Dn.(53, 83–85) As pentacoordinated tungstate is less 
frequently observed in complex with phosphatases(53, 86), the versatility in 
coordinate-bond formation makes vanadate most appealing for mimicking 
transition-state geometry.(81) Sulfate and some metal fluoride complexes, such as 
aluminum trifluoride (AlF3) and beryllium trifluoride (BeF3-), mimic the ground 
state geometries; therefore, when added together with the leaving group they can 
simulate enzyme-substrate complexes.(85, 87, 88) Notably BeF3- with one 
coordinate bond from Dn resembles the phosphoenzyme. Here we describe how 
the use of phosphate mimics in the presence and absence of the leaving group 
product can serve as ground-state, intermediate and transition-state complex 
analogs for phosphatases in the HADSF. 
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2.3.2 Intermediate bound complexes 
In the example of Lactococcus lactis (Ll) β-phosphoglucomutase (β-PGM), 
Lahiri et al. were able to successfully observe the pentavalent bisphosphorane 
intermediate (PDB ID:1O03 & 1O08). This was accomplished through 
equilibration of crystals with magnesium and either glucose 1-phosphate (Glc1P) 
or glucose 6-phosphate (Glc6P).(52) In mutases, isomerases, and racemases 
(enzymes with a single substrate and single product), equilibration of a crystal or 
co-crystallization with either substrate or product at concentrations greater than 
the KM, results in observation of the species  that predominates at equilibrium.(89) 
The structure clearly shows the apical groups belonging to the nucleophilic oxygen 
of aspartate - Dn8 and the oxygen of the substrate leaving group(52). By gaining 
insight into intermediate-bound structures, such as the bisphosphorane, one can 
discern important contributions to catalysis. For instance, the position of the Dn+2 
that forms a hydrogen bond to the bridging oxygen in this structure supported its 
identification as the general acid-base and highlighted the change in conformation 
the residues undergo between the intermediate/transition state and unliganded 
structures. This conformational change is a key component of the mechanism by 
which the enzyme discriminates between substrate hexose sugar and water, 
allowing mutase over phosphatase activity.(4) 
2.3.3 Ground-state mimic complexes 
Phosphoryl mimics in the absence of additional ligands in the active site 
resemble the ground-state, by taking on a tetrahedral geometry. From these 
structures, one can identify binding determinants for the phosphate moiety. These 
 
 41 
are usually tetravalent complexes of any of the phosphoryl mimics discussed in 
Section 2.3. 
For the HADSF sulfate-bound structures deposited in the PDB at the time 
of this writing, the sulfate ligand was introduced from the crystallization milieu 
(examples: PDB IDs: 3R4C, 3QUB, 3QUC, and 1YMQ). These structures allow for 
identification of the phosphoryl-binding site and the relative placement of catalytic 
residues. 
The fluoro phosphoryl mimics, like beryllium fluorides, are exemplified in 
structures of MjPSP(87) and calcium ATPase from Oryctolagus cuniculus (Oc) 
(PDB ID: 2ZBE)(85, 88). To identify the necessary ratios to form BeF3-, Cho et al. 
observed BeF3- complex formation using 1H-15N FHSQC spectra.(87) Sodium 
fluoride, beryllium chloride, and magnesium chloride at 54 mM, 10.8 mM and 90 
mM, respectively, were added to MjPSP prior to crystallization. In this MjPSP 
structure (PDB ID: 1J97), there is an oxygen-beryllium bond (1.55 Å) observed with 
the oxygen of the nucleophilic aspartate (Dn11) completing the tetrahedral 
geometry and mimicking the phosphoenzyme.(87) 
The Oc calcium ATPase bound to tetrafluoromagnesate (MgF42-) (PDB ID: 
1WPG) mimics the phosphate bound product complex with the MgF42- species 
exhibiting tetrahedral geometry.(85) This geometry affords insight into the 
conformation of enzyme during the second half reaction prior to product release. 
2.3.4 Transition-state mimic complexes 
As described in section 3, the choice of phosphate mimic can dictate 
whether the ground-state (tetrahedral) or transition-state (trigonal bipyramidal) 
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geometry is captured. Using tungstate or vanadate as the phosphoryl mimic is 
advantageous in obtaining a transition-state-like complex as they can make more 
than four coordinate bonds. Structures of bacterial homologs, Bacteriodes 
thetaiotaomicron (Bt) 2-keto-3-deoxy-D-glycero-D-galacto-nononate 9-
phosphate phosphatase (KDN9PP) (PDB ID: 4HGO) and HiKDO8PP (PDB ID: 
4HGP), in the presence of vanadate and product 2-keto-3-deoxy-D-glycero-D-
galacto-nononic acid (KDN) or 3-deoxy-D-manno-octulosonic acid (KDO), 
respectively, adopt transition-state-like geometry through vanadium participating 
in five coordinate bonds. The equatorial positions are occupied by three oxygens 
coordinated to vanadium, and the carboxylate of the nucleophilic aspartate and the 
C9O (KDN) or C8O (KDO) of the substrate are in the apical positions, completing 
the trigonal bipyramidal geometry. This complex mimics the first step of 
phosphoryl transfer, in which the nucleophilic aspartate attacks the phosphoryl 
group of the substrate and provides further evidence of an in-line, backside 
displacement mechanism.(83) 
Notably, several crystals of BtKDN9PP grown in a condition containing 
sodium acetate did not yield liganded structures. In these structures, acetate binds 
in the subsite of the active site where the carboxylate moiety of the sialic acid 
leaving group of the substrate would bind. This problem was circumvented by 
soaking the crystals in well solution containing the ligands of interest with an 
increased concentration of PEG (5%) in the absence of acetate. This allows for the 
ligand of interest, in this case an alternate substrate, 5-N-acetyl-β-D-neuraminate 
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(Neu5Ac), and vanadate, to outcompete any bound or remaining acetate, yielding 
a transition-state complex structure (PDB ID: 3E81).(84) 
In the case of Bt hexose-phosphate phosphatase (BT4131), the trigonal 
bipyramidal geometry was observed in a structure with tungstate bound (PDB ID: 
2RB5) as well as with vanadate bound (PDB ID: 2RBK). Three W-O coordinate 
bonds are in the equatorial positions, and the apical positions are occupied by the 
fourth W-O coordinate bond and the carboxylate oxygen of Dn8. Additionally, the 
apical oxygen is hydrogen bonding with the carboxylate of Dn+210.(53) This 
structure mimics the transition state of phosphoenzyme hydrolysis- the second-
half reaction of phosphoryl transfer. The same pentacoordinate geometry is 
assumed by vanadate in the BT4131 active site(53); these structures support the 
role of the enzyme active site in stabilizing this geometry along the normal reaction 
coordinate. 
Notably, in a structure of a variant of BT4131 with the Dn+210 replaced by 
alanine, VO3- is bound as a tetravalent complex with the Dn8 supplying the fourth 
coordinate bond (PDB ID: 2RAR). This complex displays distorted tetrahedral 
geometry in which the bond angles to the non-bridging oxygens are close to 90° 
(the VO3- moiety is close to planar) and the tetravalent Dn8-vanadate adduct is a 
mimic of the aspartylphosphate intermediate and not the pentavalent trigonal-
bipyramidal transition state. This tetrahedral geometry illustrates the importance 
of the Dn+2 in observing the trigonal-bipyramidal geometry, further supporting the 
general base mechanism of phosphoryl transfer in the HADSF.(53) 
 
 44 
Toyoshima et al. generated AlFx, ADP,– Oc calcium ATPase complexes by 
co-crystallizing with ADP and adding aluminum (III) chloride and sodium fluoride 
directly to the mother liquor prior to crystallization (PDB ID: 2ZBD). It was not 
possible to identify from the electron density whether AlF3 or AlF42- was present in 
the structure. (85) However, it is obvious that aluminum forms at least 6 
coordinate bonds:  the three (or four) equatorial positions are fulfilled by the 
fluoride ions, with carboxylate of Dn8 in one of the apical positions and an oxygen 
from ADP in the second apical position. This displays a trigonal (or tetragonal) 
bipyramidal geometry resembling the transition state.(85) 
Whether the reaction mechanism is an elimination-addition (dissociative), 
addition-elimination (associative) or concerted, the intermediate/ transition state 
takes on a trigonal bipyramidal geometry. Any transition-state/ intermediate 
analog should mimic that geometry. Previously, it has been noted that although 
the complexes of HADSF members with AlFx and VO43- provide evidence for the 
trigonal bipyramidal geometry of the transition state, they do not rigorously test 
the ability of the enzyme active site to play a role in the formation and stabilization 
of the trigonal bipyramidal complex.(53) Tungstate provides a better probe as 
pentavalent trigonal bipyramidal geometry is rare for tungstate in the active site of 
phosphotransferases.(53, 86, 90) Notably, in the case of BT4131, comparison of 
the structure of the enzyme-tungstate complex reveals the same pentavalent 
trigonal bipyramidal geometry and stabilizing hydrogen-bond interactions as are 
observed for the vanadate complex. In BT4131, the ~130-fold lower affinity of 
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tungstate to vanadate is considered to reflect the amount of binding energy to 
stabilize this higher valency state of tungstate.(53) But the extent to which any of 
these complexes mimic the transition state cannot be determined solely by 
crystallographic structure determination or binding affinity to wild-type enzyme. 
Instead, the relationship between catalytic activity and affinity for a series of site-
directed variants has been used to show mimicry of the transition state. Indeed, 
such correlations show that vanadate is not a true transition-state analog for 
protein-tyrosine phosphatase,(91) and that tungstate is a mimic for the transition 
state properties of alkaline phosphatase.(86) 
These complex structures together provide evidence useful for defining the 
catalytic and chemical mechanism of phosphohydrolase and phosphomutase 
activity of HADSF members. Coordination of the nucleophilic aspartate and the 
leaving group to vanadium completes the trigonal-bipyramidal geometry and 
allows visualization of the transition-state analog complex of the first half reaction. 
Coordination of the nucleophilic aspartate and water to vanadium or tungsten 
allows visualization of the transition-state analog complex of the second half 
reaction. Rational inhibitor design should take advantage of the hydrogen bonds 
formed to the equatorial oxygens and oxygens bridging to the leaving group as 
these are expected to be optimized in the transition state. Tungstate ions are simply 
added as tungstic acid or as the sodium salt(53, 80)  whereas procedures for 
preparation of vanadate solutions are detailed in Section 3.4. 
2.3.4.1 Equipment 
• pH probe, calibrated 
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• hot/stir plate 
2.3.4.2 Buffers and reagents 
• 6 M hydrochloric acid 
• 10 M sodium hydroxide 
• Sodium orthovanadate (CAS 13721-39-6) 
2.3.4.3 Procedure 
1. Add sodium orthovanadate (3.6782 g) to Millipore water (20.0 mL, half 
final volume) in a heat-resistant container (eg. a 100 mL pyrex bottle). 
2. Add 6 M hydrochloric acid to reach pH 10 in 100-200 µL aliquots (solution 
will turn yellow with addition of acid due to the formation of decavanadic 
acid). 
3. Cover container with aluminum foil and boil on a hot/stir-plate until 
colorless (~15 minutes). Then, cool to room temperature. 
4. Measure pH and add either 6 M hydrochloric acid or 10 M sodium 
hydroxide until the solution reaches pH 10. 
5. Repeat steps 3-4 until the pH stabilizes at pH 10. 
6. Add Millipore water to achieve the desired final volume (40 mL). 
2.3.4.4 Notes 
• Detailed protocol is for making a 40 mL, 500 mM sodium orthovanadate 
stock solution. 
• 250-500 mM stocks are ideal for minimizing volume change due to the 
addition of ligand. 
• For a 40 mL solution, add acid/base in roughly 200-500 µL aliquots. 
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• Aliquots of ~1.5 mL in Eppendorf tubes can be stored at -20°C. Samples 
may withstand 2-3 freeze-thaws. If solution is no longer colorless (begins to 
turn yellow), then the sample should be discarded. 
2.4 Inhibitors 
2.4.1 Substrate mimics as inhibitors 
Another means of obtaining information about the residues comprising the 
substrate-binding site in phosphatases is to utilize a non-hydrolyzable substrate 
mimic. Because phosphoryl transfer is not possible, these molecules are likely to 
compete for the active-site, and as such, affinity can be found through 
measurement of KI. One option is to use the sulfonate- or sulfate-substituted 
version of the phospho-substrate. Trehalose 6-sulfate is a 180 µM inhibitor of 
StT6PP(92) and was used to mimic the Michaelis complex. This approach was 
utilized for Bc phosphonoacetaldehyde hydrolase, as well (see 
phosphonoacetaldehyde hydrolase-vinyl sulfonate complex, PDB ID: 1RQL).(93) 
Alternatively, for phosphatases, substituting the substrate phosphate group with a 
phosphonate group removes the leaving group and prevents turnover. For HsPSP, 
the inhibitor 2-amino-3-phosphonopropionic acid which lacks the bridging oxygen 
to phosphorous, was used as a substrate mimic with an IC50 of 1.4 mM (PDB ID: 
1L8L).(94) 
In the HADSF, in general, the leaving group does not bind tightly. However, 
in some cases inhibitors may resemble only parts of the original substrate. For 
sugar phosphatases, other sugars can be used as inhibitors. For instance, 
structures of SsSPP were determined with the inhibitory disaccharides cellobiose, 
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maltose, and trehalose, which have poor affinity with KI values of 101, 100, and 26 
mM, respectively (PDB IDs: 2BIR, 2D2V, and 2BIQ).(95) Additionally, α-
galactose-1-phosphate (Gal1P) acts as a substrate mimic of the phosphorylated 
enzyme or a 30 µM inhibitor of Llβ-PGM. Gal-1-P was co-crystallized with Llβ-
PGM to reveal structural insight into the overall mechanism of catalysis (PDB ID: 
1Z4O).(96)  
Fortunately, most mimics of phosphatase substrates will be polar and 
therefore soluble in water. However, the ultimate goal of many projects is small 
molecule drug design that requires molecules to permeate the cell membrane. Cell 
permeable drugs are nonpolar and rarely charged;(97) thus, they are generally not 
freely soluble in water. As crystallization requires high concentrations of protein 
(generally ~300 µM) , high concentrations of inhibitors in crystallization buffer are 
necessary to achieve equimolar solutions. In Section 4.2, we describe methods to 
test protein and crystal stability in the presence of solvents and inhibitors and 
strategies to increase stability, if necessary. 
2.4.2 Protein and crystal stability in the presence of inhibitors/solvents 
2.4.2.1 Determining protein stability 
2.4.2.1.1 Equipment 
• White PCR strips or plates 
• Real-time Thermocycler 
2.4.2.1.2 Buffers and reaents 
• Solvents of interest 
• Protein (10 µL of 20 µM per sample) 
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• SYPRO® Orange Protein Dye (5,000 x; Thermo-Fisher catalog number S-
6650) 
2.4.2.1.3 Procedure 
1. Prepare solvent of interest in protein buffer. Example: Prepare 2.5, 5, 10 
and 20% DMSO solutions in buffer containing HEPES pH 7.0 and 50 mM 
NaCl. Add 10 µL of solvent mix to a well in a white PCR plate. Repeat for 
each solvent and concentration to be tested. Use 10 µL of protein buffer as 
a control. 
2. Add SYPRO® Orange dye to 20 µM protein solution at 1:500 dilution. 
3. Add 10 µL protein with SYPRO® Orange dye to each solvent mix. 
4. Cover wells with clear plastic. 
5. Record the fluorescence at 520 nm while temperature is increased from 20 
to 95 at 1 °C per minute. 
6. Analyze data: Raw data will show an increase in fluorescence as the protein 
unfolds and the SYPRO® Orange dye binds to exposed hydrophobic 
residues. The inverted derivative of the fluorescence signal will result in 
peaks corresponding to the melting temperature (Tm). Select solvents at 
concentrations that minimally decrease the Tm (≤ 5 °C). 
2.4.2.1.4 Notes 
• Centrifuge prepared PCR strip/plate to remove bubbles if necessary.  
2.4.2.2 Optimizing crystal stability 
2.4.2.2.1 Equipment 
• Crystal trays 
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• Siliconized cover slips 
• Stereo-Microscope 
2.4.2.2.2 Buffers and reagents 
• Pre-grown crystal 
• Solvent 
2.4.2.2.3 Procedure 
1. Follow procedures in section 2.2.3 for soaking crystals. If ligand is precious, 
test using solvent. 
2. Monitor crystal decay over time at various time points such as 5 min, 30 
min, 1 hour, 2 hours, 6 hours, and overnight (see Section 2.2.3 for 
discussion of decay). 
3. If crystals are stable, cryo-protect and cryo-cool for data collection. If not, 
try crosslinking(98)  or the use of alternative solvents or mixtures of 
solvents as described in Ciccone et al & Hassel et al..(99, 100) 
2.4.2.2.4 Notes 
• Prepare soaking solutions with varying concentrations of solvent (if 
material is precious) or inhibitor in solvent. Limiting the solvent content to 
less than 10% V/V is preferable. 
• The stability of protein solution and crystals to the same solution may vary. 
In solution, StT6PP is stable with up to 20% dimethyl sulfoxide (DMSO), 
but crystals rapidly decay as assessed macroscopically with >5% DMSO. 
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• When crosslinking, we use 5 µL of 8% glutaraldehyde on a microbridge in 
the crystallization well incubated for 5 minutes. During the first trial, 
monitor crystals every 5 minutes for signs of crystal decay. 
• Molecular Dimensions sells the CryoSol kit (catalog number MD1-90) of 
multicomponent solutions for solubilizing hydrophobic ligands and for 
cryoprotection. 
2.5 Summary and Conclusion 
In this chapter, we have described various techniques using single crystal 
X-ray crystallography to gain mechanistic insight into the HADSF of phosphatases. 
Using procedures such as site-directed mutagenesis and metal exchange, we 
demonstrate how one can capture a substrate-bound structure and decipher the 
binding determinants for substrate, affording mechanistic understanding and 
insight for inhibitor design. Phosphoryl mimics, such as vanadate, tungstate, 
sulfate, aluminum fluoride, and beryllium fluoride, allow for structural 
characterization of both half reactions in the overall mechanism of catalysis:  
nucleophilic attack producing the phospho-enzyme intermediate, and hydrolysis 
to release an inorganic phosphate and regenerate the enzyme. Lastly, 
characterization of substrate-like inhibitors can provide additional support for 
hypotheses regarding the binding determinants and mechanism of catalysis. 
Furthermore, the methods described can be applied to other phosphatase 
families or generally to protein-ligand complexes. The methods for soaking 
substrate into crystals in section 2.2.1 and 2.2.2 may be useful to any ligand-
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binding protein. Sections 2.2.3-2.2.5 are applicable to other families of 
phosphatase. Mutagenesis of analogous residues important for catalysis or 
removal/replacement of the metal cofactor will oblate activity and enable substrate 
binding. Additionally, co-crystallization with phosphate allows one to pinpoint the 
active site. In section 2.3, the information about phosphate mimics can be 
leveraged in other phosphoryl transfer enzymes to capture various snapshots of 
the catalytic mechanism. Finally, the concepts and methods to determine an 
inhibitor bound structure in section 2.4 can be used for any protein. These methods 
highlight complications in attaining liganded structures from the presence of 
competing ions introduced by the crystallization milieu and of poor solubility of 
ligands and some approaches that circumvent these problems. The HADSF acts as 
a testbed for phosphoryl mimics, with particularly strong applications to 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER THREE: Human phosphomannomutase isoforms: 




3.1  Introduction 
3.1.1 Eukaryotic N-linked glycosylation 
Eukaryotic N-linked glycosylation proceeds in an en bloc fashion, as 
generalized in Chapter 1. The pathway is homologous to bacterial glycosylation 
pathways with some modifications. First, as described in Chapter 1, eukaryotic N-
linked glycosylation occurs in the ER and uses dolichol phosphate (Dol-P) as a lipid 
carrier. The pathway occurs in both the cytoplasm and the lumen of the ER, and 
there are distinct GTs for each step (Figure 3.1).(101)  GDP-mannose (GDP-Man) 
is one of the main substrates for this pathway and it is synthesized in the cytoplasm 
from glucose 6-phosphate (Glc6P) in four enzymatic steps by 
phosphoglucoisomerase, phosphomannose isomerase, phosphomannomutase 
(PMM), and GDP-Man synthase (Figure 3.1). To initiate glycan synthesis, two Glc 
moieties are added sequentially onto Dol-P by N-acetylglucosamine-phosphate 
transferase (Alg7) and a glycosyl transferase (GT), generating a Dol-PP-Glc2 
glycan. Additional Man moieties are then added onto the Dol-PP-linked glycan and 
the chain is translocated from the cytoplasm to the lumen. In the lumen, the glycan 
chains are further elongated and additional branching is introduced by GTs. 
However, rather than using NDP-sugar substrates, the luminal GTs use Dol-P-
sugars as their substrate.(101) Although differing branching topologies are 
possible, all N-linked glycans are capped with a Glc moiety which is a primary 
recognition site for oligosaccharyl transferases (OTase).  
Mutations to various genes in this pathway result in hypoglycosylation and 
result in anywhere from mild to severe phenotypes and are associated with 
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congenital diseases of glycosylation (CDG). As introduced in Chapter 1, CDG-
PMM2 phenotypes are often the most severe of the CDGs. This is likely a result of 
the role of PMM2 in the biosynthesis of GDP-Man, a substrate for both N- and O-
linked glycosylation pathways. Therefore hypoglycosylation of both types of 
glycans is observed.(15)  
3.1.2 Clinical markers for galactosemia 
Galactosemia is a metabolic disorder in which there are mutations to 
galactose 1-phosphate uridylyltransferase (GALT), an enzyme in the Leloir 
pathway which transfers a UMP moiety onto galactose 1-phosphate (Gal1P), 
producing UDP-Gal.(102) The concentration of Gal1P increases in patients with 
nonfunctional or low-functioning GALT. Patients with galactosemia present with 
 
Figure 3.1. N-linked glycosylation pathway in the endoplasmic reticulum. 
Nucleotides are represented as pentagons, GDP in light yellow and UMP in dark yellow. 
The lipid carrier is represented as black bonds, and the phosphate moiety as an orange 
circle. Monosaccharides are represented following the Symbol Nomenclature for 
Glycans (SNFG) for the following sugars: Glc (blue circle), GlcNAc (blue square), Man 





hypoglycosylation of both proteins and lipids. Specifically, truncated N-glycans 
lacking sialic acid and Gal modifications are observed.(102) Galactosemia 
phenotypes are similar to those of CDG-PMM2 in that galactosemia patients 
exhibit cognitive delays, hypogonadism, and high frequency of deaths as a result 
of E. coli sepsis during neonatal stages.(103) Further, galactosemia patients often 
present with increased fucosylation and branching of serum transferrin N-glycans, 
a marker that has been attributed to chronic hepatic inflammation in CDG-PMM2 
patients.(103, 104) Further studies by Liu et al. identified that galactosemia 
exhibits hypoglycosylation of both N- and O-glycans and that patients on 
galactose-restricted diets no longer exhibit hypoglycosylation.(105) Together, 
these findings show the interconnected nature of galactosemia and CDGs. It is 
probable that lack of UDP-Gal production impacts total glycan biosynthesis. 
Alternatively, it is possible that the build-up of Gal1P, rather than the lack of UDP-
Gal, leads to inhibition of protein glycosylation. The research described herein 
seeks to elucidate whether Gal1P inhibits PMM2 activity.  
3.1.3 Phosphomannomutase isozymes  
Higher-level mammals bear two isozymes of PMM, PMM1 and PMM2. Both 
belong to the haloalkanoate dehalogenase superfamily (HADSF), and they share 
67% sequence identity.(5, 106) The physiological role of PMM2 is to produce 
Man1P using Man6P as a substrate. PMM2 knockouts in embryo show no viability, 
which is consistent with ubiquitous PMM2 expression.(107, 108) Although 
mutations to PMM2 cause CDGs with mild to severe phenotypes, PMM1 knockout 
mice models exhibit normal phenotypes, demonstrating that PMM1 cannot 
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substitute for PMM2. (106, 108) PMM2 is the primary isozyme, ubiquitously 
expressed in all tissues whereas PMM1 is expressed exclusively in the brain, lungs 
and kidneys.(108) Notably, in vitro characterization has shown that PMM1 and 
PMM2 have nearly identical catalytic efficiencies using both Man and Glc 
substrates (Table 3.1)(5), meaning that in vitro PMM isozymes do not distinguish 
at the C4 position although in vivo PMM2 does exhibit distinction.  
Table 3.1. Michaelis-Menten kinetic constants for PMM1 and PMM2 
 
Enzyme Substrate kcat (s-1) KM (µM) kcat/KM (s-1M-1) 
PMM1 Glc1P 2.85 7.5 3.8 x 105 
PMM2 Glc1P 1.72 13.5 1.3 x 105 
PMM1 Man1P 4.39 4.39 8.1 x 104 
PMM2 Man1P 3.90 3.9 2.5 x 105 
 
 
PMM isozymes exhibit the characteristic HADSF fold, with a C2b cap type. 
Mutase enzymes in the HAD superfamily have two phosphoryl binding sites: the 
transferring phosphoryl sub-site, which coordinates the catalytic magnesium ion, 
and the distal phosphoryl sub-site, which is located in the cap domain (Figure 3.2 
A).(4, 5, 52, 96, 109) In traditional mutase activity, a bisphosphorylated sugar, 
likely mannose 1,6-bisphosphate (M16P2), serves to phosphorylate the 
nucleophilic aspartate, generating the catalytically productive form of PMM. After 
activation, the substrate (Man6P in physiological conditions) binds, with the 
phosphoryl moiety in the distal sub-site and is phosphorylated at the opposite 
position (C1’). The bisphosphorylated intermediate must then exit the active site 
and rebind in the opposite orientation, followed by dephosphorylation by the 
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aspartate, producing the product, Man1P and the reactivated enzyme (Figure 
3.2B).(5)  
 
Figure 3.2. Structure and mechanism of PMM1. The structure of Man1P bound 
to PMM1 (PDB: 2FUE) is in the cap open conformation in cartoon representation, with 
Man1P depicted as sticks, and magnesium ions as gray spheres. The core domain is 
colored cyan and the cap domain is light cyan. The mechanism of PMM mutase activity, 
using Man6P as a substrate, follows steps 1-4 in a clockwise manner from the upper left. 
In this mechanism, PMM has already been activated by G16P2, forming a 
phosphoaspartate (D19).  
 
In addition to mutase activity, only PMM1 isozyme exhibits phosphatase 
activity, specifically in the presence of inosine 5-monophosphate (IMP).(106) The 
phosphatase activity was first characterized by Veiga-da-Cunha et al. identifying 
G16P2 as the substrate. Veiga-da-Cunha et al. also assessed activation of 
phosphatase activity by also testing GMP and AMP as activators. Although GMP 
does activate PMM1 phosphatase activity, the Kact (the concentration of activator 
at which 50% activation of phosphatase activity is observed) is roughly 25-fold 
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higher than activation with IMP and AMP showed no activation.(106) The 
proposed reaction mechanism begins by substrate binding and dephosphorylation 
of M16P2 as would occur for activation of PMM. The following step in mutases 
would involve transfer of the phosphoryl moiety to the phospho-sugar substrate. 
In phosphatase activity, the phosphoryl moiety is transferred instead to water.(6) 
Ji et al. confirmed that PMM2 does not exhibit phosphatase activity even at 
saturating concentrations of IMP.(6) The X-ray crystal structures of PMM1 in 
complex with IMP or Man1P were resolved to 1.92 Å and 1.75 Å resolution, 
respectively.(5, 6) These structures were both in the open conformation, and 
therefore only interactions between the ligand and the cap domain are observed.  
The X-ray crystal structure of PMM1 in complex with IMP elucidated the 
binding mode of IMP positions the phosphoryl moiety in the distal phosphoryl 
sub-site.(6) Residues that coordinate the sugar moiety of Man1P also make 
hydrogen bonds with the nucleotide moiety of IMP, with the exception of a few 
residues that only make interactions with either Man1P (R28) or IMP (N137, S182, 
G184).(5, 6) Ji et al. propose that R180 and R183 provide favorable eletrostactics 
for binding of IMP, and that binding of IMP disorders the β-strand (179-189).(6) 
Notably,  R180 and R183, are strictly conserved in PMM1 orthologs, but in PMM2 
these residues are replaced by threonine and isoleucine, respectively. The 
proposed mechanism of conversion between mutase and phosphatase activities for 
PMM1 is presented in Figure 3.3. Herein, we aim to elucidate mechanisms of 
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phenotypic divergence between the two PMM isozymes, using kinetic and 
structural techniques.  
 
Figure 3.3. Proposed mechanism of phosphatase activation of PMM1 by 
IMP. The proposed reaction scheme cycles with activation/phosphatase activity on top 
and mutase mechanism cycle below. Reactions are depicted with α-D-mannose 6-
phosphate and α-D-mannose 1,6-bisphosphate as substrates. This figure was adapted 
from Ji et al..(6)  
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3.1.4 Chapter Aims 
This chapter will investigate the in vitro activity of two PMM isozymes with 
the goal of identifying differences that may explain the differing phenotypes. We 
are interested in using mechanistic and structural techniques to understand why 
and how these two isozymes play different roles in vivo. The X-ray crystal structure 
of PMM1 in complex with vanadate and enzyme inhibition studies reveals a unique 
binding mode and preference for the distal phosphate sub-site. The second part of 
this chapter describes the use of in vitro kinetic analyses to link isozyme specificity 
to disease-relevant clinical phenotypes identified in collaboration with Dr. Miao 
He at University of Pennsylvania.  
3.2 Materials and Methods 
3.2.1 Expression and purification of PMM variants 
Plasmids containing Homo sapiens PMM1 wt and PMM1 R180T/R183I 
were previously reported(5, 6, 110). BL21 (DE3) cells were co-transformed with 
pRARE and the pET-SUMO vector harboring the PMM variant. Individual 
colonies were used to inoculate 15-20 mL Luria broth (LB) containing kanamycin 
(50 µg/mL) and chloramphenicol (35 µg/mL). Starter cultures were grown 
overnight at 37 °C with shaking. The following day, glycerol was added to the 
starter cultures to a final concentration of 20%. The resulting stocks were flash 
frozen and stored at -80 °C.  
For expression of PMM variants, starter cultures were generated, 
inoculating 20 mL LB (kanamycin (50 µg/mL) and chloramphenicol (35 µg/mL)) 
with a stab of glycerol stock and grown at 37 °C shaking overnight. Growths of 1 L 
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LB containing kanamycin (50 µg/mL) were inoculated with 3-5 mL starter culture. 
Cells were grown at 37 °C until an OD600 ~0.6 -0.8 was reached and then induced 
with 1 mM isopropyl-β-D-thiogalactoside (IPTG). The temperature was lowered to 
16 °C and cells were harvested 12-16 hrs after IPTG addition via centrifugation 
(5,000 RPM x 15 min). Cells were pelleted in 3 L portions and stored at -80 °C.  
Cell paste were resuspended in lysis buffer (3 mL/g cell pellet) containing 
50 mM Tris pH 8.2, 500 mM NaCl, 10 mM imidazole, 5 mM MgCl2, and 1 mM DTT 
and at 4 °C for an hour followed by lysis via microfluidization (18,000 PSI). The 
lysate was clarified by centrifugation (100,000 x g for 35 minutes). The clarified 
supernatant was applied to a GE HisTrap 5 mL HP column using an AKTA fast 
protein liquid chromatography (FPLC) at 4 °C. The column was equilibrated and 
washed with lysis buffer and the protein was eluted with a 20 column volume (CV) 
linear gradient from 0-100% buffer B (50 mM Tris pH 8.5, 500 mM NaCl, 300 mM 
imidazole, 5 mM MgCl2, 1 mM DTT). Elution fractions containing the PMM variant 
were pooled based on the A280 trace and the SUMO tag was cleaved using SUMO 
protease (~500:1 ratio) overnight at 4 °C while dialyzing against 50 mM HEPES 
pH 7.5, 200 mM NaCl, 5 mM MgCl2, and 1 mM DTT.  
For PMM1 wt and PMM1 R180T/R183I, solid ammonium sulfate was added 
to the dialysate to 35% saturation. Following centrifugation (100,000 x g for 35 
minutes), the supernatant was brought to 50% saturation and centrifuged again. 
The subsequent pellet was resuspended in 50 mM HEPES pH 7.5, 16% w/v 
ammonium sulfate, 5 mM MgCl2, and 1 mM DTT. The cleaved PMM1 was 
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separated from uncleaved protein, SUMO tag, and SUMO protease via 
hydrophobic interaction chromatography using a GE Butyl 5 mM column on an 
AKTA FPLC at 4 °C and a step wise gradient (10% increments) of ammonium 
sulfate from 16% to 0% ammonium sulfate. Fractions were characterized via SDS-
PAGE and dynamic light scattering (DLS)- those with at least 90% purity and 80% 
monodispersity for crystallization, or further purified via size-exclusion 
chromatography (SEC) using a HiPrep 26/60 Sephacryl S-300 HR column. 
Alternatively, for PMM2 wt cleaved variant was purified from the SUMO protease 
reaction via SEC rather than via ammonium sulfate fractionation.  
3.2.2 Crystallization, data collection, and structure determination 
Initial crystallization hits were identified via sparse matrix screening with 
PMM1 wt (20 mg/mL) cocrystallized with 10 mM of either vanadate (Na3VO4), 
IMP, or α-D-glucose. The vanadate condition that yielded diffraction-quality 
crystals was optimized in grid screens resulting in optimized conditions of 175 mM 
ammonium acetate, 23% PEG 3,350, 0.1 M HEPES pH 7.5. Crystals grown in the 
presence of any of the three ligands were three dimensional diamond shaped and 
roughly 0.3 x 0.2 x 0.1 mm3 in size. Cocrystals of PMM1/D-glucose/vanadate 
complex were optimized in grid screens containing 20-200 mM TMAO; 10-30% 
PEG MME 2,000, and 0.1 M Tris pH 8.5 and were rectangular cubes measuring 
roughly 0.2 x 0.1 x 0.1 mm3. All harvested crystals were cryoprotected in Paratone-
N prior to cryocooling in liquid nitrogen.  
Diffraction data for PMM1/vanadate were collected at Stanford 
Synchrotron Radiation Lightsource (SSRL) on beamline 9-2 at the SLAC National 
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Accelerator Laboratory (Menlo Park, CA). Data were collected using a Dectris 
Pilatus 6M PAD detector (at 100 K) and processed using HKL2000.(111) Crystals 
belonged to the space group P43212 with unit cell parameters of a=b=51.69 Å, 
c=215.98 Å and angles α=β=γ=90°. Data were phased using molecular 
replacement (Phenix.autoMR).(112) The input model (PDB ID: 2FUC) was broken 
into two minimal domains: cap (res 97-192) and core (res 12-85, 199-256) followed 
by iterative model building, simulated annealing, and density modification using 
Phenix.Autobuild.(113) Structural refinements in phenix.refine(114) included X, Y, 
and Z (reciprocal space and real space), individual B-factors, TLS parameters, and 
stereochemistry and ADP weighting. Loop residues 86-96 and 193-198 were 
manually built into density after the first round of refinement. Once the Rwork was 
below 0.25, ligand was built into density and the structure further refined with 
water building. Validation of ligand placement included generation of polder and 
omit maps using Phenix.polder.(115) The data collection and refinement statistics 
are provided in Table 3.2. 
3.2.3 Differential scanning fluorimetry 
The melting temperature (Tm) of PMM1 and PMM2 was measured using 
differential scanning fluorimetry (DSF). PMM1 and PMM2 were diluted to 20 µM 
in buffer (50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM DTT) containing 10 x SYPRO 
Orange™ dye. Protein was then screened against a panel of compounds including 
substrates, intermediates, and activators (1 mM). Protein was then subjected to a 
temperature ramp from 4-95 °C in 1 °C increments. The first derivative plot of the 
raw fluorescence versus temperature is used to determine the Tm.  
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Space Group P43212 
Cell Dimensions 
 
a,b,c (Å) a=b= 51.69, 215.98 
α, β, γ (°) 90, 90, 90 
Wavelength (Å) 0.97946 
Resolution (Å) 1.95 (2.02-1.95) 
No. of total/unique reflections 291,175/21,673 
Completeness (%) 95.5 (85.8%) 
Multiplicity 13.4 (11.5) 
I/σ(I) 23.06/2.96 
Rmerge (%) 9.75 (65.8) 
CC1/2 0.998 (0.943) 
Refinement 
 
Resolution 37-1.95 (2.02-1.95) 
Reflections used in refinement 20,762 (1,818) 
Reflections used for Rfree 1,914 (174) 
Rwork/Rfree 0.1956/0.2333 











Bond lengths (Å) 0.013 
Bond angles (°) 2.22 
Ramachandran plot (%) 
 






3.2.4 Biochemical assays 
PMM1 phosphatase assay was conducted as described previously using the 
BioMol Green inorganic phosphate detection colorimetric discontinuous assay.(6) 
Briefly, assays were conducted using 60-800 nM enzyme, 50 µM G16P2, and 100 
µM IMP and vanadate inhibition was tested at concentrations ranging from 8 µM 
to 25 mM. To determine the IC50  of vanadate for PMM1, PMM1 inhibition was 
tested using 0.78 - 50 mM vanadate (2-fold serial dilutions) keeping the 
concentration of G16P2 (50 µM) and IMP (100 µM) constant. Data were fitted 
using GraphPad Prism 8 with the equation below:  
S=Smin + (Smax -Smin)/(1+(IC50/[I])h) (3.1) 
where Smax  and Smin are the maximum and minimum activity, respectively, h is the 
hill coefficient, and IC50 is the concentration of I at which the signal is reduced by 
50 %.  
PMM1 and PMM2 mutase activity with Glc1P as substrate was conducted 
by using glucose 6-phosphate dehydrogenase (G6PDH) as a coupling enzyme and 
measuring the production of NADPH at 340 nm (1:1 ratio of Glc6P consumption 
and NADPH production) as optimized previously.(5, 6) Galactose 1-phosphate 
(Gal1P) inhibition was conducted by varying the concentration of Gal1P. The 
percent activity was calculated using PMM2 wt activity in buffer as 100% activity.   
3.3 Results and Discussion 
3.3.1 Structural and kinetic analysis of vanadate binding 
The structure of PMM1 in complex with vanadate (VO3-) was determined to 
1.95 Å resolution (Figure 3.4 A&B). The data collection and refinement statistics 
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are provided in Table 3.2. PMM1/vanadate complex crystallized in the space 
group P43212 with unit-cell parameters of: 51.68, 51.69, 215.98 Å3, consistent with 
structures determined by both Silvaggi et al.(5) and by Ji et al.(6). The structure 
was phased using the unliganded PMM1 structure (PDB ID: 2FUC) as a model for 
molecular replacement. The backbone of PMM1 is nearly identical to that of the 
PMM1/Man1P structure (PDB ID: 2FUE, RMSD=0.24 Å). The enzyme is in the 
cap-open conformation which is not productive for catalysis. The overall distance 
between cap and core domain is approximately 7 Å, consistent with Man1P and 
IMP bound structures. Vanadate acts as a phosphoryl mimic and is bound in a 
similar orientation to the phosphoryl moiety of Man1P, located in the distal 
phosphoryl sub-site rather than the transferring site. Hydrogen-bond interactions 
between the oxygen atoms of vanadate and residues R143, R150, I187 (backbone), 
and S188 are present in both Man1P  and vanadate-bound structures (Figure 3.4 
B & C). Unsurprisingly, the B-factors for vanadate are relatively high compared to 
the average protein B-factor (69 versus 58, respectively), as it is a small molecule 
(98.9 Da) bound at a solvent exposed surface of the cap domain. Notably, this 
structure is the first example of a HAD mutase enzyme with phosphoryl mimic 
preference for binding in the distal sub-site over the transferring sub-site. This 
result indicates that the distal sub-site in PMM1 may exhibit higher affinity for 




Figure 3.4. Structure of PMM1 in complex with vanadate. A. PMM1 in complex 
with vanadate, PMM1 shown as cartoon depiction and vanadate is depicted by sticks, 
colored by heteroatom. The side chains of interacting residues are depicted as sticks, 
and magnesium ions are gray spheres. B. F0-Fc omit map of PMM1/vanadate, contoured 
to 5 σ. Polar interactions are depicted as yellow dashed lines, and interacting residues 
are labeled. C.  PMM1-Man1P structure (PDB: 2FUE), illustrating the hydrogen 
bonding interactions between substrate Man1P and PMM1 residues (cyan sticks) or 
water molecules (red spheres).  
 The PMM1/vanadate complex structure described herein supports 
the hypothesis that substrate binding and cap closing occurs via a “catch and close” 
mechanism. In this mechanism, the substrate binds to the cap domain, which then 
allows for conformational change to the closed, catalytically-competent 
conformation. Although vanadate was present in excess (10 mM, 14-fold excess to 
protein), density was present solely in the distal phosphoryl sub-site. Additionally, 
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all PMM structures determined thus far have the phosphoryl moiety bound in the 
distal sub-site.(5, 6)   
3.3.2 Inhibition of PMM1 phosphatase activity 
To further investigate vanadate binding, I sought to determine the 
inhibition of PMM1 by vanadate. Attempts to measure inhibition of mutase activity 
via vanadate were unsuccessful due to high absorbance backgrounds of the 
vanadate controls (absorbances greater than 1.0). Therefore, only inhibition of 
phosphatase activity was measured. The phosphatase activity of PMM1 was 
measured in the presence of IMP (100 µM) using G16P2 as a substrate using the 
BioMol Green assay. The IC50 of vanadate for PMM1 is estimated to be between 
12.5 and 6 mM based on a 60% reduction in signal with 12.5 mM vanadate (Figure 
3.5) which is 1,000-fold higher than the KM of PMM1 for G16P2 ( 8.5 µM(6)).  
Towards identifying inhibition preference for one sub-site, we employed a 
para-nitrophenolphosphate (pNPP) assay. For dephosphorylation to occur, pNPP 
must bind with the phosphoryl moiety in the transferring sub-site, leaving the 
distal sub-site unoccupied. If vanadate inhibition occurred solely through binding 
then no change in activity would be observed with pNPP. However, if vanadate 
binds to the transferring sub-site (in any ratio), then the activity of PMM1 with 
pNPP would decrease, and an inhibition constant for vanadate at the transferring 
sub-site could be calculated.  
Attempts to assess the inhibition specifically of the transferring sub-site by 
cross-validating with a para-nitrophenolphosphate (pNPP) assay were 
unsuccessful because pNPP is not a substrate for PMM1 even in the presence of 
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IMP (results not shown). It is likely that the phosphoryl moiety of pNPP does not 
bind or also binds in the distal sub-site and therefore is not in a catalytically 
competent conformation. The finding that pNPP was not a substrate for PMM1 was 
surprising since, this is contrary to the findings for a prototypical HAD mutase, β-
PGM. β-PGM and PMM utilize the same catalytic core, but have evolved different 
cap types to catalyze the same chemical transformations. Dr. Daniel Saltzberg 
determined that β-PGM binds vanadate with a KI of 50 µM using pNPP as a 
substrate.(116) It appears that PMM1 and β-PGM diverge with respect to ligand 
affinity for the distal phosphoryl sub-site. Typically, vanadate binds to the active 
site of this family of sugar mutases and serves as a transition state analog by 
mimicking the addition of either water (phosphatase) or the phosphosugar 
substrate (mutase) to the phosphoaspartyl intermediate. However, in the case of 
PMM1, vanadate binds in the distal sub-site reflecting its its function as a 




Figure 3.5. Inhibition of PMM1 phosphatase activity by vanadate. The 
phosphatase activity of PMM1 was measured in the presence of IMP (100 µM) and 
G16P2 as a substrate using BioMol Green, a colorimetric discontinuous assay that 
measures inorganic phosphate. Error bars presented as standard deviation (n=2). 
3.3.3 Galactose 1-phosphate inhibition of PMM isozymes 
Patients with malfunctioning GALT enzymes exhibit a buildup of galactose 
1-phosphate (Gal1P) in their tissues, leading to hypoglycosylation. In addition to 
the inability to synthesize GDP-Gal due to the GALT defect could lead to 
hypoglycosylation, it is also possible that elevated levels of Gal1P inhibits the 
enzymes responsible for N-linked glycosylation biosynthesis. The most probable 
point of inhibition would be the conversion of Man6P to Man1P, catalyzed by 
PMM2. We set out to investigate whether Gal1P could inhibit PMM2. In vitro, 
PMM2 transform phosphohexose  does not distinguish in vitro between Glc and 
Man substrates, raising the possibility that it could transform additional 
phosphohexoses. Further, β-PGM is also inhibited by Gal1P. Based on the fact that 































we propose that inhibition of Gal1P by PMM2 contributes to hypoglycosylation and 
it is not exclusively the result of deficits in UDP-Gal concentrations.  
We aimed to determine if PMM isozymes are inhibited by Gal1P by testing 
inhibition of mutase activity. PMM mutase activity, producing Glc6P, was 
monitored by coupling with G6PDH and the production of NADPH measured at 
340 nm. The inhibition of both PMM1 and PMM2 mutase activity was tested first 
at 5 and 50 mM Gal1P, in the presence of saturating concentrations (1 mM) of 
Glc1P substrate (KM = 7.5 µM). As depicted in Figure 3.6, PMM2 exhibits 
inhibition at both Gal1P concentrations, whereas PMM1 is not inhibited by Gal1P 
even at 50 mM concentration.  
 
 
Figure 3.6. Inhibition of PMM1 and PMM2 by Gal1P. Inhibition of mutase 
activity of PMM2 and PMM1 by Gal1P against G1P as substrate. The formation of G6P 
was measured via the coupling enzyme G6PDH and formation of NADPH at 340 nm. 
Error bars presented as standard deviation (n=2). Activity normalized to 1.0 using 























Although the IC50 and KI of Gal1P for PMM2 was not determined, this initial 
study confirms that Gal1P is only an inhibitor of the PMM2 isozyme. This is the 
only example thus far of in vitro differences in mutase activity between PMM1 and 
PMM2. Gal1P differs from Man1P at two stereocenters, C2’ and C4’ positions. 
Previous kinetic experiments by Silvaggi et al. identified that the catalytic 
efficiencies of PMM1 and PMM2 using either Man1P or Glc1P as substrates are all 
within one order of magnitude of eachother.(5) Therefore, in vitro, there is no 
preference for the stereochemistry at the C2’ position and it is likely that the 
difference in discrimination of Gal1P between PMM1 and PMM2 is at the C4’ 
position of Gal1P. In the structure of PMM1/Man1P the C4’ hydroxyl is making 
interactions with R28 and a water molecule. As the structure of PMM1/Man1P is 
in the cap-open conformation, leaving Man1P exposed to solvent, it is difficult from 
the structure alone to deduce possible variations in the binding of Gal1P to PMM1 
and PMM2 in vitro.  
Even though the concentration of Gal1P required to inhibit PMM2 is high, 
the intracellular Gal1P concentrations can be as high as 5 mM in uncontrolled 
galactosemia patients. The intracellular concentrations of Man6P in patients with 
CDGs can reach up to 25 mM, whereas normal intracellular concentrations of 
Man6P are reported to be ~100 µM in rat liver tissue.(117) The actual intracellular 
concentrations of Man6P in human cells is unknown at this time. Taken together, 
these intracellular concentrations validate the in vitro kinetic analysis of Gal1P 
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inhibition of PMM2. Determining the KI of Gal1P for PMM2 will allow for a better 
comparison of affinity and physiological concentrations of Gal1P.  
3.3.4 DSF analysis of PMM isozymes 
The effect of metabolites (substrates, products, activators, transition-state 
mimic) on thermal stability of PMM isozymes was assessed to identify in which 
state each isozyme was most stable (Figure 3.7).  The change in melting 
temperature (Tm) was measured  using differential scanning fluorimetry (DSF). 
Briefly, PMM1 or PMM2 (20 µM) was incubated with a panel of substrates, 
activators, and transition-state mimics (2 mM). A temperature shift of 2 °C or 
greater is considered significant.(118) PMM1 exhibited enhanced thermal stability 
in the presence of nucleotide monophosphates, specifically IMP, GMP, AMP, and 
xanthosine 5-monophosphate (XMP). PMM2 was only tested against IMP and it 
did not exhibit a significant ΔTm. However, when screened against the panel of 
activators (G16P2 and fructose 1,6-bisphosphate (F16P2)), substrates, and 
transition-state mimics, PMM1 did not exhibit any significant Tm shift whereas 
PMM2 exhibited stabilization in the presence of G16P2, F16P2 Glc6P, and Glc1P. 
Notably, a ΔTm of 9.6 °C was measured for PMM2 in the presence of both 
bisphosphorylated activators.  
These observations are consistent with the fact that PMM2 is a true mutase, 
and therefore it exhibits stabilization in the activated form, whereas PMM1, 
although similar in catalytic efficiency, does not appear to act as a mutase in vivo. 
Therefore, it is unsurprising that PMM1 does not follow this same trend in 
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stabilization by G16P2 and F16P2. The stabilization of PMM1 by NMPs is likely due 
to its role in regulating the phosphatase activity of PMM1.  
 
Figure 3.7. Thermal melting temperatures of PMM isozymes. The thermal 
melting temperatures (TM) of PMM2 and PMM1  in the presence of substrates, 
activators, products, or transition-state mimic were measured via DSF. The ΔTM values 
were calculated in the presence of ligand, subtracting the buffer only control from the 
TM and plotted for (A) PMM2, (B) PMM1, and (C) PMM1 in the presence of nucleotides.    
3.4 Conclusions and Future Directions 
The X-ray crystal structure of PMM1-vanadate complex identified a 
discrepancy in binding affinity for the distal and transferring phosphoryl sub-sites. 
It revealed preferential binding to the cap domain and supports a “catch and close” 
mechanism of substrate binding to the cap domain and subsequent closure into 
the catalytically productive state, following an induced fit model of substrate 
binding. Furthermore, we are interested in determining the minimal substrate 
requirement to induce cap closure for both PMM1 and PMM2. The divergence of 
PMM isozymes from the well-characterized HAD phosphohexomutase, β-PGM 
provides support for pseudoconvergent evolution within the HADSF. Their 
structural divergence in the cap domain gives rise to differences in binding 
preference to the distal phosphoryl sub-site, and possible differences in how ligand 
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binding is coupled to cap motion. Experimental investigations on PMM isozymes 
on protein dynamics in the presence of substrate could include NMR and HDX 
experiments in the presence and absence of ligands that mimic the reaction 
trajectory. Validating this mechanism using QM/MM simulations of PMM1 and 
PMM2 could also reveal any differences in dynamics between the two isozymes.  
Efforts to determine the crystal structure of human PMM1 in the closed, 
catalytically competent conformation have not been successful. A dataset was 
collected of PMM1 in a new space group, C 2 2 21 at the Advanced Photon Source 
(APS) Life Sciences Collaborative Access Team (LS-CAT) beamline 21-ID-D at 
Argonne National Laboratory. However, phases for the data could not be 
computed, and therefore the structure has not been determined. The identification 
of a new crystal form may provide a new conformation of PMM1 in crystallo. 
Optimizations of this crystallization condition (20 mM TMAO, 20% polyethylene 
glycol monomethyl ether 2,000, 0.1 M Tris pH 8.5) for PMM1 cocrystallized with 
ligands (IMP, G16P2, or Glc6P/vanadate) could allow for determination of PMM 
in a catalytically competent conformation and identify the binding determinants 
of substrate to the core domain.  
Although PMM1 and PMM2 share high sequence identity, mutations to 
these isozymes exhibit different phenotypes- mutations to PMM2 are linked to 
CDGs, whereas PMM1 knockout models present no changes in phenotype. We 
determined via in vitro kinetic assays that Gal1P inhibits PMM2 but not PMM1. 
Although there is no direct physiological evidence of Gal1P inhibition of PMM2, 
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the phenotypic hypoglycosylation pattern of N-glycans in galactosemia patients 
resembles that of CDG-PMM2 patients and could be a result of PMM2 inhibition 
in vivo. Therefore, it is possible that it is not solely the lack of GDP-Gal substrate 
in galactosemia that causes hypoglycosylation, but rather build-up of Gal1P which 
in turn may inhibit PMM2 and block GDP-Man synthesis, and therefore N-linked 
glycosylation. Although the inhibition of PMM2 requires high concentrations of 
Gal1P, this work demonstrates physiological relevant. The relative ratios of Gal1P 
to Glc1P in inhibition assays were 50:1 (maximum), which showed an 85% 
decrease in activity. However,  Gal1P levels can reach 5 mM intracellularly in 
patients with untreated galactosemia.(105) Follow-up in vitro experiments include 
determining the KI of Gal1P for PMM2 and crystallographic studies of PMM2 in 
complex with Gal1P to identify the unique binding determinants that allow for the 
inhibition of solely the PMM2 isozyme. Cell-based metabolomic and proteomic 
experiments could identify possible connections and feedback loops between 
galactose metabolism and N-linked glycosylation pathways. 
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CHAPTER FOUR: Mapping sequence similarity network reveals 
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4.1.1 Bacterial glycosylation 
As described in Chapter 1, bacterial en bloc glycosylation pathways are 
systematic ways of building a glycan chain on a lipid carrier. In bacteria, these 
pathways use undecaprenol phosphate (UndP) as the lipid carrier. However, in 
archaea and eukaryotes, dolichol phosphate (DolP) is utilized.(119) Distinct 
operons for each glycoconjugate pathway are present in bacterial systems.(18) The 
variety of sugar-modifying enzymes are responsible for the diversity of 
glycoconjugate products, including peptidoglycan (PG)(120), wall teichoic acid 
(WTA)(121), glycoproteins(122), O-antigen of lipopolysaccharide (LPS)(123), and 
capsular polysaccharide (CPS)(124, 125). In the Campylobacter jejuni N-linked 
glycosylation pathway (Pgl), for example, a dehydratase (PglF), aminotransferase 
(PglE), and acetyltransferase (PglD) work sequentially to transform a UDP 
activated glucosamine (UDP-GlcNAc) into UDP activated N’N-diacetyl 
bacillosamine (UDP-diNAcBac), a sugar unique to prokaryotes.(126–129) In 
bacterial glycoconjugation pathways, the first membrane committed step is 
catalyzed by a phosphoglycosyl transferase (PGT), which links a soluble sugar to a 
membrane resident PrenP, undecaprenol phosphate (UndP).(12, 16) Additional 
sugar moieties are added sequentially by glycosyl transferases (GTs)(22), followed 
by translocation from the cytoplasmic to the periplasmic space by a flippase(130). 
Lastly, the completed oligosaccharide is transferred to its target by oligosaccharyl 
transferases (OTases).(131, 132) The C. jejuni N-glycosylation pathway scheme is 
depicted in Figure 4.1 as an example for bacterial glycosylation pathways. 
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However, in some pathways, sugar modifying enzymes are not necessary as they 
use common NDP-sugar pools including UDP-GlcNAc and UDP-GalNAc. This 
chapter will focus on the first membrane committed step in bacterial en bloc 
glycosylation pathways, catalyzed by a phosphoglycosyl transferase (PGT).  
There are two superfamilies of PGTs which catalyze the same reaction, 
linking a soluble sugar to PrenP, the polytopic PGT (polyPGT) and monotopic PGT 
(monoPGT) superfamilies. Although the enzyme superfamilies catalyze the same 
chemical reaction, their mechanisms, pathways in which they function, and 
structures differ substantially. PolyPGTs and monoPGTs often co-occur in a single 
organism, allowing for biosynthesis of distinct glycoconjugate products through 
differing pathways.(18, 133) As enzymes of bacterial biosynthetic pathways are 
 
Figure 4.1. C. jejuni N-linked glycosylation pathway. 
Nucleotides are represented as pentagons, UDP in dark yellow. The lipid carrier is 
represented as black bonds, and the phosphate moiety as an orange circle. 
Monosaccharides are represented following the Symbol Nomenclature for Glycans 
(SNFG) for the following sugars: GlcNAc (blue square, diNAcBac (blue hexagon), 
GalNAc (yellow square), Glc . Common CDGs are notated at the respective enzymatic 




encoded in unique operons, the polyPGT and monoPGT genes are not localized to 
the same operon. Their mechanisms, structures, and pathways will be discussed in 
the following sections.  
4.1.2 Polytopic PGT superfamily 
Polytopic PGT (polyPGT) superfamily members, both prokaryotic and 
eukaryotic, are comprised of 10 or more transmembrane (TM) helices with the 
active site at the plane of the membrane. Prokaryotic members are typified by 
phospho-MurNAc-pentapeptide translocase (MraY), WecA, and TagO members, 
enzymes involved in PG, O-antigen, and WTA biosynthesis, respectively.(134–136) 
Additional prokaryotic members include WbcO (LPS biosynthesis)(137), WbpL 
(LPS biosynthesis)(138), and RgpG (rhammose-glucose polysaccharide 
biosynthesis)(139). All prokaryotic members use UndP as the lipid carrier. 
Eukaryotic members include N-acetylglucosamine-1-phosphate transferases 
(DPAGT1) which functions in the human N-linked glycosylation pathway, and uses 
dolichol phosphate as a lipid carrier, rather than UndP.(9) Members of the 
polyPGT superfamily use a UDP-N-acetylhexosamine sugar such as UDP-N-
acetylglucosamine (UDP-GlcNAc) or UDP-N-acetylgalactosamine (UDP-
GalNAc)(10) as the sugar substrate.  
Aquifax aeolicus MraY was the first structurally characterized member of 
the polyPGT superfamily (PDB ID: 4J72, Figure 4.2A).(16) It consists of 10 TM 
helices (TMHs) and forms a dimer in the X-ray crystal structure. The dimeric state 
in crystallo was confirmed to be the biologically relevant oligomeric state.(16) 
Structures of Clostridium bolteae MraY (PDB ID: 5JNQ)(47) and human DPAGT 
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(PDB ID: 5O5E)(9) in complex with the antibiotic tunicamycin and A. aeolicus 
MraY bound to muraymycin D2, another nucleoside analog, (PDB ID: 5CKR)(140) 
reveal the conserved substrate binding site of polyPGT members. 
 
Figure 4.2. Polytopic phosphoglycosyl transferases. A. Structure of A. aeolicus 
MraY (PDB ID: 4J72) positioned in the membrane using the positioning of protein in 
membrane (PPM) server(141). Membrane plane is depicted as gray spheres. Each 
subunit of the MraY dimer is colored a different shade of magenta. B. The ternary 
mechanism of polyPGT members uses a magnesium ion to stabilize and orient the UDP-
sugar substrate for attack by the polyprenol phosphate substrate.   
The catalytic mechanism of MraY and WecA were only recently determined 
to proceed through formation of a ternary complex.(10) Initial kinetic analyses 
identified residues essential for catalysis in all members of the polyPGT 
superfamily: D117, D118, and D265 (A. aeolicus MraY numbering). MraY also has 
a conserved HHH motif (324-326, A. aeolicus MraY). Crystallographic evidence 
confirms D265 (A. aeolicus MraY) is involved in coordinating the Mg2+ 
cofactor.(16) Based on radiolabeling and site-directed mutagenesis studies, Al-
Dabbagh et al. confirmed that Bacillus subtilis MraY D98 (D117, A. aeolicus MraY) 
/ D72 Thermotoga maritima WecA) serves to deprotonate the PrenP substrate. 
The authors propose that the Mg2+ cofactor coordinates the pyrophosphate of the 
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UDP-sugar substrate. Additional site-directed mutagenesis experiments confirm 
H324 is absolutely required for catalysis. However, the role of conserved residues 
D118, and the three histidine residues identified by Chung et al(16) is yet to be 
resolved. It is predicted that the HHH motif’s role is in sugar substrate recognition 
and specificity.  
4.1.3 Monotopic PGT superfamily 
The monotopic PGT (monoPGT) superfamily can be divided based on 
domain structure, into three distinct families of enzymes: small, large, and 
bifunctional enzymes. Enzymes in the monoPGT superfamily function in the 
following pathways: protein glycosylation (N- and O-linked), O-antigen/LPS 
biosynthesis, and colonic acid/CPS biosynthesis.(18)  
 
Figure 4.3. Small and large monoPGT family structures. A. The X-ray crystal 
structure of C. concisus PglC (PDB: 5W7L) with magnesium cofactor (dark gray sphere) 
and phosphate molecule (sticks). B. Structure prediction model (RaptorX contact 
prediction(142)) of E. coli WcaJ Both structures are positioned in membrane using PPM 
server(141), membrane planes are shown as light gray spheres. 
The small monoPGT family are the smallest members (ca. 200 amino acids) 
and are comprised of one domain, termed the PGT core domain: the minimal 
catalytic unit for phosphoglycosyl transferase activity. Recent structural 
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characterization of Campylobacter concisus by Ray et al. elucidated a novel 
mechanism of membrane insertion using a re-entrant membrane helix (RMH) as 
part of the core catalytic domain.(12) The characteristics of the RMH will be 
investigated using bioinformatic tools in Chapter 5. This unique monotopic 
topology allows for PglC to interact with only one leaflet of the membrane. Large 
monoPGTs have 4 TMHs and a soluble cytoplasmic domain of unknown function 
at the N-terminus of the PGT core domain (Figure 4.3B).(143) The bifunctional 
family of monoPGTs include an accessorizing domain of distinct function. In this 
work, novel bifunctional enzymes were identified and catalogued into subclasses 
of the bifunctional family. The only biochemically characterized member of the 
bifunctional family is Neisseria gonorrhoeae PglB, which contains an N-
acteyltransferase domain fused to the PGT core domain.(144) In this example the 
N-acetyltransferase domain catalyzes the acetyltransfer to the C4 amino group on
the intermediate sugar, producing UDP-diNAcBac, which is then utilized by the 
PGT domain, producing the Und-PP-diNAcBac product. A summary figure 
delineating the superfamily, family, and subclass nomenclatures of PGT enzymes 



















































































































































































All monoPGT enzymes require a catalytic Asp-Glu dyad (D93-E94, C. 
concisus numbering) and a magnesium ion cofactor for catalysis. The Asp-Glu 
dyad coordinates the magnesium cofactor and the aspartyl residue serves as the 
nucleophile in the enzymatic reaction. In contrast to the ternary complex 
mechanism followed by the polyPGTs, monoPGTs employ a ping-pong 
mechanism(11). First, the nucleotide-activated sugar, UDP-diNAcBac for C. jejuni 
and C. concisus PglC, binds to the active site. Next, the  phosphoglycosyl-enzyme 
intermediate is formed by nucleophilic attack of the aspartyl residue (D93 C. 
concisus PglC). After release of the first product, UMP, UndP binds and accepts 
the phosphosugar from the aspartyl residue, producing the UndPP-linked sugar 
product (Figure 4.5).(11) Crystallographic evidence confirms the DE motif also is 
involved in coordinating the magnesium ion.(12) Mutagenesis studies have 
confirmed that, in addition to D92 and E93 of the dyad, R87 and R111 in C. jejuni 
PglC are also essential for catalysis. R87 coordinates the magnesium cofactor 
(through the backbone carbonyl) and assists in charge mitigation of the phosphoryl 
moiety. R111 is predicted to interact with the nucleotide base component of the 
NDP-sugar substrate.(12, 14) Although R111 is not absolutely conserved across all 
members, how or if nucleotide identity varies between family members is not well 




Figure 4.5. MonoPGTs employ a ping-pong mechanism for catalysis. 
Residues are labeled based on C. concisus PglC residue numbers.  
4.1.4 Evidence for regulation in bacterial glycosylation pathways 
Regulation of glycosylation pathways in bacteria has recently been 
investigated as the glycoconjugates they synthesize often function as virulence 
factors. The PGT reaction, catalyzed by either the monoPGT or polyPGT 
superfamily, is the first membrane-committed step in the pathway. Therefore, it 
may serve as a point of regulation of flux through a variety of glycosylation 
pathways all using UndP as the lipid carrier. If this reaction isn’t tightly regulated, 
there could be a shortage of lipid carrier, which could affect all glycosylation 
pathways in an organism.  
The major mechanism of regulation observed is via two-component 
regulation systems which regulate glycosylation pathways either at the 
transcription level via transcription factors or at the enzyme level via 
phosphoregulation. of enzymatic activity. The regulator of capsule synthesis (Rcs) 
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two component system in Excherichia coli colanic acid biosynthesis is an example 
of regulation at the transcription level. An example of regulation at the 
transcription level The regulator of capsule synthesis (Rcs) two-component system 
in the Escherichia coli colanic acid biosynthesis is an example of regulation at the 
transcription level. There is a transmembrane sensor domain (RcsC), a response 
regulator (RcsB), and a positive regulator (RcsA) which function to regulate the 
transcription and subsequent expression of colanic acid biosynthetic genes.(146) 
At 37 °C, RcsA protein levels are low, and thus colanic acid is not synthesized. At 
lower temperatures or in stressful environments, the RcsC sensor domain 
phosphorylates the RscB regulator, which in turn activates RscA, leading to 
upregulation of genes in the colanic acid biosynthetic pathway.(146, 147)  
An example of a two-component system regulating via phosphorylation is 
the  Wzy-dependent polymerization pathways (pathways using Wxz/Wzy as the 
flippase and transferase at the completion of the pathway). There are conserved 
transmembrane signaling and protein tyrosine kinase (PTK) domains that serve to 
regulate the respective pathways. In each pathway containing a PTK, there is a 
corresponding phosphatase to dephosphorylate the protein tyrosine kinase, and 
therefore further control pathway regulation.(148) 
The regulatory systems for production of CPS and EPS in Gram-positive 
bacteria have been better resolved than their Gram-negative counterparts. Systems 
have been described with respect to enzymatic regulation within: the EPS 
pathway(149) in Streptococcus thermophilus, and the CPS pathway (Cap 
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operon)(150) in Staphylococcus aureus.  Notably, both of these examples include 
phosphoregulation of a monoPGT enzyme, which results in regulation of flux 
through the pathway. The transmembrane and kinase domains of the two-
component systems are two separate proteins, with EpsC and CapA corresponding 
to the transmembrane domain and EpsD and CapB to the tyrosine kinase 
domain(45). In S. aureus CPS, CapA signals CapB to autophosphorylate in an ATP-
dependent manner, followed by phosphotransfer to CapM (monoPGT) at a highly 
conserved tyrosine residue (Y157). This phosphorylation event increases the 
activity of CapM, resulting in an increase in pathway flux (lipid II production), 
therefore positively regulating the CPS pathway.(150)  
Taken together, there appears to be diverse means of regulation of bacterial 
glycosylation pathways, some of which occur at the PGT reaction. Notably, these 
regulatory events in pathways producing essential cellular wall components or 
necessary virulence factors in pathogenic bacteria may serve to control the 
pathogenesis of these respective organisms(148). Further, in commensal bacteria 
regulation of CPS or EPS production may modulate their respective host-cell 
interactions.  
4.1.5 Chapter aims 
Chapter 4 employs bioinformatic tools to catalogue and annotate the 
monoPGT superfamily through creation and analysis of a sequence similarity 
network (SSN). Prior to this work, the monoPGT was broken into three families: 
small, large, and bifunctional. However, the bifunctional enzymes were thought to 
only include fusion enzymes to N-acetyltransferase enzymes. The work described 
92 
herein, identified and catalogued three subclasses within the bifunctional family of 
PGT domains fused to one of the following domains: sugar modifying, glycosyl 
transferase, or regulatory. The presence of regulatory domain containing fusions 
provides more direct evidence for regulation at the PGT reaction. Interestingly, a 
unique fusion containing both a polyPGT and monoPGT domain was also 
identified, providing a possible evolutionary link between the two superfamilies.  
4.2 Materials and Methods 
4.2.1 Sequence dataset curation and SSN generation 
Sequence dataset curation for the sequence similarity network (SSN) was 
conducted following the methods described by Copp et al..(151) Briefly, all 
sequences in the InterPro family IPR003362 (63,152 sequences) were downloaded 
from UniProt (www.uniprot.org) and converted to FASTA format using 
Galaxy.(152)  The dataset also includes one PDB entry (C. consisus PglC, 5W7L) 
and 9 biochemically characterized enzymes.(11, 14, 48, 144, 150, 153–156) The 
dataset was reduced using the Cluster Database at High Identity with Tolerance 
(CD-HIT) webserver(157) (http://weizhongli-lab.org/cdhit_suite/cgi-
bin/index.cgi) with two sequential cutoffs by percent identity (90% and 70%). The 
70% identity reduction dataset reduced the number of sequences from 63,152 to 
19,221 non-redundant sequences. All eukaryotic sequences (28) were removed, as 
manual inspection of codon usage analysis indicated they were most likely the 



























































































































































































































































































































































































































































































































All-by-all BLAST calculations were executed using the Enzyme Function 
Initiative-Enzyme Similarity Tool(158) (EFI-EST; https://efi.igb.illinois.edu/efi-
est/) with an alignment score threshold of 90, and further filtering by sequence 
length with a minimum and maximum requirement of 180 and 1000 amino acids, 
respectively (note that 180 should be of sufficient length to include the catalytic 
core). To facilitate visualization, the final network generated was 40% 
representative, collapsing sequences of 40% identity into a representative node 
(8,927 nodes and 58,663 edges), and visualized using Cytoscape.(159) 
4.2.2 Genome neighborhood network 
Genome neighborhood networks and diagrams were generated using the 
Enzyme Function Initiative-Genome Neighborhood Tool(160) (EFI-GNT;  
https://efi.igb.illinois.edu/efi-gnt/) with the SSN generated above (BLAST E-
value of 1 x 10-90). The neighborhood reading frame was set to 20-frames and the 
minimal co-occurrence was set to 20%. Additional genome neighborhood 
diagrams were generated using the FASTA search option on the EFI-GNT 
webtool.(160)  
4.2.3 Phylogenetic reconstruction 
The representative node comprised of the largest number of sequences was 
selected from each of the largest 100 clusters (based on total number of 
representative nodes in cluster). Biochemically or structurally characterized 
members were also included (E. coli WcaJ, S. enterica WbaP, S. aureus CapM, N. 
gonorrhoeae PglB, C. jejuni PglC, and C. concisus PglC, UniProt IDs listed in 
Table 4.1). Lastly, curated sequences of additional sugar modifying or glycosyl 
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transferase bifunctional enzymes localized to smaller clusters not represented in 
the largest 100 clusters were included. A multiple sequence alignment and 
phylogenetic reconstruction of the curated sequences was generated using 
ClustalOmega(161). The phylogenetic reconstruction was visualized using the 
Interactive Tree of Life webserver (https://itol.embl.de/).(162) The UniProt IDs 
contained in the reconstruction starting with the starred sequence (Figure 4.14) 
and following clockwise are provided in Appendix A5 (Table A5.1).  
4.2.4 Structure prediction, structural analysis and comparison calculations  
Deep-learning structure prediction models were generated using RaptorX 
Contact Prediction(142). The models were visualized and analyzed using UCSF 
Chimera.(163) Homology models were generated either using Phyre2(164) or 
RaptorX structure prediction.(165)  
4.3 Results and Discussion 
4.3.1 Global mapping of the monotopic PGT superfamily 
The sequence dataset for the monoPGT superfamily was curated from the 
InterPro family (IPR003362) using methodology described by the Babbitt and 
Copp laboratories(151) followed by an all-by-all pairwise alignment at an E-value 
of 1 x 10-90 using the EFI-EST webtools.(158) The 40% representative node network 
is representative of 38,878 non-redundant sequences (<95% sequence identity) 
comprising 8,927 nodes (18,571 sequences) and 58,663 edges. Nodes are grouped 
into 1,359 unique clusters comprising a total of 6,833 unique nodes. The remaining 
nodes (2,094 nodes) are classified as singletons, meaning that they are not 
connected by an edge to any other node. Visualization of the network by domain of 
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life using Cytoscape(159) shows the superfamily as predominantly prokaryotic, 
aside from a single cluster of archaeal nodes and a few additional archaeal nodes 
included in the largest cluster. The archaeal enzymes fall within the large 
monoPGT subclass,  consisting of 4 TMHs, a cytoplasmic domain, and the core 
catalytic domain. Although the UniProt database contains 28 eukaryotic sequences 
corresponding to the monoPGT superfamily (IPR003362), investigation of codon 
usage and frequencies determined that they are misannotated as eukaryotic, and 
in fact are bacterial in origin. Notably, the network includes three families of 
monoPGT enzymes: small, large, and bifunctional. Upon further analysis of 
domain architectures, we suggest a breakdown of the bifunctional family into three 
subclasses of fusion proteins containing one of the three domains: sugar-







Figure 4.6. Sequence similarity network of the monoPGT superfamily 
colored by domain of life (A) or subclass (B). The 40% representative node 





4.3.2 Analysis of bifunctional/fusion monoPGTs 
The bifunctional family of monoPGTs comprise 4% of the superfamily 
(18,571 non-redundant sequences), with the bifunctional family categorized into 
three subclasses: sugar modifying (Figure 4.6B red), glycosyl transferase (GT) 
(Figure 4.6B yellow), and regulatory domain (Figure 4.6B cyan) containing 
fusions. Additionally, two clusters of enzymes contain domains from both polyPGT 
and monoPGT superfamilies fused together (Figure 4.6B  magenta). Some 
domains were not included in these classifications because of their low frequency 
and poor characterization (Figure 4.6B gray). All outlier families are included in 
Appendix 5 (Figure 4.6B  light pink).  
Presence of fusions containing either sugar-modifying or glycosyl 
transferase domains suggests investigation into whether they occurred as gene 
fusion events (operon architecture driven) or were driven by pathway throughput 
(sequential steps in pathway)(166). Together, the identification and presence of 
fused monoPGT proteins is consistent with potential cross-talk and interaction of 
proteins within a glycoconjugate pathway. In the case of the GT-monoPGT fusion 
enzymes, biochemical evidence corroborates close interaction- likely direct 
protein-protein interaction of these enzymes in the pathway. Reconstitution of the 
Campylobacter GTs (PglA, PglJ, PglH, and PglI) in vitro demonstrates complete 
transformation to final product GalNAc-α1,4- GalNAc-α1,4-(Glcβ1,3)- GalNAc-
α1,4- GalNAc-α1,4-GalNac-α1,4-diNAcBac.(22) The lack of detectable 
accumulation of intermediates in this system suggests that there is close 
interaction between these pathway enzymes(22).  
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The identification of fused regulatory domains suggests the possibility of 
pathway regulation. Previously, characterization of regulation via phosphorylation 
within the capsular polysaccharide pathway in Staphylococcus aureus showed that 
phosphorylation of the monoPGT led to increase in total lipid II production(150). 
The monoPGT/regulatory domain enzymes represented in the SSN, often 
phosphoregulatory, may serve a similar function in their respective pathways.  
A topology diagram depicting the proposed N to C architecture for a 
representative from each subclass is shown in Figure 4.7. In all cases except for 
the polyPGT-monoPGT fusion enzymes, the monoPGT domain can occur at either 
the N-terminus or the C-terminus, depending on the fused enzyme; there is no 




Figure 4.7. Topology diagrams of bifunctional monoPGT subclasses. 
Representative subfamilies of bifunctional monoPGT enzymes. Predicted topologies of 
fusions of the PGT core domain modeled with representative enzymes with (A) sugar-
modifying enzymes (represented by aminotransferase (WbpE as model), (B) glycosyl 
transferases (GT-B fold, WbnH as model), (C) regulatory domains (SpoIIAA as model), 
and (D) polyPGT (MraY as model). In all cases the PGT domain is represented by PglC 
at the C-terminus. Topology diagrams were generated based on experimentally 
determined structures using the PDB ID: 5W7L for the monoPGT domain and the 
following PDB IDs for the fused domain: A. 3NU8, B. 4XYW, C. 1TIL, D. 4J72. 
4.3.3 Sugar-modifying bifunctional enzymes 
A variety of enzymatic transformations on nucleotide activated sugars occur 
within glycoconjugate pathways to afford the unique sugar building blocks  such 
as N,N’-diacetylbacillosamine (diNAcBac), N-acetyl quinovosamine, (QuiNAc), or 
N-acetylfucose (FucNAc). These transformations often involve dehydration, either 
retaining or inverting the stereochemistry, aminotransfer, N- or O-acetylation, 
and/or reduction (Figure 4.8). Within the context of the monoPGT superfamily, 
there are 10 unique superfamilies of sugar-modifying enzymes fused to a 
monoPGT either at the N-terminus or the C-terminus. Eight of the 10 
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superfamilies can be confidently functionally assigned based on sequence 
conservation (summarized in Table 4.2).  
 
Figure 4.8. Example sugar modifying reactions. General dehydratase (reactions 
A-C), aminotransferase (D), acetyltransferase (E), and reductase (F) reactions are 
shown at position C4 or position C6 (dehydratase only) of the NDP-hexose substrate. 
The most prevalent sugar-modifying bifunctional enzymes include a 
dehydratase domain (either stereochemistry retaining or inverting). The well-
characterized, stereochemistry-retaining 4,6 dehydratase enzymes, PglF (N-linked 
glycosylation) and CapD (capsular polysaccharide), share conservation of a three-
residue motif: Thr395, Asp396, and Lys397 (numbering for C. jejuni PglF).(126, 
167) In contrast, the stereochemistry-inverting dehydratases involved in 
pseudaminic acid biosynthesis (flagellin post-translational modification), FlaA1 
and PseB, retain the Thr, Asp, Lys motif, yet do not utilize the Thr for 
dehydrogenation of the C4 hydroxyl of the sugar moiety, but instead utilize a Tyr 
in a position non-homologous to any in the triad(168). In all of the 
stereochemistry-retaining 4,6 dehydratases, this Tyr is mutated to a Met. 
Enzymatic function of sugar modifying domains for members of both classes of 
dehydratases were inferred by using these sequence markers in conjunction with 
overall sequence identity and superfamily identifiers. Altogether, 26 
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stereochemistry retaining and 63 stereochemistry inverting 4,6-dehydrataese 
fusions with monoPGTs were identified (Table 4.2). 
 
Table 4.2. Sugar modifying families 
 
InterPro Family 








(IPR003869) CapD (37-41%)  C2’,4’ dehydratase C-term 
Hexapeptide repeat 
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Another large group of bifunctional enzymes included the monoPGT 
domain (either small or large) fused to an N-actetyltransferase. This sugar 
modifying enzyme catalyzes the transfer of an acetyl group from acetyl CoA to the 
N’4 position in the modified sugar producing UDP-diNAcBac followed by linkage 
to UndP catalyzed by the monoPGT.(144) The only biochemically characterized 
member, N. gonnorrhoeae PglB, contains a small monoPGT domain with an N-
acetyltransferase domain at the C-terminus of the proteinBased on the operon 
architecture of these members, N-acetyltransferase-monoPGT fusions are not 
found solely in N-linked glycosylation pathways. Other predicted pathways include 
exopolysaccharide, colonic acid, and capsular polysaccharide biosynthesis. All N-
acetyltransferase bifunctional enzymes in the InterPro family IPR041561 bear the 
acetyltransferase domain on the C-terminus of the fusion protein. Therefore, the 
gene fusion event could have occurred in an ancient progenitor which was then 
retained in differing glycosylation pathways of similar organisms. In each of the 
respective pathways, there are still examples without the monoPGT-N-
acteyltransferase fusion, and therefore the retention would be specific to distinct 
organisms. Alternatively, the fusion events may have occurred independently as 
they each occur in different operons. Further evolutionary analysis will be required 
to differentiate between these two possibilities. 
Further sugar-modifying elaborations include reductase, O-
acetyltransferase, dehydrogenase, and aminotransferase domains. Based on 
InterPro accession and sequence identity, a total of 15 enzymes have been 
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identified from one of these classes (Table 4.2). However, functional information 
about each of these respective domains is limited, especially with respect to active-
site conservation. Because of their low redundancy within the superfamily, we 
consider these fusions to be outliers of the sugar modifying subclass. 
4.3.4 Glycosyl transferase bifunctional enzymes 
Bifunctional enzymes containing monoPGT and GT domains consist of 
approximately 2% of the total monoPGT superfamily, 50% of all monoPGT fusions. 
GTs allow for addition of subsequent glycan modifications onto the Und-PP-linked 
sugar at the membrane interface. GT-A, GT-B, and GT-E  folds are the 
predominating GT architectures fused to a monoPGT. GT-A and GT-B folds are 
comprised of two Rossmann-fold (α/β/α) containing domains with divergence in 
the insertion point of the two domains (Figure 4.9).(169) GT-E folds contain only 
one Rossman-fold domain rather than two observed in GT-A and GT-B folds.(170) 
Substrate specificity for GTs is driven both by the donor sugar (NDP activated 
sugar) and by the acceptor sugar. Each GT has a differing acceptor sugar length 
requirement; however, the specificity determinants for glycan length are still 
unclear. Additionally, stereochemistry specificity is not driven by the GT-fold type, 
as there are examples of inversion and retention in both fold types. The 
mechanisms of inversion and retention of stereochemistry are distinct, and 
proceed through either a base-assisted SN2 reaction (inversion) or an SNi or 
double-displacement mechanism (retention).(171)  
 
 106 
At the time of writing, there are 110 GT-families annotated in the CAZy 
database(172) (http://www.cazy.org/GlycosylTransferases.html). Using 
sequence-guided approaches, 9 of 14 GT clusters of monoPGT fusions have 
predicted GT homologs based on structural homology to well-characterized GTs,  
CAZy, and InterPro annotations. The functions of the remaining 5 clusters cannot 
be predicted due to a lack of reliable homology to any characterized protein. GT-
fusion enzymes, separated by cluster and annotated by GT fold and predicted 
homologs based on conservation of catalytic residues and genomic context (operon 
location) are summarized in Figure 4.10 and Table 4.3. 
 
Figure 4.9. Glycosyl transferases: structure and mechanisms.  
A. Glycosyl transferases catalyze a transfer with either inversion (GT-1 or GT-2) or 
retention (GT-4) of stereochemistry at the anomeric carbon position of the donor sugar. 
B. The three GT folds observed in the monoPGT SSN. GT folds are colored orange and 
accessorizing domains are in gray.GT-A fold: Pyrococcus furiosus dolichol-
phosphomannose synthase (DPMS), PDB ID: 5MM1. GT-B fold: C. jejuni PglH 








Figure 4.10. Glycosyl transferase families present in the monoPGT SSN. 
 Sequence similarity network of the monoPGT superfamily colored by structural family 
(40% ID representative node network, E-value cutoff of 1 x 10-90). Glycosyl transferase 
bifunctional enzyme clusters are circled, numbered, and annotated in the table based 





Based on sequence analysis, most members of clusters 1 and 2 do not retain 
the absolutely conserved catalytic residues of biochemically characterized 
monoPGTs. The catalytic dyad “DE”, conserved across monoPGT enzymes, has 
been mutated to “NR” and the canonical “PRP” motif proposed to be involved in 
nucleotide binding has been mutated to “PEL”. Therefore, the PGT domains of 
these fusions are predicted to be pseudoenzyme domains as they are unlikely to 
exhibit catalytic activity without the catalytic dyad. The GT domain of cluster 1 
Table 4.3. Glycosyl transferase containing fusion clusters in the monoPGT 
SSN annotated by Interpro or Pfam family.  
GT 
cluster InterPro or Pfam family 





GT-2 like (IPR001173) or 
Galactosyltransferase 
(IPR027791) 
WbbL (23-38%) N-term 
2 GT WecB/TagA/CpsF (IPR004629) TagA (28-30%) C-term 
3 GT WecB/TagA/CpsF (IPR004629) TagA (25-31%) N-term 
4 GT-2 like (IPR001173) PglI (11-25%) C-term 
5 GT-2 like (IPR001173) or GT, family 1 (IPR001296) PglA (22-28%) N-term 
6 GT like family 2 (PF13641) GlfT2 (15-20%) N-term 
7 GT-2 like (IPR001173) PglI (18-23%) N-term 
8 
GT, family 1 (IPR001296) or 
GT1 subfamily 4 
(IPR028098) 
inconclusive N-term 
9 GT1 subfamily 4 (IPR028098) inconclusive N-term 
10 
GT, family 1 (IPR001296) or 
GT1 subfamily 4 
(IPR028098) 
PglA (24-32%) N -term 
11 GT WecB/TagA/CpsF (IPR004629) TagA (28-41%) C-term 
12 
GT, family 1 (IPR001296) or 






shares sequence identity with WbbL (23-38% ID), a rhammosyltransferase that 
uses TDP-activated rhammose, rather than UDP-activated sugars used in most 
pathways. (173, 174)  Therefore, due to the possible difference in nucleotide 
specificity from most monoPGTs (UDP-activated sugars), it is possible that the 
“PRP” motif is altered to increase specificity towards TDP-activated sugars.  
Notably, three clusters (2, 3, 13) contain GT domains from the 
WecB/TagA/CpsF InterPro family (IPR004629). TagA enzymes are the only 
members of this superfamily which have been biochemically and structurally 
characterized, exhibiting a novel GT-E fold.(170) Clusters 2 and 3 are the largest 
clusters containing TagA fusions and are connected through one linkage between 
two representative nodes (UniProt IDs: A0A433I5J1 and A0KWR7). The 
divergence between clusters 2 and 3 is based on domain architecture and 
conservation of the catalytic "DE" dyad in the monoPGT domain. In Cluster 2, the 
GT domain is on the C-terminus and most sequences lack the “DE” and “PRP” 
motifs. In contrast, Cluster 3 enzymes retain the “DE” and “PRP” motifs and the 
GT domain is on the N-terminus. This diversity of N-to-C domain architecture in 
the case of the glycosyl transferase bifunctional enzymes is consistent with our 
hypothesis that fusion events in the monoPGT superfamily are generally not driven 
by operon architecture.  
4.3.5 Regulatory domain fusions 
The two most highly represented classes of regulatory domains in monoPGT 
fusions are the signal transduction response regulators (IPR001789) and the 
sulphate transporter and antisigma factor antagonist (STAS) family (IPR002645) 
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consisting of 49 and 29 representative nodes, respectively. Both these domains are 
involved in phosphoregulation of their effector protein targets.  
 
 
Figure 4.11. Schematic of signaling in two-component signal regulation in 
IPR0011789. 
Response regulatory domains (IPR001789) act as receiver domains in  two-
component response regulation systems, paired with a sensor kinase, to relay a 
signal to its effector protein, either a transcription factor or an enzyme. Stimulation 
of the sensor kinase in response to environmental signal induces its 
autophosphorylation. The receiver domain then catalyzes phosphotransfer to 
itself, resulting in a signal, typically a induced by conformational change, to its 
effector protein (Figure 4.11). CheY, a prototypical receiver domain, requires a 
magnesium-ion cofactor for catalysis, coordinated by D12, D13, the carbonyl of 
N59, and the catalytic aspartyl residue D57 (numbering for E. coli CheY), which 
becomes phosphorylated. Response regulatory domains which are fused to 
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monoPGT domains have either a D or E in the position corresponding to D57 in 
CheY, a prototypical receiver domain. Across all the response regulatory domains 
fused to a monoPGT, the coordinating aspartyl residues are mutated to either 
glycine or alanine. 
Previous research shows that two residues in E. coli CheY, T87 and K109, 
play a role in the conformational change induced by phosphorylation of D57.(175) 
However, these residues are not absolutely conserved amongst CheY homologs and 
therefore are not essential for phosphorylation/dephosphorylation of CheY. These 
two residues are also not conserved in response regulatory domains fused to a 
monoPGT domain. T87 has been mutated to a serine in many sequences, but even 
the basic characteristic of K109 is not conserved (there is no consensus at this 
position). It is thus possible that these are not functional or have a differing 
mechanism of action.  
A homology and deep-learning model of a PGT-regulatory domain fusion is 
shown in Figure 4.12. The predicted fold generated via deep learning (co-
evolution weighted) is homologous to E. coli CheY, with an RMSD=2.01 Å. A 
depiction of E. coli CheY magnesium ion coordination including beryllium 
trifluoride (phosphoryl mimic) with the corresponding residues in A0A0Q1DMB5 
(Response regulator-monoPGT fusion) is shown in Figure 4.12. Therefore, it is 
unclear whether these regulatory domains will have the same function in the 




Figure 4.12. Structure prediction models of UniProt ID: A0A0Q1DMB5 
receiver domain. The receiver domain of A0A0Q1DMB5 (cyan) is aligned to E. coli 
CheY (dark gray). The PGT domain is shown as blue. 
 
 The second major superfamily of regulatory domains found in the 
monoPGT superfamily is the STAS family of anti-anti sigma factors. A well 
characterized system containing a STAS domain is the sporulation regulation 
system. A serine kinase (SpoIIAB) binds and sequesters a transcription factor in 
the inhibitory state. However, when regulatory domain, SpoIIAA (STAS domain) 
binds to SpoIIAB, SpoIIAA is phosphorylated, which results in release of the 
transcription factor. Lastly, the system is paired with a phosphatase, SpoIIE, which 
dephosphorylates SpoIIAA, allowing SpoIIAB to sequester the transcription factor 
again.(176, 177) Anti-anti sigma factors such as SpoIIAA share conservation of a 
motif flanking the absolutely serine: MDS[S/T]GLGV.(178) This serine is the 
phosphorylation site in SpoIIAA that triggers a downstream signal for its effector 
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protein.(179) All monoPGT-STAS fusion enzymes exhibit conservation of this 
motif, and the serine is absolutely conserved. The presence of monoPGT-
regulatory domain fusions, as well as strict conservation of phosphorylation sites, 
proposes their role in glycoconjugate regulation at the monoPGT step. 
4.3.6 Context of sugar modifying, glycosyl transferase, and regulatory fusions 
on glycosylation pathways 
The identification and classification of bifunctional monoPGT enzymes has 
allowed for a broader understanding of their roles in bacterial glycosylation 
pathways. The prevalence of sugar-modifying and glycosyl transferase bifunctional 
enzymes is consistent with the existence of protein-protein interactions facilitating 
substrate/intermediate shuttling.. Fusions with regulatory domains points to 
possible regulation of glycosylation at the PGT reaction specifically, allowing for 
conservation of UndP, the common substrate in these glycosylation pathways. 
Bifunctional monoPGTs fused to sugar-modifying domains could impart a 
unique advantage to their respective pathways, especially if the sugar modifying 
domain catalyzes the final sugar transformation before the monoPGT links it to 
UndP. Such a bifunctional enzyme could allow for the increase of local 
concentrations of the soluble sugar substrates. This could be advantageous to 
bacteria which encode multiple glycoconjugate biosynthetic pathways. Since they 
all use UndP as the lipid carrier(45), shuttling the modified sugar directly from the 
sugar modifying domain to the PGT for linkage to the polyprenol-phosphate 
carrier could increase flux through the pathway or provide selectivity for the 
modified sugar substrate due to increased local concentration. Indeed, the 
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predominating theme in GT-monoPGT bifunctional enzymes is that each fused GT 
and monoPGT catalyze sequential steps in their respective glycosylation pathways.  
Regulation of glycosylation pathways at the PGT reaction may be the most 
efficient means for tuning pathway flux, in that it is the first membrane-committed 
step in the pathway. This design conserves UndP,~0.075% of total lipid extracts in 
C. jejuni(180), and allows for triaging between the glycosylation pathways within 
the bacterial cell. In the case of teichoic acid and peptidoglycan biosynthesis, 
metabolomic and transcriptional studies identified that late inhibition (farther 
down the pathway) of teichoic acid biosynthesis decreased peptidoglycan total 
product. This cross pathway inhibition is a result of teichoic acid pathway depleting 
the cellular concentrations of UndP.(181) Although biochemical analysis needs to 
be undertaken to understand if and how these regulatory domains modulate 
phosphoglycosyl transferase activity, identification of monoPGT domains fused to 
regulatory domains supports the hypothesis that the PGT reaction step can be a 
key regulatory point in glycoconjugate production. (45) 
4.3.7 Polytopic-monotopic PGT fusion 
Through network analysis, one of the most intriguing fusions was identified 
that contains both a polyPGT (IPR018480) and a monoPGT (IPR003362) domain. 
There are two clusters within the sequence similarity network comprised of 
proteins with this domain structure. Comparison of the sequences in one cluster to 
that of MraY and PglC revealed that the catalytic residues from both domains are 
retained, suggesting these fusions possess functional polytopic and monotopic 
PGT domains (polyPGTF-monoPGTF). In contrast, the second cluster contained 
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sequences in which only the polyPGT catalytic residues are conserved but the 
monoPGT catalytic dyad is not (polyPGTF-monoPGTNF). Notably, the 
pseudoenzyme domain of polyPGTF-monoPGTNF enzymes retains sequence 
similarity in the re-entrant membrane helix (RMH) motif (Figure 4.3A) used for 
interaction with the membrane. The KXXXD motif at the start of the RMH is 
absolutely conserved across all polyPGT-monoPGT fusions, and a general pattern 
of aliphatic residues flanking a proline (or bulky hydrophobic residue) at the kink 
of the helix is also conserved. Notably, this RMH motif is conserved in all three 
families (large, small, and bifunctional) .(12, 14)  
This fusion of the monoPGT to polyPGT is particularly striking, because 
typically polysaccharide/glycoconjugate biosynthetic pathways encode a polyPGT 
or monoPGT, but not both. Therefore, oligosaccharide biosynthesis operons do no 
typically encode both types of PGT. A genome neighborhood diagram (GND) 
shown in Figure 4.13 contains representative members of both polyPGTF-
monoPGTF and polyPGTF-monoPGTNF fusions. The genome neighborhoods of 
polyPGT-monoPGTs, both functional and nonfunctional do not show similarities 
to any characterized monoPGT. However, in some of the pathways, enzymes 
involved in peptidoglycan biosynthesis are observed (MurC, MurM, MurJ) which 
further implies that the polyPGT domain is functional. However, several of the 
proteins present in each operon are still uncharacterized. Notably, a subset of 
polyPGTF-monoPGTNF fusions have a second non-functional monoPGT gene in the 
operon, which is fused to a glycosyl transferase. These PGT-GT fusion enzymes are 
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found in GT cluster 1 (Section 4.3.4, highest sequence identity to WbbL). WbbL 
acts in the mycobacterial mycolylarabinogalactan-peptidoglycan pathway, which 
commonly use a polyPGT, and therefore it is reasonable to assume that these 
polyPGTF-monoPGTNF enzymes also act in polyPGT-dependent pathways. 
 
Figure 4.13. GND of polyPGTF-monoPGTNF fusion enzymes. The operons of six 
polyPGTF-monoPGTNF genes are aligned to the polyPGT-monoPGT gene (red). Sugar 
modifying, glycosyl transferases, regulatory domains, and other enzymes present in 
glycoconjugate biosynthetic pathways are identified and labeled. UniProt IDs: 
A0A1V4RUK6 (A), A0A3M2FN56 (B), A0A3N9MXS9 (C), H1XS79 (D), A0A1F4X332 
(E), A0A1F4XPX4 (F). 
 
The most unexpected finding was that of the presence of fusions containing 
a domain from each of the two distinct PGT superfamilies. The structural and 
mechanistic divergence of these two superfamilies is indicative of independent 
evolution of the protein fold and function, leading to the emergence of non-
homologous isofunctional enzymes.(182, 183) The monoPGTs and polyPGTs have 
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distinct folds. It is possible that these polyPGTF-monoPGTNF fusion enzymes 
resemble an ancestral enzyme. The evolution of these isofunctional enzymes may 
have been driven by the necessity to bind and transform the membrane-embedded 
PrenP substrate. Notably, the monoPGT core fold, exemplified by C. jejuni PglC, 
has been shown to increase the local membrane concentration of the PrenP 
substrate in styrene-maleic acid lipoparticle (SMALP) compared to empty SMALP 
discs (no PglC present).(180) Such an enrichment could increase catalytic 
throughput of the fused polyPGT enzyme and confer a selective advantage.  
4.3.8 Phylogenetic reconstruction of the monoPGT superfamily 
A representative phylogenetic tree was generated by curating a set of 
representative sequences from each of the largest 100 clusters in the SSN,  (Figure 
4.14) all biochemically-characterized enzymes, and representative sequences from 
the largest bifunctional-GT fusion clusters. Members from each family (small, 
large, bifunctional) are represented in the phylogenetic reconstruction. This 
analysis provides complimentary information to the SSN, using multiple sequence 
alignments rather than pairwaise alignments to support substantial divergence in 
the superfamily. Rather than dependence on pairwise alignments between each 
member, phylogenetic reconstructions depend on multiple sequence alignments 
and includes all sequences comparatively. The evolutionary pattern of branching, 
described as “radial burst” evolution by Babbitt and coworkers(184), shows several 
early divergence events, followed by subsequent branching in a radial manner. 
Notably, the phylogenetic reconstruction supports a model in which the distinct 
monoPGT architectures were reinvented in different clades to generate the same 
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enzyme architecture. Specifically, the small monoPGT architecture has branched 
off from a large monoPGT in multiple clades in the phylogenetic tree. This 
reconstruction indicates that the small “PglC-like” architecture is the most modern 
version of this superfamily, as it has evolved from the large “WcaJ-like” enzymes 
in each of the major clades in the phylogenetic reconstruction. 
 
Figure 4.14. Phylogenetic tree of the monoPGT superfamily. The 
reconstruction is colored by family and subclass of enzymes: small “PglC-like” (blue), 
large “WcaJ-like” (green), sugar-modifying bifunctional (red), glycosyl transferase 
bifunctional (yellow), regulatory bifunctional (cyan), polyPGT-monoPGT fusions 
(magenta), and uncharacterized members (black). A full list of UniProt IDs used in the 
reconstruction is provided in Appendix 5 (Table A5.1, listed in a clockwise direction 
starting from the sequence marked by *).  
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4.4 Conclusions and future directions 
The monoPGT superfamily SSN contains 18,571 non-redundant sequences, 
of which 826 are fusion enzymes (4.5% of the network).  By generating the SSN, 
we identified unique bifunctional enzymes and characterized their genome 
neighborhoods. Additional subclasses of the bifunctional family were categorized 
to include sugar modifying, glycosyl transferases, and regulatory domain 
containing enzymes. PolyPGT-monoPGT fusion enzymes may serve as an 
evolutionary link between two analogous superfamilies of enzymes. Together, 
these findings allow a new understanding of the PGTs serving as the entry point 
into their respective glycoconjugate pathways. 
Investigation of the frequency of fusion events will allow for understanding 
the driving force for evolution and retention of bifunctional enzymes in the 
monoPGT superfamily. One possibility is that bifunctional enzyme evolution is a 
function of the need for increasing flux in the glycoconjugate biosynthetic 
pathways. With respect to soluble enzymes such as the sugar modifying enzymes, 
fusion allows for co-expression and co-localization to the membrane. Additionally, 
in pathways that take common sugars such as Glc or Gal as the first sugar, fusion 
of PGT with GTs can allow for pathway throughput and prevent loss of product to 
competing glycoconjugate pathways.  
Regulation of glycosylation pathways at the PGT reaction has recently been 
identified in S. aureus capsular polysaccharide pathway(150). However, the 
mechanism of activation or inhibition of glycoconjugate biosynthesis is still not 
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well understood. Specifically, this analysis of the SSN revealed that there might be 
much more regulation involved since a surprisingly large number of bifunctional 
PGTs were fused to regulatory domains. For fusions containing the response-
regulator domain, it will be useful to identify the kinase enzyme in the operon and 
co-express with the monoPGT-regulatory domain fusion to evaluate the 
mechanism of PGT regulation. Further, little to no evidence of regulation of N-
linked glycosylation pathways have been identified. Therefore, further 
investigation into the Campylobacter pathway for evidence of regulation can allow 
for a better understanding of regulation of N-linked glycosylation and other 
glycoconjuate biosynthetic pathways. As pathway products are often implicated in 
pathogenesis, understanding how the organism regulates the respective pathways 
(i.e. virulence factors) could assist in identifying novel targets and mechanisms for 
therapeutic intervention.  
Our ability to accurately interpret and derive new information from the SSN 
of the monoPGT would be greatly improved if there was more understood about 
their biochemical and biophysical properties For example, the high specificity of 
monoPGTs for their respective substrates has been characterized in a few members 
(C. jejuni and C. concisus PglC, A. hydrophila WecP), yet the means of achieving 
high specificity is not well understood. With respect to drivers of sugar substrate 
specificity, elucidation of liganded structures of diverse monoPGTs is necessary. 
Multiple liganded structures of Michaelis-complex mimics can inform the 
determinants of specificity for such sugars within the superfamily. The ability to 
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then map these specificities back onto the SSN generated here, will allow for a 
deeper understanding of the evolution of this superfamily. 
This study revealed that the monoPGTs are also found in archaea, rather 
than solely bacteria, as originally assumed. Archaeal glycosylation pathways use 
dolichol phosphate rather than undecaprenol phosphate as the lipid carrier. 
Identification of these family members could provide an opportunity to study the 
substrate-binding determinants and possible recruitment and localization of the 
polyprenol phosphate substrate.  
The surprising finding that there are such diverse bifunctional enzymes 
within the monoPGT provides a new area for analysis, as currently only one 
member of this monoPGT family has been biochemically characterized (N. 
gonorrhoeae PglB). Confirming activities of both domains for select bifunctional 
enzymes will be critical to understanding the interconnection of fusion domain 
activities. These fusions can provide a mechanism for  probing pathway 
throughput and the effect of the sugar-modifying or glycosyl transferase domain 
on PGT activity. We are interested in understanding how the flux through a 
glycoconjugate pathway is modulated by protein-protein interactions in cells. In 
particular, we are intrigued by whether a fusion protein replacing two 
monofunctinal enzymes will alter the flux or equilibrium through the respective 
pathway. Furthermore, analysis of the three-dimensional structure and dynamics 
of bifunctional enzymes can allow for identification of protein-protein interaction 
interfaces and possible tunnels for shuttling of product from PGT active site to the 
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active site of the GT for PglA-like fusions. Research in the Imperiali Lab supports 
protein-protein interactions within the Pgl pathway, and the structural 
characterization of either sugar-modifying or glycosy transferase bifunctional 
enzymes can inform co-localization and interaction studies of the single domain 
enzymes.  
The results of this study defined novel classes of monoPGT enzymes, 
highlighting their possible role in glycosylation pathways. In addition to the 
original three families of the monoPGT supefamily, we created the first 
comprehensive annotation of the bifunctional family to include sugar modifying, 
glycosyltransferases, and regulatory domain subclasses. A new fusion subclass, the 
polyPGT-monoPGT fusion enzymes, were identified providing a potential 
evolutionary link between the two superfamilies of enzymes. Annotating these 
novel domain architectures in the context of the sequence similarity network 
provides a categorization of the superfamily, allowing for future experiments in 
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Phosphoglycosyl transferases (PGTs) have the unique challenge of binding 
a water-soluble nucleotide diphospho sugar and a lipophilic polyprenol phosphate 
(PrenP). All bacterial monoPGT superfamily members use UndP as the lipid 
carrier and the NDP-sugar substrate varies. Archaeal members make up 
approximately 0.5% of the monoPGT superfamily and use dolichol phosphate 
(DolP) rather than UndP as the lipid carrier. To accommodate both soluble and 
lipophilic substrates, monoPGTs have adopted a novel fold allowing interaction 
with one leaflet of the membrane. This chapter will delve into a statistical and 
evolutionary analysis of the monoPGT superfamily. Specifically, I have worked to 
develop a first-round hidden Markov model (HMM) of the re-entrant membrane 
helix (RMH) motif (Figure 5.1), to ascribe rules for its unique topology and search 
protein sequence databases for uncharacterized RMHs in other protein families. 
Secondly, using the SSN analyzed in Chapter 4, I have predicted evolutionary 
functions of the cytoplasmic domain of unknown function and provided insight 




Figure 5.1. Re-entrant membrane helix motif of C. concisus PglC. RMH is 
shown as gray with sidechains depicted in stick models colored by heteroatom. PDB ID: 
5W7L, positioned in membrane using PPM server.(141) 
5.1.2 Hidden Markov models (HMMs) in the context of membrane proteins 
Hidden Markov models (HMMs) are probabilistic mathematical models 
used to describe a motif or signature. They can be used to describe linear patterns 
and differences between states. A particular sequence string is designated as a 
unique state which helps confer the structural integrity of the model. HMMs have 
been used in speech recognition and linguistics, wherein sounds are represented 
by distinct states, and following states are dependent on proceeding ones.(185) In 
the case of computational biology, HMMs were first used to annotate genome 
structure(186), followed by gene(187, 188) and protein(189, 190) 
structure/profiles. In protein families, HMMs, were first generated and tested 
using three test families: globins, protein kinase catalytic domain, and EF-hand 
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calcium binding motif.(189) Within protein families, HMMs can be used to 
describe signature motifs and are used by superfamily servers such as Pfam(191) 
and InterPro(192) for designating a superfamily of enzymes. Further, these 
statistical models can also be used to search for other proteins containing similar 
motifs. The HMMER software suite(193, 194) allows for generation of HMMs from 
a multiple sequence alignment and iterative searching for other proteins 
containing the query motif.  
Within the context of protein topology predictions, a robust HMM 
algorithm was developed to predict TMHs within a protein, named TMHMM 
(https://services.healthtech.dtu.dk/service.php?TMHMM-2.0).(195, 196)  A 
training set was generated containing 160 integral membrane proteins and a set of 
645 proteins that do not interact with the membrane (structures were available at 
the time of model testing) as a negative test set. Each sequence in the training set 
was ascribed one of seven possible states: globular domain, cytoplasmic loop, 
cytoplasmic helix cap, helix core, non-cytoplasmic helix cap, or non-cytoplasmic 
loop (short or long) (Figure 5.2). One common rule that is used in TM predictions 
is referred to as the “positive-inside rule” meaning that a loop on the cytoplasmic 
side has a higher propensity for positively charged residues. Together with 
biochemical and biophysical studies, this model training provided the statistical 
basis for architectural rules for TMHs. The major descriptors include length of 




Figure 5.2. TMHMM linear connection possibilities. The membrane is depicted 
as a gray box, with each white box depicting a possible state. The figure is adapted from 
Krogh et al..(196) 
Given the unique topology of PglC, TMHMM predicts that the RMH motif 
is a single-pass transmembrane helix. However, the TM-HMM does not account 
for the fact that at residue position 18 of the 31-residue RMH motif, there is a 
proline residue (P23, C. concisus PglC) that serves to kink the helix, producing the 
re-entrant topology, rather than a single-pass TMH. Confirming the structural 
analysis with the substituted cysteine accessibility method (SCAM) showed the 
RMH topology is indeed physiological.(12) Towards developing a robust method 
for identifying and predicting RMH topologies in other proteins, I generated a 
HMM for the RMH motif in monoPGTs. These findings break the motif into three 
states: cytoplasmic loop, helix, and helix-kink and is conserved across all 
monoPGT members (even pseudoenzymes).  
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5.1.3 Protein evolution 
Each approach in studying protein evolution seek to address unique 
questions that stem from the overarching question: what are the drivers for 
enzyme evolution on the planetary timescale? There are two major types of protein 
evolution: divergent and convergent. Divergent evolution occurs when a group of 
enzymes evolves either a novel function in place of or in addition to the ancestral 
enzyme function. This can occur in the context of a superfamily of enzymes, in 
which they use the same architecture and chemistry to catalyze distinct 
reactions.(182, 183) An example of divergent evolution is the phosphatase and 
phosphomutase enzymes within the HADSF. They are divergent from one another 
in function yet retain the same catalytic motif and overall mechanism. 
Diversification can occur through sequence drift or through insertion of accessory 
domains which provide novel functions for the respective enzymes.  
In contrast, convergent evolution is the process by which unrelated families 
of enzymes independently evolve to catalyze the same chemical reaction.(197) The 
monoPGT and polyPGTs are examples of convergent evolution, they have unique 
topologies and catalytic mechanisms which carry out the same overall function (as 
described in Chapter 4).  One focus of this chapter is to use bioinformatic analyses 
to propose evolutionary connections between these two superfamilies through the 
analysis of the polyPGT-monoPGT fusion proteins.  Analysis of nonfunctional 
monoPGT domains reveal a possible secondary function to be further evaluated.  
 
 129 
5.1.3.1 Pseudoenzymes  
In some cases in enzyme evolution the essential catalytic residues are not 
retained. These proteins which can no longer perform the primary function of the 
enzyme and termed pseudoenzymes. However, this does not mean that the protein 
is completely nonfunctional.(198) In many cases, the pseudoenzyme retains a 
secondary function of the enzyme, often allosteric regulation.(199) Fusion 
enzymes containing a monoPGTNF domain are likely pseudoenzymes, with 
uncharacterized secondary functions. Pseudoenzymes are thought to arise from a 
gene duplication event followed by eventual loss of catalytic activity for one copy, 
while maintaining any secondary functions.(199) The most common and well-
characterized pseudoenzyme domain is the pseudokinase, comprising about 10% 
of each species' kinome.(200) The field of pseudoenzymes is new, and rapidly 
growing. Ongoing efforts to understand these proteins include 
computational/bioninformatic identification; biochemical and structural 
characterization; elucidation of the novel cellular functions; and analysis of 
evolutionary trajectories of pseudoenzymes relative to their catalytic 
homologs.(199)  
Recent efforts to compare the evolutionary trajectories of psuedoenzymes 
relative to their catalytically active homologs has revealed that each as unique 
pattern of conservation.(201) Mapping sequence conservation of a family of 
enzymes radially from the active site, a linear trend is observed; as the radial 
distance from the active site increases, the conservation of sequence 
decreases.(202) However, in the case of pseudoenzymes this long-range 
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evolutionary conservation is not observed. The conservation drops rapidly as the 
distance from the active site increases, in a non-linear fashion. Surprisingly, the 
same rapid loss of conservation is observed even in pseudoenzymes that retain the 
ability to bind the substrate of its cognate enzyme.(201) The enzyme-
pseudoenzyme pairs exhibit the same tertiary structure (average RMSD 1.5 
Å)(201), yet their degree of conservation as they radiate from the active site vary 
drastically. This may be a result of catalysis requiring the coupling of long range 
conformational selection of the enzyme scaffold to catalytic events. 
5.1.3.2 Protein fusion events 
Gene fusion is one mechanism of enzymatic diversification that can lead to 
novel functions. One theory is that gene duplication events occur first and then the 
redundant copy can form a novel chimeric fusion gene.(203) Chimeric proteins can 
evolve independently of their respective mono-domains to either gain a novel 
function, or to become more specific/specialized. The new domain architecture 
could also allow for downstream effects including: changing the subcellular 
localization of the protein, protein-protein interactions between novel protein 
partners, or regulation of enzymatic activity, all of which may be advantageous if 
the mono-domains function in the same biological pathway.(204) Large scale 
studies that have investigated the frequency of gene fusion events across genomes 
elucidated that gene fusions are prevalent across all domains of life, and that their 
frequencies vary based on type of enzyme the respective genes encode.(205, 206) 
One study identified that the majority of fusion proteins are metabolic enzymes, 
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and is likely a preferred architecture as a result of substrate shuttling between 
metabolic enzymes in a pathway.(206)  
Evolution of fusion proteins is typically independent of the evolution of the 
mono-domains. Using alcohol dehydrogenase as an example, Jones & Beghun 
identified chimeric proteins containing an alcohol dehydrogenase domain fused to 
the N-terminus of another protein.(203)  They mapped the evolutionary trajectory 
of these chimeric proteins, and observed a burst of divergence immediately after 
the chimeric protein is formed, followed by decreased divergence over time.(203) 
This trajectory is consistent with an initial drive for adaptive evolution, to evolve 
the novel function or other characteristics of the nascent chimeric protein, 
followed by a slowed evolutionary rate of mutation. A complementary study 
conducted by Bashton and Chothia analyzed multidomain proteins that have been 
structurally and functionally characterized.(207) They determined that the 
chimeric domains can increase enzyme specificity, or regulate enzymatic activity. 
In all of the examples that they studied (172 multidomain proteins), the fusion 
protein has a more specific or complex function than the respective single domain 
homolog.(207)  
5.1.4 Chapter Aims 
Chapter 4 described the creation and analysis of the monoPGT SSN, 
focusing on identification and characterization of monoPGT subclasses. The aim 
of Chapter 5 is to delve deeper into the bioinformatic analyses towards function 
predictions of uncharacterized domains and possible substrate recognition motifs. 
The three major undertakings of this chapter are as follows:  
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(1) To generate a first-generation HMM of the RMH motif to use as a tool 
for predicting RMH motifs in silico. 
(2) To analyze the evolutionary divergence of the small and large monoPGT 
families and to ascribe a predicted role/function of the cytoplasmic 
domain of large monoPGTs. 
(3) To analyze and predict possible accessory functions of monoPGT 
pseudoenzyme domains.  
5.2 Materials and Methods 
5.2.1 Generating a HMM  
Datasets for all monoPGT HMMs were derived from the sequences in the 
SSN generated in Chapter 4. However, the E-value was relaxed to 1 x 10-50 to 
provide the potential for more first neighbor nodes and therefore larger datasets 
for HMM generation. First and second neighbor sequences were selected after 
visualization of SSN using Cytoscape(159), in the organic layout. The first or first 
and second neighbors were selected for each of the following monoPGT targets: 
small monoPGT C. concisus PglC (UniProt ID: A7ZET4, representative node 
UniProt ID: A0A085L597), large monoPGT E. coli WcaJ (UniProt ID: P71241 
representative node UniProt ID: A0A1B7HPD9), and large monoPGT Aeromonas 
hydrophila WecP (UniProt ID: B3FN88, representative node UniProt: 
A0A081G0C7). Notably, the small monoPGT sequence selected include the N-
acetyltransferase-containing bifunctional enzymes, as they are first neighbors. The 
first-neighbor datasets contain 101 (C. concisus PglC), 383 (E. coli WcaJ), and 555 
sequences (A. hydrophila WecP). The first and second neighbor containing 
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datasets contain 213 (C. concisus PglC), 2,783 (E. coli WcaJ), and 3,583 sequences 
sequences (A. hydrophila WecP), respectively. To generate a HMM that 
encompasses small and large monoPGT members, the full sequence dataset for C. 
concisus PglC was used. In order to reduce the WcaJ first-neighbor dataset, first 
neighbors were selected using an E-value cutoff of 1 x 10-90, providing 111 
sequences. Multiple sequence alignments (MSAs) were generated for each dataset 
using Clustal Omega(161), followed by truncation of the MSA to the RMH motif 
using Chimera(163). Statistical analysis and HMM searches for sequences 
containing the HMM motif were conducted using HMMER HMM search web-
server (https://www.ebi.ac.uk/Tools/hmmer/search/hmmsearch).(194)  
LpxM SSN was generated using InterPro family IPR004960. The initial 
data set included 42,752 sequences, which was reduced using CD-HIT(157) and 
collapsing sequences into 75% identity nodes (11,095 sequences). Fragments were 
filtered using a minimal length requirement of 180 amino acids using the Galaxy 
web-server(152) (www.usegalaxy.org). EFI-EST web tools 
(https://efi.igb.illinois.edu/efi-est/) were used to conduct all-by-all BLAST 
calculations with an E-value of 1 x e-30, and further sequence filtering to only 
include sequences with 250-450 amino acids. The final 50% representative node 
network contains 7,776 representative nodes (10,080 sequences) and 1,918,699 
edges. The HMM datasets were generated as described above using targets 
Acinetobacter baumannii LpxM (UniProt ID: S3TFW2, representative node 
UniProt ID: R8YP40) and E. coli K12 LpxM (UniProt ID: P24205, representative 
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node UniProt ID: A0A378BGL9). These two sequences were selected as they have 
been characterized either structurally via X-ray crystallography (A. baumannii, 
PDB ID: 5KN7)(208) or biochemically using SCAM analysis (E. coli K12)(209). 
The first neighbor containing datasets contain 514 (A. baumannii LpxM) and 204 
sequences (E. coli K12 LpxM), respectively and the first and second neighbor 
containing datasets contain 3,371 (A. baumannii LpxM) and 1,787 (E. coli K12 
LpxM) sequences, respectively. 
5.2.2 Consensus sequence calculations 
The overall process for consensus-sequence determination and analysis 
followed work published by Pey and coworkers(210). The two datasets for C. 
concisus PglC and E. coli WcaJ were curated by selecting the representative node 
from the 40% representative node network with an E-value of 1 x 10-50 (PglC) or 1 
x 10-90 (WcaJ) and selecting its first neighbors in Cytoscape. A less stringent E-
value was selected for PglC in order to generate a larger dataset. Additional 
sequence length filters were applied to each dataset (300 aa maximum for PglC 
and 400-500 aa for WcaJ). Multiple sequence alignments for each dataset were 
calculated, followed by removal of poorly aligned sequences (>15-20 aa 
elaborations at either N-terminus or C-terminus). The final data sets included 64 
sequences of 185-260 aa with 29-67% identity to one another for PglC and 99 
sequences of 400-500 aa with 20-40% sequence identity to one another for WcaJ. 
The file was converted to a FASTA file and input into a spreadsheet calculator to 
concatenate and determine the frequency of each of the 20 amino acids at every 
position, n. The maximum frequency at position n was divided by the frequency of 
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the target sequence amino acid at the same position to determine the frequency 
ratio. The frequency ratios were plotted against residue position using GraphPad 
Prism (version 8.0.1) and positions with frequencies ≥10 were identified and 
mapped onto the structure of PglC (PDB ID: 5W7L) or the structure prediction 
model for WcaJ generated using RaptorX.(142) 
Sequence conservation mapping onto structural models was generated 
using UCSF Chimera(163). Multiple sequence alignments for the targets of interest 
were generated using Clustal Omega(161) and then input into UCSF Chimera.  The 
Shannon entropy was calculated using the AL2CO entropy conservation 
calculation(211) in UCSF Chimera(163). 
5.3 Results and Discussion 
5.3.1.1 monoPGT HMM of RMH motif 
HMMs were generated using sequence alignments of three datasets, the 
first neighbors of each of the respective exemplary homologs: C. concisus PglC 
(UniProt ID: A7ZET4), E. coli WcaJ (UniProt ID: P71241) and A. baumannii WecP 
(UniProt ID: B3FN88). Notably, two datasets were generated for large monoPGT 
using either targets E. coli WcaJ or A. hydrophila WecP because they have differing 
sugar specificities, UDP-Glc and UDP-GalNAc, respectively.(154, 155) The RMH, 
30 amino acids corresponding to residues 7 to 37 in C. concisus PglC, was selected 
using UCSF Chimera(163). The HMMER server was then used to complete HMM 
statistical analysis and search for other proteins containing the RMH motif.(193) 
N. gonorrhoeae PglB and C. concisus PglC are first neighbors, and therefore, their 
HMMs are identical. The models include positively charged residues on the N-
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terminus, with a highly conserved proline (or tryptophan) residue roughly 18 
amino acids from the N-terminus. There are some positively charged residues at 
the C-terminus loop, however they are poorly conserved. This proline kinks the 
helix and allows for its re-entrant topology (Figure 5.3). The conserved aspartate 
residue at position 11 (C. concisus PglC numbering) is critical for the PGTs’ 
structural topology as it is involved in a hydrogen bond with a highly conserved 
serine residue (Ser107) in the neighboring β-strand. Co-evolution calculations 
using Gremlin(212) show that Ser107 and Asp11 have a 98.9% probability of co-
varying, further substantiating Asp11 as important for the proper folding of 
monoPGTs. Aliphatic residues are observed in positions 6-16 and 19-27 
(numbering of RMH HMM, assuming K of KXXXD is position 1). Although there 
is not high conservation of a specific residue, the aliphatic nature of the residues is 
strictly conserved in these positions. One of the following amino acids is observed 
in each of the positions in these segments: L, A, I, V, and with less frequency but 
still present: F, Y, M.  
Notably, the large monoPGTs WcaJ and WecP both exhibit a feature unique 
to the large family: conservation of polar/acidic residues DS as the last two 
residues (30 and 31) of the RMH motif. In contrast, the small monoPGTs have poor 
conservation at these two positions, although generally position 30 is polar/basic 
residue conservation (N/K) and position 31 is hydrophobic/aliphatic (L/M). 
However, because there is no X-ray crystal structure of a member of the large 




Figure 5.3. HMM of RMH motif of three monoPGT families. 
 
Towards the goal of generating one uniform and robust HMM for the RMH, 
data sets from small and large monoPGT families were combined in equal ratios. 
The model generated follows the same pattern as the individual models. There are 
positively charged residues at the N-terminus, followed by 10-12 aliphatic residues, 
a proline/tryptophan to kink the helix, 10-12 aliphatic residues, terminating with 
positive/polar residues. Searching for RMH motifs using HMM search(194) 
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against the reference proteome database with this combined model results only in 
sequences in the monoPGT superfamily.  
The next step in generating a robust prediction model was to relax the 
stringency for aliphatic residues, providing more potential options. Although using 
this model to search for novel RMH-containing proteins in the reference proteome 
database was unsuccessful, our collaborators in the Imperiali lab simultaneously 
identified and confirmed RMH topology in a fatty acid acyltransferase functioning 
in lipid A biosynthesis (LpxM) using manual curation followed by SCAM 
assays.(209) Further characterization of the LpxM's RMH showed that although 
the overall pattern and rules dictated by monoPGT RMH HMM are conserved, 
there were a few unique features to LpxM RMH (Figure 5.4A). First, there are 
two positions towards the N-terminus which have highly conserved Trp (positions 
3 and 6 in HMM). In addition, the stretch of aliphatic residues following the 
proline kink is not strictly conserved in LpxM. Instead, there are both basic and 
acidic residues starting at position 21. Based on the positioning of LpxM (PDB ID: 
5KN7) in the membrane using PPM server(141), the RMH is positioned at a depth 
of only 7.4 Å into the membrane, compared to 14.5 Å in the case of C. concisus 
PglC(12). This positions the C-terminal helix of the RMH co-planar to the 
phospholipid head groups of the cytoplasmic leaflet. Surprisingly, there is a  
presence of positively charged residues in the C-terminal helix which is predicted 
to be embedded in the first leaflet of the membrane. This mode of interaction was 
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confirmed in the literature via SCAM analyses to be the physiological mode of 
interaction of LpxM with the membrane using E. coli LpxM homolog.(209)  
 
Figure 5.4. LpxM exhibits RMH topology.A. The structure of A. baumannii LpxM 
(PDB ID: 5KN7) positioned in the membrane using the positioning of protein in 
membrane (PPM) server. The membrane plane (phospholipid head groups) are 
depicted as blue spheres, and the RMH is colored in gray (by heteroatom). B. The RMH 
motif of LpxM, with sidechains depicted as sticks colored by heteroatom. C. The HMM 
of LpxM using the E. coli LpxM first-neighbors dataset.  
The HMMs designed in these studies have identified the overall consensus 
characteristics: a positively charged N-terminus and an aliphatic helix containing 
a kink in the center, caused by either a proline or a tryptophan in most cases. It is 
likely that no new proteins have been identified with the current HMM because 
our current algorithm model is too specific. Therefore, future development of a 
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prediction model to relax the preferences at aliphatic residues to have equal 
probabilities of any aliphatic residue may assist the prediction power of this model. 
It is also possible that this motif is highly specific to proteins functioning in 
glycoconjugate biosynthesis, as LpxM, the only other protein confirmed to interact 
with the membrane via an RMH,  functions in lipid A biosynthesis.  
5.3.2 Evolutionary analysis of monoPGTs 
The monoPGT superfamily is composed predominately of large monoPGTs 
(see Chapter 4). The phylogenetic reconstruction shows that the large monoPGTs 
are the origin of the small and bifunctional families, in that in each clade there are 
small or bifunctional monoPGTs branching off from the large monoPGTs (Figure 
4.12, Chapter 4). In order to further understand the divergence of the three 
monoPGT families, each family was characterized using bioinformatic analyses 
including sequence analysis, structure prediction models, and genome 
neighborhood networks to identify the operons or gene co-location.  
5.3.2.1 Consensus sequence analysis of small and large monoPGTs 
Towards identification of the sequence conservation of the small and large 
monoPGT families, the consensus sequence was calculated based on multiple 
sequence alignments for each family. This consensus-based approach was taken 
towards two goals: (1) to investigate the possible ancestral members of the 
monoPGT supefamily and (2) to identify new constructs that are more amenable 
for crystallization. The consensus sequence for a particular protein is determined 
from a multiple sequence alignment of several homologous protein sequences, 
which have conserved function, mechanism, and structure. The frequency of each 
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of the natural 20 amino acids is calculated for each position, n, in the sequence is 
calculated. The amino acid frequency ratios are compared to the frequency of the 
target sequence amino acid at that particular position and defined as the frequency 





where fr is the frequency ratio, fc is the maximum amino acid frequency 
(consensus frequency) and ft is the amino acid frequency of the target sequence at 
position n. When the ratio is 1, the consensus and target amino acid is the same. 
However, an increase in fr is indicative of the target sequence diverging from the 
consensus sequence. A value of zero occurs when there is either an insertion or 
deletion at this position. (210, 213, 214)  
In order to understand both the small monoPGTs, represented by C. 
concisus PglC, and large monoPGTs, E. coli WcaJ, a consensus sequence was 
calculated and the residue positions with a frequency ratio greater than or equal to 
ten were identified on either the X-ray crystal structure (C. concisus PglC, PDB ID: 
5W7L) or a deep learning structure prediction model (E. coli WcaJ, Raptor 
X(145)). The dataset of sequences for each monoPGT family consisted of the 
representative-node containing target protein (C. concisus PglC or E. coli WcaJ) 
and their respective first neighbors. A summary of the final datasets are included 
in Table 5.1. 
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Table 5.1. Consensus sequence dataset summary 
 
 Small monoPGT Large  monoPGT 
Target sequence C. concisus PglC E. coli WcaJ 
UniProt ID A7ZET4 P71241 
Total sequences 64 99 
Sequence lengths 185-260 400-500 
Percent identity 29-67% 20-40% 
 
 
The frequency ratios for C. concisus PglC (small monoPGT) are plotted in 
Figure 5.5 and summarized in Table 5.2. All positions with a ratio greater than 
or equal to ten were selected for further investigation. There are eight positions in 
the C. concisus PglC that diverge from the consensus sequence, which is typical for 
proteins the size of PglC (200 aa).(14) The first 67 positions are omitted from the 
plot because there are a few sequences with an extended terminus, and therefore 
C. concisus PglC residue 1 is at consensus position 67. 
 
Figure 5.5. Consensus frequency mapping against target C. concisus PglC. 
Frequency ratios greater than or equal to 10 are annotated with the mutation in red. 
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The positions of these residues localize to two regions on the protein 
(Figure 5.6), at the plane of the membrane (Helix B and C) and at the solvent 
exposed side of the globular domain (helix E and F). The most prominent 
divergence of C. concisus PglC sequence from the consensus sequence is at residue 
D40, with a ratio of 49. Notably, C. concisus PglC is the only sequence in the dataset 
with an acidic residue at this position, where most sequences have a proline at this 
position. It is unusual that C. concisus PglC retained a negatively charged residue 
at this position. Based on positioning of protein in membrane (PPM) calculations 
described in the following section (section 5.3.2.2), D40 is located in plane with 
the phosphate head groups of the phospholipids. Further, the substitution of 
aspartate to proline at this position (residue 40, C. concisus numbering) could 
allow for rigidification of the extended loop connecting strand 2 with helix C. 
Within the globular domain of C. concisus PglC, T125E increases the negative 
charge. Co-evolution calculations described in Ray et al.(12) identified that residue 
Table 5.2. Consensus sequence results for C. concisus PglC 
 
Position* Ratio C. concisus PglC Consensus 
22 11.7 T L 
32 14 F L 
37 28 V L 
38 21.5 S G 
40 49 D P 
81 25 G T 
121 26 I L 
125 17 T E 
*Position numbering are for C. concisus PglC sequence 
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125 has an 81% probability of covarying with E155 (C. concisus numbering), 
meaning they are likely to interact with each other. Therefore, mutation of 125 
from a threonine to a glutamate would likely result in electrostatic clashing. 
Moving forward, for crystallographic purposes a C. concisus PglC variant 
containing the following mutations will be designed: T22L, F32L, V37L, S38G, 
D40P, G81T, and I121L. The consensus sequence will also be used in the pseudo-
enzyme analysis in section 5.3.2.3. Most of the defined mutations are 
conservative (aliphatic to aliphatic), however, some may improve the structural 
stability of the protein through reduction of potential electrostatic clashes or to 
rigidify a loop. 
 
Figure 5.6. The positions of the consensus divergence labeled on the 
structure of C. concisus PglC. The structure of C. concisus PglC (PDB ID: 5W7L) 
depicted in cartoon format with residues of consensus divergence labeled and shown in 
stick model colored by heteroatom.  
When calculating the consensus sequence for WcaJ (large monoPGT), the 
residue positions which diverged from the consensus sequence were localized 
mostly to either TM or the cytoplasmic domain rather than the PGT core domain. 
The frequency ratios are summarized in in Table 5.3. The positions with 
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frequency ratios greater than 10 are identified on the RaptorX structure prediction 
model of E. coli WcaJ as shown in Figure 5.7. There are a total of 14 residues that 
diverge from the consensus with a frequency ratio greater than 10. The frequency 
ratio values encompass a wider range (with respect to primary sequence) 
compared to the C. concisus PglC consensus sequence, partially due to the larger 
dataset (99 sequences). Notably, two positions, M160 and Q106 have frequency 
ratios of 51 and 45, respectively, and no other sequence in the data set had either a 
methionine at position 160 or a glutamine at position 106.   
 
Table 5.3. Consensus sequence analysis compared to E. coli WcaJ target 
protein.  
Position* Ratio E. coli WcaJ Consensus 
103 13 N T 
107 13.3 T F 
108 45 Q S 
109 14.3 L R 
120 14.3 S P 
146 30 M R 
160 51 M A 
178 35 H D 
180 15 P R 
213 26.3 Q P 
215 10 C R 
235 28.5 L Y 
245 9.9 I L 
294 19 C L 
372 29.5 T Q 
*Position numbering are for E. coli WcaJ sequence 
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The residue positions of divergence were identified and labeled on a deep 
learning structure prediction model of E. coli WcaJ generated in RaptorX.(145) 
The low frequency of mutations in the PGT domain is notable, with a total of two 
mutations compared to the six in the C. concisus PglC sequence that deviated from 
consensus. Further the positions of divergence are also unique, in that there is one 
mutation in the RMH (C294L). The TM and soluble cytoplasmic domains of large 
monoPGTs are not well conserved in general, as described in the following section 
(section 5.3.2.2). The cytoplasmic domain has no known function, and has not 
been resolved structurally. All mutations (N103T, T107F, Q108S, L109R, S120P, 
M146R, M160A, H178D, P180R, C215R, Q213P, L235Y, I235L, C294L, T372Q) are 
ideal for optimization of a crystallization construct. Based on these analyses, we 
can conclude that the PGT domain aligns with the consensus sequence, while the 
TM and cytoplasmic domains are more divergent. Additional analyses of the 
conservation of the TM and cytoplasmic domains will be conducted in following 
sections using the consensus sequence to further probe the connection between 





Figure 5.7. The positions of E. coli WcaJ sequence divergence are localized 
to the TM and cytoplasmic domains. The RaptorX structure prediction model of 
E. col WcaJ. Residue positions with frequency ratios greater than 10 are labeled and 
represented as sticks. Prediction model colored by domain (dark green, TMH; yellow-
green, soluble domain; lime green, PGT core).  
5.3.2.2 Evolutionary analysis of the monoPGT superfamily 
The PGT catalytic core domain is well conserved across all families of 
monoPGTs.(12) Based on docking studies by Dr. Leah Ray(215) there are three 
proposed subsites for substrate binding: NDP, sugar, and UndP subsites (Figure 
5.8). The highest sequence conservation is observed in the NDP subsite, likely 
because most monoPGTs act on UDP activated sugars, and therefore all bind UDP. 
Although based on sequence identity alone, the UndP subsite is not well conserved. 
However, as described in previous sections, the RMH exhibits a conserved pattern 
of aliphatic hydrophobic residues as we would predict could participate in van der 
Waal interactions with the isoprene tail of UndP. Lastly, the conservation of the 
amino acids lining the sugar binding subsite is low when comparing across the 
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small, large, and bifunctional monoPGT families. Most of the large monoPGTs use 
UDP-Glc (WcaJ),  UDP-Gal (WbaP), or UDP-GalNAc (WecP) as their substrates, 
whereas the monoPGTs take more unique sugars such as UDP-diNAcBac 
(Campylobacter PglCs) or FucNAc (S. aureus Cap5M). Because of this diversity, it 
is unsurprising that the sugar subsite is not well conserved across all families of 
monoPGTs. However, when analyzing the sugar subsite in a specific family or 
subclass which take the same UDP-sugar, there is high sequence conservation. For 
example, when analyzing the sequence conservation of WbaP homologs which 
takes UDP-Gal as its substrate, there is greater conservation within the predicted 




Figure 5.8. Conservation of monoPGTs A. small B. large WbaP- first 
neighbors. Ribbon depictions are colored by Shannon entropy from low conservation 
in red to high conservation in blue using UCSF Chimera.(163, 211)  
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Although the large monoPGTs share similar conservation in the PGT core 
domain to small monoPGTs, the TM and cytoplasmic domains are not well 
conserved. Within the TM domain, there are typically 4 TMHs, however the loops 
connecting the TMHs and the TMHs themselves can vary substantially in length. 
The cytoplasmic domain belongs to the Pfam “CoA-binding 3” (PF13727). Within 
this family of proteins there are 27 unique architectures, all but the solo domain 
are fused to enzymes in glycosylation pathways- either GTs, sugar-modifying 
enzymes, or monoPGTs. Structure homology model predictions (RaptorX and 
Phyre2) identify a member of the CoA-binding 3, UDP-QuiNAc dehydrogenase 
(UniProt ID: Q5E8F4) from Vibrio fischeri as a potential structural homolog for 
the cytoplasmic domain of the large monoPGT family (~12-15% ID across large 
monoPGTs). Although UDP-QuiNAc dehydrogenase is structurally characterized, 
it has not been biochemically characterized.  
To gain insight into the function of UDP-QuiNAc dehydrogenase, a genome 
neighborhood diagram (GND) was generated , which suggests that it functions in 
a glycosylation pathway. Furthermore, the UDP-QuiNAc dehydrogenase gene is 
immediately downstream from a gene encoding a small monoPGT (UniProt ID: 
Q5E8F5). One hypothesis is that this cytoplasmic domain of unknown function 
present in large monoPGTs may serve to bind and recruit NDP-sugar substrates 
for the PGT core domain. Prediction models of this domain all follow an α/β 
repeating pattern resembling a Rossmann fold, a canonical domain for nucleotide 
binding. Additionally, the cytoplasmic domain is only present in monoPGTs that 
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take sugar substrates such as UDP-Glc, UDP-Gal, or UDP-GalNAc, substrates 
which are used by numerous metabolic and glycosylation pathways. These 
common sugar substrates are not typically synthesized by genes in the same 
operon as their respective monoPGT genes, in the way that the unique sugars such 
as UDP-FucNAc are synthesized. Therefore, it is reasonable to propose that 
recruitment and localization of common sugar substrates to the membrane where 
the respective glycosylation pathway is functioning may be necessary to initiate 
glycan biosynthesis in pathways using large monoPGTs.  
5.3.2.3 monoPGT pseudoenzyme domains  
There are at least three clusters of an apparent nonfunctional monoPGT 
domain in the monoPGT superfamily SSN. In all cases identified thus far, these 
nonfunctional domains are fused to either a GT, or to a polyPGT. MonoPGT 
pseudoenzyme domains are identified based on lack of conservation of the “Asp-
Glu” catalytic dyad and surrounding residues. As illustrated in Figure 5.9, there 
is a unique signature following the conserved “Asp-Glu” motif (residues 93-94 C. 
concisus numbering). In functional PglC enzymes, there is a general consensus for 
“DELP” (residues 93-96, C. concisus numbering) whereas, in the polyPGTF-
monoPGTNF pseudoenzymes the this same region has a “YKLP” consensus 
sequence (Figure 5.9B).Upon further inspection, it was found that this region of 
the monoPGT varies depending on the domain to which the monoPGTNF is fused. 
In the case of the GT cluster 1 fusions, the consensus sequence is “NRPL”. For GT 
cluster 2, the “DELP” consensus is changed to “[R/K]xL[A/P]. In addition, the 
“Pro-Arg-Pro” nucleotide binding motif (residues 111-113, C. concisus numbering) 
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is only well conserved in fusions found in GT cluster 2. The “WbbL-like”-
monoPGTNF fusions (GT cluster 1) do not have any conservation of the “Pro-Arg-
Pro” motif. This is notable because as discussed in Chapter 4, WbbL is a TDP-
rhammnosyl transferase, and therefore has a differing NDP specificity compared 
to the majority of monoPGTs, which take UDP-activated sugars. Notably, there are 
three residues that are nearly absolutely conserved across functional and non-
functional classes- GxxSxxG (residues 104-110, C. concisus numbering), which 
play a  structural, rather than functional, role. These are positioned at one of the 
loops in the globular domain, and the conserved Ser participates in a hydrogen 
bond with a conserved Asp in the RMH motif, which could serve to position the 




Figure 5.9. Sequence logo for catalytic motif for select monoPGTs and 
pseudoenzyme domains. A. C. concisus PglC first neighbors, B. polyPGTF-
monoPGTNF, C. GT cluster 1 fusions (WbbL-monoPGTNF) and D. GT cluster 2 fusions 





It is known that the residence of PglC in nanodiscs doubles the UndP 
concentration, compared to empty nanodiscs.(180) Because the monoPGTNF 
domain cannot catalyze the PGT reaction, we hypothesize that the monoPGT 
domain may function to recruit and localize the membrane-soluble PrenP 
substrate to the biosynthetic enzymes in its respective glycosylation pathway. In 
order to investigate this hypothesis, sequence conservation (Shannon entropy) of 
the monoPGTNF domain (combining sequences from GT-monoPGTNF and 
polyPGTF-monoPGTNF proteins) was calculated by UCSF Chimera(163, 211) using 
a multiple sequence alignment generated in Clustal Omega(161) of monoPGTNF 
domains and PglC enzymes (small monoPGT) to analyze any differences sequence 
conservation between functional and nonfunctional domains. The conservation of 
monoPGTNF sequences was mapped onto the structure of C. concisus PglC (PDB 
ID: 5W7L), colored from red to blue to represent low to high conservation, 
respectively, for the monoPGTNF (Figure 5.10) and C. concisus PglC first 
neighbor sequences (Figure 5.8A). This analysis reveals that there is poor overall 
conservation in the pseudoenzyme domains compared to the small monoPGT 
functional sequences. The locations of highest conservation for the monoPGTNF 
domain include the RMH and one plane of the amphipathic helix. These motifs 




Figure 5.10. Structure of C. concisus PglC colored by conservation. C. 
concisus PglC (PDB ID: 5W7L) is depicted as a cartoon, and colored from low 
conservation in red to high conservation in blue using UCSF Chimera.(163)   
Notably, PglC enzymes (small monoPGTs) exhibit high conservation of 
amino acids throughout its sequence, especially in the globular domain and β-
helix, which are proposed to confer specificity for the NDP activated sugar 
substrate.(215) Although the RMH exhibits poor conservation aside from the 
KxxxD and proline kink residues, the residues flanking the proline kink all are 
similar in composition, mostly small aliphatic residues.  
 
 
Figure 5.11. Combined HMM for pseudoenzyme RMH motif. 
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There is a subset of pseudoenzyme domains which are approximately 150 
amino acids in length (compared to ~180-200 average for small monoPGT 
domain). The truncation of amino acids is mostly localized to loss of the extended 
loop (ANGEL loop) between β-strands. However, the overall fold is still intact, and 
the ΔGtransfer calculated by the PPM server(141) using a homology model generated 
in Phyre2(164) (UniProt ID: A0A1W6LJ76, Figure 5.12) is -32.5 kcal/mol, 
compared to -39.5 kcal/mol for C. concisus PglC structure. This calculation 
predicts the energy of transfer from water to the membrane, and illustrates that 
transfer of the truncated pseudoenzyme domain is just as favorable as transfer of 
C. concisus PglC. The depth the truncated pseudoenzyme is embedded in the 
membrane leaflet is also consistent with C. concsisus PglC with depths of 13.9 Å 
and 14 Å, respectively. These calculations are obviously biased by the fact that the 
C. concisus PglC structure was used as a model for threading. However, based on 
the fact that the RMH topology is conserved, these predictions are also what would 
be expected for RMH embedding. The structure prediction (both homology and 
deep learning models) and PPM computations allow us to predict that the 
truncated monoPGT pseudoenzyme domains should retain structural integrity and 




Figure 5.12. Homology model of the monoPGT pseudoenzyme domain of a 
GT-monoPGT fusion in the membrane. RMH is colored gray, by heteroatom. 
Membrane plane depicted as blue spheres. UniProt ID: A0A1W6LJ76. Homology model 
generated using Phyre 2.(164) Protein was positioned into the membrane using PPM 
server(141).  
5.4 Conclusions and future directions 
Thus far, searches using the HMMs generated above result solely in 
bacterial transferase domains (PGT) and therefore, the next efforts will aim to 
provide a more general HMM for the RMH motif. First, rather than providing 
specific residue identifiers in the aliphatic positions, a model that more generally 
assumes aliphatic residues in these positions is necessary. Furthermore, 
combining this HMM with other families, such as LpxM and PlsC, identified by 
Allen et al.(217) could provide a less biased model. RMH topology of LpxM has 
been confirmed by Entova et al. via SCAM analyses(209). Using these sequences 
to broaden the HMM could allow for detection of novel proteins with the RMH 
motif topology. Further, a more sophisticated model is necessary in which the 
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motif is broken into three possible states: cytoplasmic loop, helix, and helix-kink. 
Based on TMHMM predictions and the positive-in rule, cytoplasmic cap motifs 
may have a higher propensity for positively charged residues than periplasmic or 
extracellular cap motifs.(195, 196) However, there is no evidence of proteins 
interacting with the outer-leaflet of the cell membrane via a RMH motif. Therefore, 
current HMMs are specific for monotopic proteins interacting with the 
cytoplasmic facing leaflet of the membrane.  
The divergence of monoPGT domain architectures is appears to also be 
linked to the soluble sugar substrate specificity. All biochemically characterized 
small monoPGTs are highly selective for unique sugar substrates such as UDP-
FucNAc (CapM) or UDP-diNAcBac.(11, 150) In contrast, the large monoPGTs, 
containing the cytoplasmic domain of unknown function, use common sugars such 
as UDP-Glc, UDP-Gal, or UDP-GalNAc.(154) There is some evidence that 
suppressor mutations in S. pneumoniae CpsE (large monoPGT) prevent capsular 
polysaccharide (CPS) biosynthesis(45), which is unsurprising. However, the 
suppressor mutations occur in both the PGT core domain and the cytoplasmic 
domain, emphasizing the possible importance of the functionality of the 
cytoplasmic domain.(45) The initial studies do not follow up on the mutational 
analysis of CpsE, so future studies could look at the impact of the cytoplasmic 
domain on sugar recognition and rate of catalysis. Possibly, the small monoPGTs 




Investigation of the monoPGT pseudoenzyme domains reveals the overall 
poor sequence conservation yet the overall RMH motif is retained. This finding 
supports our hypothesis that the function of the RMH motif, in addition to 
membrane interaction, is to recruit and bind the lipid carrier substrate. The 
predicted pseudoenzyme domains should be characterized biochemically first to 
confirm lack of catalytic activity, and second to identify whether the 
pseudoenzymes can bind either an NDP-sugar or a PrenP substrate. Although they 
do not appear to retain phosphoglycosyl transfer activity, they may have a 
secondary function in the context of pathway regulation or recruitment and 
localization of either the NDP-sugar substrate, or more likely, the UndP substrate.  
Investigation of the RMH with respects to UndP recognition and 
recruitment can be studied in the context of the pseudoenzyme fusion enzymes, 
specifically polyPGTF-monoPGTNF and the enzymes in GT cluster 1. Previous 
studies of C. concisus PglC confirm that PglC has the ability to increase the 
concentration of UndP in a liponanoparticle.(180) One possible path for PGT 
family evolution is that the large monoPGTs have evolved from the polyPGT 
superfamily and that the pseudoenzymes are a link between the two. Testing the 
UndP concentrations in nanodiscs hosting the pseudoenzyme in comparison to a 
polyPGT alone and to polyPGTF-monoPGTF can allow for comparison and 










































This chapter will summarize Chapters 4 and 5 and provide suggestions for further 
exploration within glycoconjugate biosynthesis and the monotopic phosphoglycosyl 




Prokaryotic glycan biosynthesis produces  glycoconjugates essential for 
structural integrity and virulence factors essential for their pathogenesis.(18)    
Inhibition or silencing mutations of enzymes in these  pathways yield decreased 
glycoconjugate production and decreased virulence of pathogenic species, 
validating glycosylation pathways as  ideal targets for development of novel 
therapeutics.   One of the appealing targets include  enzymes catalyzing the first 
membrane committed step in en bloc glycosylation, phosphoglycosyl transfer. 
Phosphoglycosyl transferases (PGTs) are separated into two isofunctional 
superfamilies based on domain architecture: polytopic PGTs (polyPGTs) and 
monotopic PGTs (monoPGT), defined by their insertion into the membrane. 
PolyPGTs are comprised of 10-11 transmembrane helices (TMHs) and proceed 
through a ternary complex, with direct transfer of the phosphosugar to the lipid 
carrier. In contrast, monoPGTs interact with the membrane with a novel, re-
entrant membrane helix (RMH) topology whereby they interact with only one 
leaflet of the lipid bilayer.(12) Additionally, mechanistic work by Das et al. using 
Campylobacter concisus PglC elucidated the bi-bi ping pong mechanism in a 
phosphoglycosyl aspartate intermediate is formed before phosphoglycosyl transfer 
to the lipid carrier.(11)  
Before the studies described in Chapters 4 and 5, the monoPGT superfamily 
was delineated into 3 major classes of enzymes based on domain architecture: 
small monoPGTs, large monoPGTs, and N-acetyltransferase-small monoPGT 
bifunctional enzymes. The small monoPGTs were termed the PGT catalytic core, 
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the minimal catalytic unit, while the large monoPGTs are comprised of 4 TMHs, a 
cytoplasmic domain of unknown function, and the PGT core domain.  One 
bioinformatic study described in Lukose et al. used multiple sequence alignments 
of exemplar members in the family to identify highly conserved motifs, and then 
confirmed their roles via site directed mutagenesis and biochemical assays.(14) 
However, the divergence of small monoPGTs and large monoPGTs with respect to 
the additional domains was unclear. Furthermore, the diversity of the monoPGT 
superfamily as a whole was undersampled and underappreciated.  
Chapter 4 and 5 describe a bioinformatic approach to studying the 
monoPGT superfamily. Through generation of a sequence similarity network 
(SSN) we identified that approximately 5 % of all superfamily members are fusion 
proteins. Based on this analysis, we reassigned defining categories of the monoPGT 
superfamily. The superfamily is broken into three families, building off previous 
work: small monoPGTs, large monoPGTs, and bifunctional monoPGTs. The 
bifunctional family containing fusion enzymes of accessorizing domains fused to 
either the small or large monoPGTs, is now further categorized into four 
subclasses, defined by the accessorizing domain: sugar-modifying, glycosyl 
transferase, regulatory, or polyPGT-monoPGT. The phylogenetic reconstruction of 
the monoPGT superfamily provides support that the large monoPGT enzymes 
were the original monoPGT enzymes, as both the small and bifunctional monoPGT 




Each subclass of bifunctional monoPGTs were further analyzed by the 
accessorizing domain. The sugar-modifying subclass contains dehydratases 
(stereochemistry retaining or inverting), aminotranserases, N-acetyltransferases, 
dehydrogenases, and reductases. The glycosyl transferase family was more difficult 
to define based on the high structural similarity and low sequence identity across 
homologs. However, homologs were predicted for each cluster of GT-monoPGT 
fusions present in the SSN based on sequence identity to target homologs and 
superfamily identifiers. The regulatory domain containing bifunctional subclass 
are predominately represented by either response-regulatory domains 
(IPR001789) or STAS domains (IPR002605). Conservation of crucial catalytic 
motifs confirm that these domains should be functional. The presence of these 
regulatory domain bifunctional enzymes supports the hypothesis that the PGT 
reaction may be tightly regulated. As it is the first membrane-committed step, this 
reaction requires recruitment of the common lipid carrier substrate. Therefore, the 
flux of each pathway is likely dependent on each independent glycosylation 
pathway in that there must be some form of equilibrium/regulation between 
pathways as they all use the same lipid carrier substrate to synthesize the building 
glycan.  
The identification of polyPGT-monoPGTs elucidates a new evolutionary 
link between these isofunctional superfamilies, which is explored in Chapter 5. In 
most of these fusions, the monoPGT domain is likely to be nonfunctional 
(pseudoenzyme) in that the catalytic dyad “Asp-Glu” motif and predicted 
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nucleotide binding motif “Pro-Arg-Pro” is not  conserved. One hypothesis our lab 
in collaboration with the Imperiali Lab (MIT) has developed is that the monoPGT 
domain, specifically the RMH has  evolved as a domain for recruiting and binding 
the lipid carrier substrate, undecaprenol phosphate (prokaryotic systems).   
Bioinformatic investigation of pseudoenzyme domains across the bifunctional 
family (glycosyl transferases and polyPGT-monoPGT subclasses)  identified 
overall poor conservation, yet the RMH motif was absolutely conserved at the 
KXXXD as well as the aliphatic hydrophobic  residues  broken up by either a 
proline or tryptophan that form the helix-break-helix motif. 
The generation of consensus sequences using exemplar enzymes C. concisus 
PglC (UniProt ID: A7ZET4) and E. coli WcaJ (UniProt ID: P71421)  identified 
residue positions of divergence between the target and the consensus. Notably, in 
E. coli WcaJ, most of these mutations were localized to the TMH and cytoplasmic 
domains. The cytoplasmic domain of unknown function is poorly conserved across 
all large monoPGT families, and even within respective orthologs (E. coli WcaJ, S. 
enterica WbaP, A. hydrophila WecP).  Investigation of the cytoplasmic domain 
using homology search engines (Phyre2 and RaptorX)(164, 165)  identified UDP-
N-acetylquinovosamine (UDP-QuiNAc) dehydrogenase as a structural homolog of 
this domain. UDP-QuiNAc dehydrogenase has not been biochemically 
characterized but is predicted to function in a glycosylation pathway based on its 
genome neighborhood. The domain is repeating α/β unit, resembling a Rossmann 
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fold,  a canonical nucleotide binding domain. Therefore, we propose that this 
domain may serve to bind and recruit NDP-sugar substrates for the PGT reaction.  
Together, these bioinformatic studies provide a deep analysis of the  
monoPGT superfamily via identification and bioinformatic characterization of the 
three monoPGT families.   With this framework, future work can identify the 
mechanistic and structural divergence of each of these families of enzymes.  As 
there is little known about this superfamily of enzymes still, there are many 
different avenues to explore for future experiments.  
Understanding pathway flux and regulation will be crucial for target 
validation for therapeutic development. Specifically, generating a mechanistic 
model for a glycoconjugate pathway can elucidate specific steps in the pathway that 
would be the best targets for therapeutic intervention. Using the information we 
have built through bioinformatic analyses of the superfamily, bifunctional 
enzymes could be exploited to answer questions of pathway flux, protein-protein 
interactions, and pathway regulation.   
First, from the perspective of pathway flux and pathway throughput- the 
bifunctional class of enzymes are an ideal family of enzymes to explore.  Our 
laboratories (Imperiali and Allen) have been interested in exploring the role of 
protein-protein interactions in pathway flux, specifically among glycosyl 
transferases, and between glycosyl transferases and the monoPGT. Structural 
characterization of these members could identify the protein-protein interface, as 
well as any potential tunnels for shuttling the product of one domain to the active 
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site of the next.  Furthermore, solution dynamic experiments via small angle 
neutron scattering and hydrogen-deuterium exchange mass spectrometry (HDX-
MS) in nanodiscs could provide a mechanistic model for substrate recruitment and 
binding. Small angle neutron scattering is particularly appealing to this system in 
that there can be specific isotopic labeling of the lipids versus protein and substrate 
in order to distinguish between the lipid nanodisc and protein that could not be 
done via small angle X-ray scattering.   
Building off the question of pathway flux, regulatory mechanisms could 
definitely impact the overall flux through a glycoconjugate pathway. Within the 
bifunctional family, the regulatory domains provide a unique opportunity for 
studying regulation of the monoPGTs. Little is understood about pathway 
regulation in glycoconjugate pathways, especially with respect to the PGT reaction. 
Therefore, studying these systems, and identifying any potential complimentary 
proteins in the operon (ie: protein phosphatases, kinases) will allow for 
investigative experiments to elucidate any regulatory mechanisms.  
A secondary avenue for further exploration foucses on elucidating 
mechanisms of substrate specificity and evolution across the monoPGT and 
polyPGT superfamilies. The re-entrant membrane helix (RMH) motif and 
cytoplasmic domain of unknown function (large monoPGTs) should be 
investigated to probe the question of lipid carrier (RMH) or NDP-sugar 
(cytoplasmic domain)  substrate recruitment. The pseudoenzymes would be ideal 
domains to study from the standpoint of lipid carrier recruitment, particularly the 
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smaller (~150 aa) domains because they are likely to be the structural core of the 
protein. Furthermore, potential differences in recruitment and specificity between 
bacterial (undecaprenol phosphate) and archaeal members (dolichol phosphate) 
could provide insight into differences not only between monoPGT members, but 
between potential organismal differences in substrate recruitment.  
Lastly, towards an understanding of the evolution of two isofunctional 
superfamilies of enzymes, the function of the polyPGT-monoPGT fusions should 
be explored. These provide a unique opportunity to evaluate differences between 
these  enzymes. Bioinformatic and future structural analyses can probe the 
question of whether the TM domain of large monoPGTs evolved from the polyPGT 
domains. Additionally, questions of lipid carrier recruitment can be explored as 
well, through investigation into whether the monoPGTNF domain in polyPGTF-
monoPGTNF fusions increases the local concentration of lipid carrier 
(undecaprenol phosphate) compared to the monodomain-polyPGT enzymes.  
Together, these proposed experiments seek to answer mechanistic 




APPENDIX A1: Lanthanide-Binding Tags for 3D X-Ray Imaging of 
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X-ray Fluorescence Microscopy (XFM) is a powerful method for imaging 
the trace-element concentration, distribution, and speciation in cells and tissues. 
Even though the technique has been around for more than 30 years, only recently 
have advances in X-ray sources, optics, and detectors enabled two- and three-
dimensional imaging at the nanoscale with attogram detection sensitivity.(218–
221) A few recent examples include the observation of “zinc sparks” in oocyte 
fertilization,(222) copper binding to amyloid plaques in Alzheimer’s disease,(223) 
manganese accumulation within nanovesicles of the Golgi apparatus in 
Parkinson’s disease(224), new approaches for neuroprotection with chemotherapy 
treatment,(225) and heme detoxification by the malaria parasite.(226)  
Despite the recent advancements in focusing optics(227) and faster 
fluorescence detectors,(228, 229) the spatial resolution of  XFM has been limited 
to a few hundred nanometers in 2D and typically the micron scale in 3D making it 
difficult to image subcellular organelles and individual proteins. Here, we address 
this challenge by taking advantage of the development of new multilayer Laue X-
ray lenses (MLLs) for imaging in 2D and 3D with a sub-15 nm beam.(230)  
Additionally, there are very few X-ray sensitive tags for co-localizing 
individual proteins of interest with the trace-element distribution in subcellular 
structures.(231, 232) Today, fluorescence microscopy is a ubiquitous method for 
imaging individual proteins within the context of a living cell, where fluorescent 




conjugation and genetically encoded fusion tags have provided target-specific 
visualization.(233, 234) But there remain major opportunities for the development 
of new methods and tags to enhance spatial resolution with minimal interruption 
of native structures and interactions. 
In this study, we build upon the concept of using encoded fusion tags as a 
method for visualizing specific proteins in cells by introducing X-ray sensitive tags 
that improve the image resolution beyond the diffraction limit of visible light. 
Lanthanide-binding tags (LBTs) are short peptides (15-20 amino acids) comprised 
almost entirely of a nanomolar-affinity lanthanide-binding domain.(235–237) 
When complexed to a lanthanide ion, the LBT in a fusion protein has previously 
been used for investigations involving photoluminescence(238), NMR 
spectroscopy,(239–241) MRI,(242) and X-ray crystallography.(243, 244)  
A1.2 Materials and Methods 
A1.2.1 Expression of LBT-fusion proteins in E. coli 
The strategy for inserting LBTs into loop regions of proteins has been 
described previously. (236)For OmpA, the crystal structure of the membrane-
spanning region was used to identify extracellular loops for LBT insertion (PDB ID 
1BXW). The LBT peptide sequence (YIDTNNDWIEGDEL) was inserted between 
residues 109 and 112 of OmpA, with deletion of residues 110 and 111. Synthetic 
genes for LBT-OmpA and wild-type OmpA (P0A910) were purchased from 
Genewiz.   The target genes sequences were cloned via PCR into pDONR221 using 







TATGCGTCACCGATGTTGTTGGT-5’ (Genewiz) followed by insertion into 
pDEST14 via Gateway cloning. The gene encoding Ubi-dLBT was synthesized and 
cloned into pET2a vector as described previously.(235, 239) In these constructs, 
the dLBT gives a greater signal than the sLBT due to the two ion binding sites; 
however, when inserting LBTs into loops, the sLBT is less disruptive to the OmpA 
structure. The KD values for Eu(III), Tb(III) and Er(III) for 
YIDTNNDGWYEGDELLA are 62±4 nM,  57±3 nM and 78±6 nM 
respectively.(244) The dissociation constants for the dLBT have been previously 
measured by observing sensitized terbium luminescence. The KD values for Tb(III) 
are 2.4 nM and 23 nM for the first and second binding events compared to Tb(III) 
for the sLBT. Thus we anticipate the values for Eu(III) and Er(III) would be in the 
same low nM range far below the saturating concentrations used in the presented 
experiments.(239) 
SoluBL21 E. coli cells were transformed with plasmids containing OmpA-
LBT or OmpA genes and BL21 DE3 cells were transformed with plasmids 
containing the Ubi-dLBT or ubiquitin genes. Individual colonies were picked to 
generate single cell-stocks stored at -80°C. LB/Ampicillin (100 µg/mL) was 
inoculated with one stab of the cell stock and grown overnight at 37 °C with 
agitation at 200 rpm. Cultures (20 mL LB/Ampicillin) were inoculated with 150 




of 0.6-0.8 they were induced with 1 mM IPTG and grown for 4 hours at 37 °C 
shaking (200 rpm) to a final OD600 = 0.9-1.2.  Cells were harvested by centrifugation 
(3,000 x g for 2 minutes) and resuspended in wash buffer [150 mM NaCl] (0.3 mL) 
to remove excess phosphate. Cells were washed three times, and then resuspended 
and incubated for 15 min in 150 mM NaCl with 5 µM EuCl3 or ErCl3. The cells were 
then washed again (3x) with wash buffer to remove unbound lanthanide ions.  
BL21 DE3 E. coli cells were transformed with pET2a-dLBT-ubiquitin 
(YIDTNNDGWIEGDELYIDTNNDGWIEGDELLA). The dLBT-ubiquitin was 
expressed in BL21 DE3 E. coli cells to OD600 = 0.6-0.8 and induced with 1 mM 
IPTG for 4 hours (final OD600 = 0.9-1.2). EuCl3 or ErCl3 (1 mM) was added at the 
time of induction. The addition of lanthanide post-induction had no appreciable 
impact on growth rate, suggesting that E. coli were not adversely affected by 
exposure to these lanthanides. Cells were harvested by centrifugation. Cells were 
then resuspended and washed 3x in 1 mL of 150 mM NaCl to remove phosphate 
and excess lanthanide ions. 
Eu-LBT and Er-LBT were chosen for these experiments because these non-
endogenous elements were easier to observe when present. Er and Eu have similar 
affinities for the LBTs, and similarly low toxicity. For both LBTs, the following 
conditions were used: (1) Protein only, no lanthanide, no LBT; (2) Protein+LBT, 
no lanthanide; (3) Protein+lanthanide, no LBT; (4) Protein+LBT+lanthanide. 
Once the cells were prepared and washed, they were spun down to a loose 




the cell pellet was resuspended into a 2 µM NaCl solution with 0.025 OD 100 nm 
gold nanoballs (CytoDiagnostics, #GRF-100-20) and thoroughly mixed. The gold 
nanoballs were added as fiducial markers to aid in the tomography reconstruction. 
A one microliter aliquot of the cell solution was pipetted onto a silicon 
nitride membrane (Norcada XT01N-R) for APS data collection or a silicon 
substrate “diving board” (Norcada NCT4155P-III-Cr) that has Cr fiduciary grids 
for HXN data collection. The cells were left to air dry overnight.  At that 
concentration of NaCl, the E. coli cells became embedded in salt microcrystals (1-
20 µm wide). The NaCl crystals provided a nonaqueous medium to retain the 3D 
structure of the E. coli while minimizing radiation damage due to a shorter scan 
time.(221)  
A1.2.2 Scanning electron microscopy 
Samples were pre-screened with a visible light microscope (Nikon Eclipse 
LVDIA-N with a DsRi2 camera attachment) and a benchtop Scanning Electron 
Microscope (JEOL JCM 6000) for cell identification, correlation and navigation 
during data acquisition at the beamline.  It should be noted that SEM prescreening 
with the silicon nitride substrates was not possible due to charging effects due to 
the substrate’s poor/low conductance.  
A1.2.3 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
ICP-MS sample preparation and measurements were carried out in the 
Elemental Analysis Core at OHSU. Cell pellets were digested with 50 µl of 
concentrated HNO3 (trace metal grade, Fisher) directly in the 15 ml polypropylene 




digested for 1 hr at 90˚C using a heating block. After cooling, 1000 µl of 1% HNO3 
(trace metal grade, Fisher) was added to each sample. The final volume of 3 
random samples was determined to be 1050 µl.  
ICP-MS analysis was performed using an Agilent 7700x equipped with an 
ASX 500 autosampler. The system was operated at a radio frequency power of 1550 
W, an argon plasma gas flow rate of 15 L/min, Ar carrier gas flow rate of 0.9 L/min. 
Elements were measured in kinetic energy discrimination (KED) mode using He 
gas (4.3 ml/min). Data were quantified using an 11-point (0, 0.5, 1, 2, 5, 10, 20, 50, 
100, 500, 1000 ppb (µg/kg)) multi-element standard for K, Ca, Mn, Fe, Cu, and Zn 
(CEM 2, (VHG-SM70B-100) and a single element standard for Er (VHG-PERN-
100)). For each sample, data were acquired in triplicate and averaged. A coefficient 
of variance (CoV) was determined from frequent measurements of a sample 
containing ~100 (200 for Ca) ppb of all elements. An internal standard (Sc, Ge, Bi) 
continuously introduced with the sample was used to correct for detector 
fluctuations and to monitor plasma stability. Accuracy of the calibration curve was 
assessed by measuring NIST reference material (water, SRM 1643f) measurement 
and found to within +/- 6 % of the published concentrations for all elements listed 
by NIST (no Er). 
A blank sample tube was prepared along with the samples to determine 
background counts from the tubes and the concentrated acid. With the exception 
of Ca (~15% for 2 samples and <10% for all others), the background concentrations 




concentrations. A NIST bovine liver control (SRM 1577c) and a sample containing 
100 ppm Er were prepared using the same procedure as for the cell pellets and 
measured to evaluate recovery and accuracy of the digestion procedure. For the 
Bovine NIST standard, recovery was within +/- 15 % of the published 
concentrations for all elements listed by NIST (no Er). Recovery of Er in the Er 
control sample was 95% of the expected concentration. 
A1.2.4 X-ray fluorescence microscopy and tomography 
Two-dimensional XFM was performed at the Bionanoprobe (BNP) at 
beamline 21-ID-D (now at 9-ID-B) at the Advanced Photon Source at Argonne 
National Laboratory. Three-dimensional X-ray nanotomography was performed at 
the Hard X-ray Nanoprobe beamline 3-ID at the National Synchrotron Light 
Source II (NSLS-II) at Brookhaven National Laboratory.   
At the BNP, 2D experiments were performed using a double-crystal Si 
monochromator to produce 10 keV incident X-rays, and a Fresnel zone plate to 
produce a focus spot with a resolution of ~85 nm.(245) An energy-discriminating, 
four-element silicon drift detector was oriented at 90° to the incident X-ray beam 
direction to collect the X-ray fluorescence signal. Coarse scans were collected in 
continuous fly-scan mode using a step size of 100 nm/pixel and a dwell time of 50 
ms, whereas high resolution scans were collected with 50 nm/pixel and a dwell 
time of 100 ms.  
At 3-ID, experiments were performed with a monochromatized energy fixed 
above the Zn K-edge at 12 keV. The beam was focused to a sub-15 nm spot (14 nm 




discriminating, three-element silicon drift detector was oriented at 90° from the 
incident X-ray beam direction to collect the X-ray fluorescence signal. Two-
dimensional fluorescence, via continuous fly-scan, was performed using a step size 
of 20 nm/pixel and a dwell time of 250 ms. The tomography datasets were 
obtained using projection images of 100 × 80 pixels at a 20 nm pixel size, with a 
dwell time of 100 msec per pixel, over a rotation angle range of -39 to 132° in 3° 
increments. After each rotation interval, a short coarse scan (~1 min) was used to 
center the sample in the field of view of the projection image, resulting in a total 
imaging time for a complete cell of approximately 15 hours, excluding overhead. 
A1.2.5 XRF image analysis and tomography reconstruction 
The element-specific images were generated with either the MAPS 
software(246) (APS)  or PyXRF software(247) (NSLS-II). Each pixel was fitted and 
the concentrations of Cl, Ca, Fe, Cu, Zn, Eu, and Er were determined. For the fitting 
process, the summed spectrum was first fitted using the non-linear least squares 
method to determine the global parameters such as the energy-calibration values, 
widths of the global peaks, and parameters related to the Compton and elastic 
peaks. Once the correct global parameters were obtained, the peak area of each 
element under the XRF spectrum of each single pixel was then fitted using a 
nonnegative least squares approach.(221) To obtain representative spectra from 
the different sample treatments, regions of interest were selected over entire 
bacteria to extract a summed spectrum over the pixels selected. 
TomoPy software package was used for processing of the datasets.(248) The 




The aligned image stack was reconstructed using the maximum-likelihood 
expectation-maximization (MLEM) method(250) and 20 iterations were used to 
reconstruct each slice. To correct for any attenuation (due to the thickness of the 
diving board, since the XRF photons are detected through the diving board for 
some projections), the total intensity of the fluorescence images was normalized to 
be constant for all the images taken at different projection angles. From the 
normalized intensity reconstructions of Er and Zn, isosurface images were created 
by plotting Er values of 1.0 and 0.46 for Er and Zn respectively. To estimate the 
spatial resolution of the tomographic reconstruction, a power spectral analysis was 
done using the Er tomography dataset. For low-photon statistics images like XRF 
images, one can use the fact that Poisson fluctuations (‘shot noises’) are 
uncorrelated from pixel to pixel so that, at high spatial frequencies, one arrives at 
a noise floor in Fourier power analysis.(251)  
A1.3 Results and Discussion 
We have adapted the use of LBTs for XFM, with the goal of imaging 
individual target proteins at a spatial resolution approaching 10 nm within intact 
cells, while simultaneously co-localizing the trace-element distribution and 
concentration. As lanthanides are rare in living organisms, the use of LBTs 
provides a protein-specific tag for visualizing proteins with XFM without 
competing signals from endogenous metal ions. The LBTs can easily be 
incorporated into the target protein sequence, and their small size minimizes any 




cell. The high affinity of the LBTs for lanthanides means that experiments can be 
performed at a low lanthanide concentration to mitigate toxic effects. The 
dissociation constants for Eu3+ and Er3+ with a single LBT are 62±4 nM and 78±6 
nM, respectively. (244) 
For LBTs to be useful for nanoscale cellular imaging, they must be 
detectable at low concentrations, where the background signal (e.g. non-specific 
binding) is minimized. First, we demonstrate the use of trivalent Eu- and Er-LBTs 
to image a membrane protein, Outer Membrane Protein A (OmpA), located on the 
surface of Escherichia coli (E. coli) (Figure A1.1). Amongst membrane proteins, 





Figure A1.1. XFM images of E. coli cells harboring OmpA-LBT reveal 
distribution of Cl, Eu, and Zn. Zn, Eu, and Cl are visualized as green, red, and blue, 
respectively, and an overlay of all in the lower left. Images were collected with zone plate 
optics and a 85 nm beam size. Scale bar is 2 microns an concentration units are µg/cm2. 
Here, E. coli cells were embedded in small NaCl crystals (1-20 µm), which 
we have found to maintain the three-dimensional shape of the cells.(221) In 
addition, the cells provide a negative contrast in the Cl XRF image, making them 
easy to locate.  Figure A1.1 shows a cluster of five E. coli cells embedded in NaCl 
crystals wherein OmpA was tagged with the LBT (YIDTNNDWIEGDEL) into an 
outward-facing loop and the cells were exposed to 5 µM EuCl3. The XFM images of 
the Cl, Eu, and Zn distributions are shown, along with the 3-color composite image. 
The outline of the cells can be visualized in the Cl image, where they appear as dark 




The Eu XFM image shows that Eu is mostly concentrated at the outer 
surface of the cells. As Eu is not endogenous to the cell, it is only expected to be 
associated with the LBT which is bound to the extracellular loop of OmpA. Hence 
the XFM image is consistent with a membrane-bound Eu-LBT.  
XFM can simultaneously detect multiple trace elements in the cell, so other 
elements were also examined. The Zn image shows an inhomogeneous distribution 
in some cells where the Zn concentration is localized at the poles. In bacteria, 
divalent zinc is strongly associated with the ribosomes, which are typically located 
at the polar-end caps of cells(253–256) and has been observed with XFM 
previously.(221) 
We also examined the ability to visualize proteins tagged with LBTs in the 
cytosol (Figure A1.2). In this case, a double LBT (dLBT; 
YIDTNNDGWIEGDELYIDTNNDGWIEGDELLA) was fused to the N-terminus of 
ubiquitin (Ubi-dLBT) and heterologously expressed in E. coli with ErCl3 added at 
the time of induction. Ubiquitin and ubiquitin-like proteins are abundant in cells 
and act as protein modifiers that regulate proteosomal degradation.(257–259) For 
example in HEK293 cells, the ubiquitin concentration is ~85 µM in both free and 





Figure A1.2. Visible light image and XFM images  of E. coli cells with Ubi-
dLBT incubated with 1 mM EuCl3. The distribution of Ca and Er are represented as 
blue and green, respectively.  An overly of Ca and Er in the E. coli cells is shown in the 
bottom right. Au nanoballs (in red) are 100 nm in diameter and were added as fiducial 
markers for tomography reconstruction. Images were collected with zone plate optics 
and an 85 nm beam size. Scale bar is 2 microns and concentration units are µg/cm2. In 
the visible image, each yellow arrow indicates an E.coli cell. 
 
For visualizing intracellular proteins, the detection sensitivity is also 
dependent upon the transport of the lanthanide into the cells. Although the entry 
of lanthanide ions is not yet fully understood, studies suggest that lanthanides are 
transported into the cytosol via the sodium-calcium exchanger and calcium-ion 
pumps using electrochemical gradients.(261, 262) They may also be transported 




Mass Spectrometry (ICP-MS) performed on the OmpA-LBT cells as a function of 
Eu concentration showed that the lanthanide reduced both the potassium and 
calcium concentrations in the cells, supporting the literature reports of ion-
channel transport (Figure A1.3).  
 
Figure A1.3. ICP-MS data from E. coli cell digests. The concentrations of 
potassium (A), calcium (B), and erbium (C) are plotted as a function of Er concentration 
in the cell media. , as the Er concentration increases in the media, more Er is taken up 
into the cells. However, both the K and Ca concentrations decrease with increased Er, 
suggesting that the K and Ca ion channels may be involved in Er transport. 
Figure A1.2 shows the optical and XFM images of a cluster of seven E. coli 
cells expressing Er-loaded Ubi-dLBT. The Ca image shows that this ion is 
homogeneously distributed in all cells. A similar uniform distribution was seen for 
Er, which is consistent with the fact that ubiquitin is expressed throughout the 
cell.(264) However, although Er was uniformly distributed, it was only visualized 
in one dividing cell, which can clearly be seen in the 3-color composite image, 
indicating that the lanthanide uptake efficiency and/or tag expression need to be 
further optimized for future studies. In cells not expressing Ubi-dLBT, there was 
no discrete emission signal in the presence of Er, suggesting that the lanthanide 




X-ray fluorescence spectra from Ubi-dLBT-encoded cells exposed to 1 mM 
EuCl3, revealed distinct Eu X-ray fluorescence (Figure A1.4). Without expression 
of the tag, i.e. uninduced Ubi-dLBT, the Eu fluorescence peaks are absent. 
Similarly, for OmpA, distinct X-ray fluorescence peaks for Eu were seen at 5.85 
keV (Lα1) and 6.46 keV (Lβ1) (Figure A1.4). However, in cells that were exposed 
to Eu in the absence of the OmpA-LBT construct, X-ray fluorescence peaks from 







Figure A1.4. The energy dispersive spectra from cell samples. (A) The energy-
dispersive spectra from E. coli incubated with Eu in the presence of the OmpA-LBT tag 
(solid red) and in the absence of the LBT tag (dashed red). The Eu Lα and Lβ peaks are 
seen at 5.85 and 6.46 keV respectively in the spectrum with the LBT. (B) The energy-
dispersive spectrum of cells with Ubi-dLBT (+Eu) is seen in solid blue, uninduced Ubi-
dLBT (+Eu) is seen in dashed blue. The Eu Lα and Lβ peaks are seen at 5.85 and 6.46 
keV respectively in the spectrum with the induced cells. (C) The energy-dispersive 
spectrum of cells with Ubi-dLBT (+Er) is seen in solid green, and the spectrum of the 
control cells (-LBT, -Er) is seen in dashed green. The Er Lα and Lβ peaks are seen at 6.95 
and 7.81 keV respectively in the spectrum with the LBT. Yellow vertical lines in all panels 
represent the XRF L-lines for Eu (A, B) and Er (C). Contributions from Ni and W are 
from components of the X-ray microscopes. Cl*Cl pile-up peaks are seen at 5.4 keV in 
(A) and (C). The results of the various conditions show that, when the LBT is present, 
the lanthanide ion binds to the tag and its L-lines are seen in the spectra. When the tag 





The design of LBTs is such that the binding site can accommodate different 
lanthanides, all with nanomolar affinity.(265, 266) Since the fluorescence spectra 
are fitted to extract the concentration of the element present in the cells, it is 
beneficial to choose a lanthanide that minimizes overlaps of fluorescence emission 
lines with the trace element(s) of interest. For example, the Lα and Lβ peaks of Eu 
are found at 5.85 keV and 6.46 keV, respectively. In this spectral range, the Mn Kα 
and Fe Kα peaks fall at 5.90 keV and 6.40 keV, respectively, and can overlap with 
the Eu signal. This overlap can be reduced by using Er-LBT, where the Lα and Lβ 
peaks fall at 6.95 and 7.81 keV respectively. However, although there would be no 
overlap with the Mn Kα¸ there would be an overlap with the Fe Kβ and Cu 
Kα.(Figure A1.4). Hence, the appropriate lanthanide should be selected based on 
the trace element(s) of interest in the study. 
Due to the long penetration depth of X-rays, XFM with LBT-fusion proteins 
can also be used to visualize targeted proteins in cells in three dimensions. 
Tomographic imaging is particularly important for localizing proteins in 
subcellular structures and organelles at the nanoscale, e.g. visualizing membrane 
proteins. Tomographic imaging was performed on a single E. coli cell expressing 
OmpA-LBT and exposed to ErCl3. During the tomography scan, the cell was 
rotated along the XZ (green) axis plane and imaged with a 15 nm X-ray beam. Er 
isosurface images (Figure A1.7) were calculated from the normalized X-ray 




analysis, a spatial resolution of 36 nm was calculated from the 3D Er tomography 






Figure A1.5. Normalized intensity map of the Er distribution.  
To obtain the isosurface images displayed in Figure A3.7 and Figure A3.8, an isosurface 
threshold value of 1.0 was chosen from the normalized intensity map. A normalization 





Figure A1.6. Estimate of the spatial resolution of the Er XRF E. coli 
tomogram using power spectral analysis. The power spectrum signal declines 
with the spatial frequency before reaching a noise floor. The cutoff point is at a half 
period of approximately 36 nm in the X direction. The Er tomogram is from a 3D data 
set using a 20 nm step size and 0.1 s dwell time. 
Figure A1.8 shows the three-dimensional distribution of zinc and erbium 
in the cell. The zinc distribution is consistent with the findings observed in Figure 
A1.1, i.e. the zinc is distributed throughout the cell with the highest concentrations 
at the polar end caps. For the Er distribution, the tomogram shows a “shell” of Er 
on the surface, with a smaller amount of Er interior to the cell. These findings can 
also be seen in Figure A1.7. For the XY and YZ planes (Figure A1.7 B and C, 
respectively), the Er appears primarily located on the outer surface of the cell. 
However, for the XZ plane in Figure A1.7 D there is also evidence of some Er 





Figure A1.7. Isosurface and virtual slices of the Erbium X-ray 
nanotomagram of a single E. coli cell expressing OmpA-LBT.(A) Isosurface 
plot. Virtual slices through the cell are seen in the XY, YZ and XZ planes in (B), (C), and 
(D), respectively. During the tomography scan, the cell was rotated along the XZ axis. 
The thickness of the illustrated sections in B-D are approximately 40 nm, 115 nm, and 






Figure A1.8. Isosurface representation of Erbium (yellow) and zinc (red) in 
an X-ray nanotomogram of a single E.coli cell expressing OmpA-LBT and 
incubated with Er. During the tomography scan, the cell was rotated along the XZ 
(green) axis plane as shown in Figure 3 and imaged with a 15 nm X-ray beam. The 
dataset was obtained using projection images of 100 × 80 pixels at a 20 nm pixel size, 
with a dwell time of 100 msec per pixel, over a rotation angle range of -39 to 132° in 3° 









The primary role for OmpA in E. coli is to stabilize the outer membrane via 
the beta-barrel structure.(267–269) The high copy number of OmpA has made it 
a target for incorporation of other fusion tags in the exterior loops including 
GFP(270) and FLAG and C-Myc epitope tags,(271) both of which have 
demonstrated the shell-like structure at lower resolution. Dynamics studies have 
shown that OmpA is immobile in the outer membrane, with no long-range lateral 
diffusion.(272)  
In addition to its structural role in the outer membrane, OmpA has also 
been shown to act as a porin.(273) Its porin activity is slow and produces non-
specific diffusion channels for various small solutes with low permeability(274). As 
such, it is often a target for antibiotic resistance.(275–277) Due to its non-specific 
transport properties, OmpA may be a route for lanthanides to transit the outer 
membrane to the periplasm, gaining access to transporters, thereby facilitating 
entry and providing an explanation for the presence of a small amount of erbium 
inside the cell.  
In summary, lanthanide-binding tags (LBTs) can be used for 2D and 3D 
nanoscale imaging with X-rays. LBTs are short peptides comprising a nanomolar-
affinity lanthanide-binding domain. The high affinity of LBTs for lanthanides 
allows experiments to be performed at low concentrations, thereby mitigating toxic 
effects. The LBTs can be easily incorporated into target protein sequences, and 
their small size minimizes deleterious effects on target protein expression, 




imaging of two LBT-protein conjugates, a membrane protein (OmpA) and a 
soluble protein (ubiquitin) with nanoscale spatial resolution. As the conjugation of 
LBTs and proteins follow standard molecular biology protocols, we propose that 
XFM with LBTs could become a widespread tool for 3D imaging of protein 
distribution and localization within cells with a high spatial resolution while 
simultaneously obtaining trace element distribution. Moreover, the long 
penetration depth of X-rays enables nanoscale visualization of the internal 









































A portion of the work presented in this chapter is included in the following 
published article: Harvey, C.M., O’Toole, K.H., Liu, C., Mariano, P., Dunaway-
Mariano, D., Allen, K.N. (2020)  Structural analysis of binding determinants of 
Salmonella typhimurium trehalose-6-phosphate phosphatase using ground-state 




Enzymes in the trehalose biosynthetic pathway have recently been explored 
as potential targets for a variety of bacterial and parasitic diseases including 
tuberculosis (Mycobacterium tuberculosis) and elephantiasis (Brugia malayi and 
Wuchereria bancrofti). Trehalose can serve as a carbon source and is used for 
energy storage, especially for organisms in stressful environments such as 
dessication. Additionally, in the case of Mycobacteria, trehalose is also used in the 
biosynthesis of mycolic acids for cell wall biosynthesis.(278)   
Trehalose is synthesized in two steps, glycosyl transfer from UDP-Glc to 
Glc6P, producing trehalose 6-phosphate (T6P) catalyzed by trehalose-6-phosphate 
synthase (T6PS) followed by dephosphorylation of T6P by trehalose-6-phosphate 
phosphatase (T6PP), producing trehalose.(279) T6PP knockdown models of 
Caenorhabditis elegans and M. tuberculosis have confirmed that lack of T6PP 
leads to organism death.(280, 281) However, T6PS knockdowns are not lethal. 
Furthermore, T6PS and T6PP combined knockdowns rescue the cells from the 
toxic phenotype. Therefore, these studies identify that it is the buildup of T6P, 
rather than lack of trehalose, that is lethal.(280) Furthermore, this biosynthetic 
pathway is not present in higher-ordered species including mammals. Therefore, 
this is an optimal target for designing therapeutics for tuberculosis and helminth-
borne diseases.  
T6PP is a member of the HAD superfamily, and adopts the C2b cap-type 
comprised of α-helices and anti-parallel β-strands.(279, 282) X-ray crystal 
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structures were determined previously in our laboratories of Salmonella 
typhimurium (St) T6PP in complex with trehalose, trehalose 6-sulfate (T6S), and 
an inhibitory probe, 4-n-octylphenyl α-D-glucopyranoside 6-sulfate (OGS), in the 
cap-closed catalytically productive conformation.(282) The substrate is broken 
into three sub-domains is for comparison of tolerance to chemical modifications 
necessary for rational design of inhibitors of T6PP.(282, 283) The phosphoryl 
moiety is coordinated through the catalytic magnesium cofactor and residues in 
the core domain which are conserved amongst all HADSF members. Trehalose is 
broken further into the two glucosyl rings, that are proximal and distal to the 
phosphoryl moiety. The proximal glucosyl ring makes interactions with the cap 
domain. Three residues in particular (Glu123, Lys 125, Glu167, StT6PP 
numbering), are highly conserved amongst T6PP orthologs, and also retain 
interactions with substrate-analogs or inhibitory probe molecules.(282) Previous 
work in development of the OGS probe identified that the proximal glucosyl moiety 
did not tolerate replacement with a phenyl moiety, as no binding was 
detected.(283) Therefore, additional scaffolds or modifications should be tested to 
find a more ideal glucosyl mimic. Lastly, the glucosyl moiety distal to the 
phosphoryl group participates in interactions with the cap domain as well as the 
C1 loop. Notably, hydrogen-bond interactions observed are solely with the back 
bone, and most side-chain interactions are van der Waals interactions.(282) This 
explains the fact that the distal glucosyl moiety can tolerate different chemical 
modifications, as interactions in this sub-site are not well conserved. 
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The goals of this project were to determine the mode of inhibition of T6PP 
via two lead scaffolds, cephalosporin C and closantel (Figure A2.1). These 
compounds were first identified via screening of the Johns Hopkins Clinical 
Compound library and then further characterized to determine the KI of 
cephalosporin C to be 1.0 µM and the IC50 of closantel to be 5 µM (both measuring 
inhibition of Brugia malayi (Bm) T6PP) .(284) Further kinetic characterizations 
identified (1) that cephalosporin C does not actually inhibit T6PP, but the zinc-ion 
of the zinc-salt does and (2) that closantel is a slow-binding inhibitor of T6PP.  The 
inhibition of BmT6PP was further characterized by Dr. Christine Harvey and 
myself- the KI of ZnCl2 was determined to be 12.5 nM.(284) Dr. Harvey screened a 
panel of di-valent metals for their inhibition, while I assessed their effects on the 
stability of T6PP by measuring the Tm and monodispersity of BmT6PP in the 
presence of a panel of divalent metals via differential scanning fluorimetry (DSF) 
and dynamic light scattering (DLS). With respect to the closantel scaffold, I 
focused efforts on determining inhibition equilibrium constants for closantel and 
an analog library, corroborating inhibition versus aggregation via DLS. The focus 
of these experiments is to determine the atomic structures of Salmonella 
 
Figure A2.1 Chemical structures of initial inhibitor hits, cephalosporin C 
(A) and closantel (B). 
 
 196 
typhimurium and Caenorhabditis elegans (Ce) T6PPs in complex with inhibitors 
synthesized by our collaborators in the laboratory of Kim Janda at The Scripps 
Research Institute (La Jolla, CA). By determining these complexed structures, we 
can identify the conserved binding determinants and increase the affinity and 
potency of each inhibitor in concert with identifying the KI using BmT6PP 
(nematode model) and StT6PP or Mycobacterium marnium (Mm) T6PP (bacterial 
models).  
A2.2 Materials and Methods 
A2.2.1 Expression and purification of T6PP orthologs 
The expression and purification of T6PP orthologs Bm, St, and Ce were 
conducted following the previously published method for StT6PP.(282) In 
addition, the buffer was optimized for size-exclusion chromatography to minimize 
the protein loss as was previously described. The buffer including 50 mM MOPS 
pH 7.0, 100 mM NaCl, 5 mM MgCl2, and 5% glycerol was identified using 
differential scanning fluorimetry to identify a stabilizing buffer.  
A2.2.2 Inhibition kinetics 
The inhibition of T6PP was measured using two different phosphate 
detection assays. All kinetics were conducted in “kinetics buffer” containing: 100 
mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2 and 0.1mg/mL bovine serum albumen. 
BioMol Green is a colorimetric discontinuous assay that measures inorganic 
phosphate production with a detection range of 3 – 100 µM, and was used for spot-
test assays assessing analog libraries and initial slow-binding assays were also 
conducted using BioMol Green assay at 2.5 mM T6P (KM = 360 µM for BmT6PP).  
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The EnzChek assay was used to measure initial and steady-state velocities of 
BmT6PP. Conditions were previously optimized by Dr. Christine Harvey.(284)  
A2.2.3 Crystallization efforts 
Crystallization conditions to yield StT6PP crystals of high diffraction-
quality for soaking experiments were determined previously as described by 
Harvey et al..(282) The condition consisted of 17-19 % PEG 3,350, 375 mM lithium 
citrate, 10 mM magnesium chloride, 2% dioxane, and microseeding. Soaking 
experiments were conducted in the cryoprotectant solution containing PEG 3,350 
(~5% increase), 10% ethylene glycol, 10-100 mM magnesium chloride, and the 
inhibitor/ligand of interest at varying concentrations.  
Co-crystallization efforts of StT6PP, BmT6PP, and CeT6PP in the presence 
of closantel analogs were conducted initially from sparse-matrix screening at 10-
20 mg/mL enzyme plus 1.2-1.5 eq closantel sodium salt. StT6PP and CeT6PP (pre-
incubated with 1.2-fold excess of sodium closantel) were sent to Hauptmann 
Woodward Institute (HWI) high throughput crystallization center, where a high-
throughput screen comprised of 1536 unique crystallization conditions was 
screened against both StT6PP and CeT6PP. After four weeks, initial hits were 
imaged under visible light, SONICC, and UV-TPEF to identify well-ordered protein 
crystals (10/1536 conditions yielded protein crystals). I have further optimized two 
conditions from this screen to yield single crystals of sufficient size (> 0.05 mm). 
Thus far, crystals have not diffracted with high enough quality (3.5 Å maximum 
resolution), and therefore, further optimization of these crystals is necessary in 
order to collect a high-resolution (> 2.5 Å) data set in order to observe small-
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molecule inhibitors. A summary of crystallization conditions and diffraction 
quality is summarized in Table A2.1.  
A2.2.4 Differential scanning fluorimetry 
The melting temperature (Tm) of T6PP was measured using differential 
scanning fluorimetry (DSF) as described for PMM isozymes in Chapter 3. T6PP 
was screened against a panel of divalent metals at equimolar concentrations. 
Additionally, StT6PP and closantel were screened against the buffer screen 
containing 0.1 M buffer from pH 3-10, ± 100 mM NaCl and ± 5% glycerol to assess 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A2.2.5 Dynamic light scattering 
Protein sample was diluted in crystallization buffer (0.1 M MOPS pH 7.0, 
100 mM NaCl, 5 mM MgCl2, and 5 % glycerol) to 17.4 µM and incubated with 
equivalent concentration of either closantel analogs or divalent metal chloride. The 
sample was incubated on ice for 1.5 h followed by spinning down in a centrifuge 
for 30 minutes prior to data acquisition. The monodispersity of the sample (10 µL) 
was then measured at room temperature using dynamic light scattering (10 
acquisitions).  
A2.3 Results and Discussion 
A2.3.1 Divalent metal inhibition of T6PP 
BmT6PP was screened against divalent metals at equimolar concentration 
to determine if the inhibition is specific to aggregation/destabilization of T6PP. 
The Tm of BmT6PP was not altered in the presence of divalent metals. There are 
two unfolding events for BmT6PP and therefore two measurable Tms, 48.9 and 62.1 
°C for native, unliganded BmT6PP. The Tms did not vary by more than 1 °C, which 
is within the error of the assay. Further, measuring monodispersity via DLS show 
that Ca2+ and Co2+ decrease the polydispersity by roughly 6 or 5 %, respectively. 
Otherwise, no divalent metals make significant changes to the polydispersity of the 
sample. Together, these findings support the competitive inhibition of T6PP by 
divalent metals rather than the divalent metals promoting unfolding/aggregating 
of the protein. These results are summarized in Table A2.2, along with the 
inhibition constants previously determined.(284)  
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Table A2.2 Kinetic and biophysical characterization of divalent metal 
inhibition of BmT6PP. 
Metal IC50 (nM) %PD %Mass TM 1 TM 2 
none ND* 18.3 99.7 48.9 62.1 
Mg2+ ND* 21.6 99.9 47.9 62.7 
Ni2+ ND* 25 100 48.3 62.3 
Ca2+ ND* 11.9 100 48.0 61.9 
Co2+ ND* 12.7 100 48.1 61.8 
Cu2+ 104 19.6 99.3 47.8 61.7 
Zn2+ 12.9 19 100 47.4 61.7 
Cd2+ 7 16.7 100 47.8 61.6 
*ND: not determined
A2.3.2 Closantel inhibition kinetics 
Closantel has been identified as a slow-binding inhibitor with an IC50of 10 
µM (C. Harvey). To further probe this mechanism, I designed time-course 
experiments to optimize the pre-equilibration step prior to kinetics analysis to 
determine the KI of BmT6PP for closantel (sodium salt). As there were concerns 
about both protein stability and compound solubility, the effect of DMSO on the 
Tm of BmT6PP was measured via DSF (Figure A2.2). The Tm of BmT6PP 
decreases linearly as a function of DMSO concentration. Future experiments limit 




Figure A2.2. Thermofluor analysis of destabilizing effect of DMSO on 
BmT6PP.  
Protein was tested at 20 µM in kinetics buffer lacking BSA containing varying 
percentages of DMSO. A. The measured Tm of BmT6PP. B. The change in Tm using 
BmT6PP in 0 % DMSO as a baseline. C. The ΔTm plotted as a function of DMSO (%). 
Error is represented as standard deviation (n=2). 
 The slow-binding kinetic assay was optimized to aim for incubating 
long enough to achieve binding equilibrium of closantel, but not decreasing the 
stability and therefore activity of the enzyme. The protein was pre-incubated with 
sodium closantel for various time points up to 4 h and then activity was measured 
(2.5 mM T6P, 10 minutes). The results shown in Figure A2.3 illustrate a decrease 
in activity over the preincubation time, with an overall stabilization of change at 





Figure A2.3. Time-dependent nature of closantel inhibition of BmT6PP at 4 
°C. BmT6PP was pre-incubated with sodium closantel for up to 4 h followed by 
introduction of substrate (2.5 mM T6P, 10 min). The four lines represent different 
concentrations of sodium closantel in µM. The purple line represents the uninhibited 
enzyme, incubated at 4 °C for the same time points. Signal was normalized to the 
uninhibited enzyme (buffer + DMSO). Error is represented as SD (n=2).  
 




= 11 + ([I]/K-
∗/00 (A1.1) 
where vi is the initial rate at [I], and v0 is the initial rate of the uninhibited sample.  
Using this equation, the KI*app of closantel for BmT6PP is 4.5 µM (Figure A2.4A). 
A secondary analogue library (SB library-28 compounds) retained the ether 
linkage, shown to be efficacious in compounds MG-3 and MG-7 (284), and 
substituted the diiodo benzyl ring with a dichloro benzyl ring for increased stability 
and pharmacokinetic properties (Figure A2.4B). In this library, the substituents 
about ring B were varied at the meta- and ortho- positions to ether linkage (Figure 























A2.5). Additionally, chemical modifications at the para position in ring C were also 
tested (Figure A2.5, SB14, SB17, SB19, SB21, SB22, SB23, SB24, SB26).  
 
Figure A2.4. Inhibition of BmT6PP by closantel. (A) Inhibition kinetics of 
BmT6PP inhibited by closantel (sodium salt). The ratio of initial rates of reaction to the 
initial rate of uninhibited BmT6PP as a function of closantel concentrated were plotted 
to calculate the KI*app of closantel for BmT6PP. B. The chemical structures of closantel 
and general structures of MG and SB analog series.  
 
 
Figure A2.5 Closantel SB analog library.  
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The inhibition of BmT6PP was tested in the presence of 10 µM inhibitor 
after a 1 h pre-incubation as an initial inhibition test (Figure A2.6). Inhibition of 
BmT6PP by closantel was used as a control in this experiment (70% decrease in 
activity). Follow up inhibition and stability assays were conducted for all inhibitors 
which decreased activity by roughly 90% for BmT6PP for inhibitors: SB-1, SB-7, 
SB-16, SB-17, SB-21, SB-24, SB-26, and SB-28.  
 
Figure A2.7. Inhibition of BmT6PP by closantel SB analog library. Percent 
activity was normalized to BmT6PP in 5 % DMSO with no inhibitor present. Error is 
plotted as SD with two replicates.  
Follow-up experiments aiming to measure the IC50 of compounds SB-1, SB-
16, SB-21, and SB-26 following a 1-hr pre-incubation with inhibitor. Compounds 1, 
16, and 21 were selected as a first test because they were the most soluble in 
aqueous solutions (with 5-10% DMSO). The IC50s were calculated to be 6.24 µM, 














































































































Figure A2.8. Inhibition of BmT6PP by closantel analogs.  
To confirm that compounds were not causing aggregation and instability of 
BmT6PP, I analyzed each using dynamic light scattering (DLS) to identify the 
radius of gyration and monodispersity of each sample in solution. A change in 
polydispersity greater than 5% would be indicative of aggregation. The addition of 
DMSO increases polydispersity by roughly 10%, however, the addition of most 
inhibitors actually decreases the polydispersity back to within 5% of the buffer 
control showing that they actually stabilize the protein (Table A2.3).  The 
inhibitor SB-24 caused aggregation to the point that DLS data could not be 
measured due to auto-attenuation failures of the instrument often induced by 
polydisperse and aggregated samples. Therefore, we will not continue pursuing 
this analog. 























Table A2.3. Polydispersity of BmT6PP incubated with closantel SB analogs. 
Inhibitor Radius (nm) %PD* %Mass 
(+) DMSO 5.3 25.8 100 
SB1 4.1 14.5 99.8 
SB7 4 8.7 100 
SB16 4.2 16.3 100 
SB17 2.7 10 98.2 
SB21 4.2 13.8 100 
SB24 ND** ND** ND** 
SB26 3.6 19.3 99.7 
SB28 2.1 8.6 95.6 
NaClosantel 3.7 10.4 99.9 
(+) buffer 3.9 12.5 99.5 
*PD: polydispersity; **: not determined. Auto-attenuation error as a result of highly 
aggregated sample. Accurate measurements were not possible.  
Compounds SB-17, SB-24, and SB-26 were omitted from future inhibition 
experiments due to their decreased ligand efficiency, and SB-24 induced 
aggregation of BmT6PP. Issues with solubility of the SB analog series were 
prevalent throughout optimizations and hindered the ability to determine the KI 
of most inhibitors. The KI*app could be calculated by comparing the steady state rate 
(vs) to the uninhibited rate (vo) for SB-7 and SB-16, as with sodium closantel 
(Figure A2.9). Both inhibitors have KI*app within 2-fold of sodium closantel. Table 
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X summarizes all the inhibition constants determined for the closantel analogs. 
Overall, all SB analogs inhibit BmT6PP within 3-fold of closantel, and all are 
weaker inhibitors than closantel.  
 
 
Figure A2.9. Inhibition of BmT6PP by SB-7 and SB-16.  
 
The last goal of this research was to elucidate the selectivity of closantel 
analogs for BmT6PP over common human protein tyrosine phosphatases (PTP). 
These efforts were to identify whether closantel was a general phosphatase 
inhibitor, or if it was selective towards T6PP. The selectivity of closantel (sodium 
salt), SB-16, and SB-21 were assessed by screening against PTP-1B and SHP-2 
human PTPs using para-nitrophenol phosphate (pNPP) as a substrate (Figure 
A2.10). SHP-2 is inhibited fully by all three inhibitors at 50 µM. Because SHP-2 
also has an allosteric site, it is unclear whether these inhibitors are binding directly 
to the active site or are allosteric inhibitors. Compounds SB-16 and SB-21 do 
exhibit moderate selectivity for T6PP over PTP-1B, with 60% and 30% inhibition, 













respectively. Therefore, SB-16 and SB-21 although not increasing the affinity 
towards T6PP compared to closantel, do exhibit improved selectivity.  
 
Figure A2.10. Closantel analogs are selective for T6PP over 
PTP-1B. The human phosphatases PTP-1B and SHP-2 were 
screened against Closantel, SB-16, and SB-21 at 50 µM inhibitor. All 
compounds fully inhibit SHP-2 at this concentration. Although 
closantel fully inhibits PTP-1B at 50 µM, PTP-1B retains 40% and 
70% activity in the presence of SB-16 and SB-21, respectively.  
 
There are only two differences in the structures of SB-16 and SB-21 which 
may provide SB-21 with increased selectivity. First, SB-16 has an iodo substituent 
in the meta-position to the ether linkage in Ring B, while SB-21 has no substituents 
about Ring B. Secondly, SB-16 has a chloro substituent in Ring C para to the ether, 
while SB-21 has a fluoro substituent in this same position. Therefore, future 
inhibitor design could remove a substituent about Ring B and assess different 
substituents at the para position in Ring C to afford increased selectivity towards 
T6PP. Unfortunately, efforts to determine the X-ray crystal structure of either 









































unsuccessful and we are limited to using kinetic analyses to inform inhibitor 
design.  
A2.4 Conclusions 
In conclusion, the inhibition of BmT6PP by closantel and SB analog library 
were assessed via optimization of slow-binding kinetic assays. Although structural 
characterizations of closantel or analogs in complex with a T6PP ortholog have 
been unsuccessful thus far, cocrystallization efforts have yieleded an optimal 
condition for further refinement. Because of solubility and stability problems, true 
KI values for inhibitors were unsuccessful with these studies. Future experiments 
could include NMR to confirm the mode of binding compared to substrate analog 
trehalose 6-sulfate) and potentially the KI  via STD-NMR experiments.  
Initial experiments in nematode models (C. elegans) confirmed that 
closantel and analogs SB-7, SB-16, and SB-21 slow the development of C. elegans 
in a dose dependent fashion. The next steps would be to confirm that inhibition of 
T6PP is the mode of action for the closantel series of analogs.  One question which 
has not been answered is “what is the mechanism of trehalose 6-phosphate 
inhibition in nematodes and bacteria?” Towards answering this question, large 
scale metabolomic and proteomic experiments in the respective organisms after 
knocking down the pathway could elucidate upregulation or downregulation of 
proteins or metabolites after increasing trehalose 6-phosphate concentrations.  
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This work was conducted in collaboration with Dr. Barbara Imperiali’s laboratory 
at MIT. Expression and purification of targets was conducted by Katherine 
O’Toole, Hannah Bernstein (Imperiali Lab) and Dr. Gregory Dodge (Imperiali 
Lab). Sparse matrix screening was conducted by Katherine O’Toole and Dr. 
Gregory Dodge, optimization of crystallization was conducted by Katherine 
O’Toole. Cryo-EM and LCP crystallization efforts are not described here, but were 
conducted in tandem by Dr. Gregory Dodge.  
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A3.1 Introduction 
The work described in this appendix outlines the crystallization screening 
and optimization of target monoPGT enzymes (Table A3.1). Enzyme targets from 
all families of monoPGTs were selected and efforts were triaged based on solubility 
and stability of enzyme, and overall crystallization.  
In addition to new targets, we also aim to determine the liganded structure 
of C. concisus PglC. However, in the current crystal form, the “ANGEL” loop from 
protomer B binds at the interface of the loop and β-hairpin loop, forcing the 
“ANGEL” loop of protomer A to be fully extended. Based on co-evolution analyses 
and site-directed mutagenesis studies, it is predicted that the ANGEL loop closes 
in toward the globular domain, protecting the active site from bulk solvent. 
Therefore, we aim to generate variants of C. concisus PglC, mutating residues in 
the ANGEL loop to prevent this crystal packing formation.  We selected residues  

















































































































































































































































































































































































































































































































































































































































































































































































































A3.2 Site-directed mutagenisis of C. concisus PglC 
C. concisus PglC variants: E72V/R67T, E72V/R79S, E72A/R67A and
E72A/R79A were generated using the Q5 site-directed mutagenesis kit (New 
England BioLabs) using pE-SUMO C. concisus PglC plasmid as a template for 
single mutation variants. Primer sequences were designed using NEBase changer 
and Sigma-Aldrich OligoEvaluator 
(http://www.oligoevaluator.com/OligoCalcServlet) to identify any potential 
hairpin or primer-dimer formations. The resultant primer sequences are provided 
in Table A3.2. Double mutants E72V/R67T and E72V/R79S used E72A plasmid 
as a template, while E72A/R67A and E72A/R79A used E72A as a template. 
Mutation incorporation was confirmed via sequencing analysis by Genewiz. 
Expression and purification of C. concisus PglC variants were performed following 
the purification protocol for PGT homologs as described in the following section.  
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Table A3.2. Primers for site-directed mutagenesis of C. concisus PglC 
Primer Sequence 
E72V forward 2 5’ GCAAATGGCGTGCTCTTG 3’ 
E72 reverse 3 5’ GTCACGCTCATCGCTCAT 3’ 
E72A forward 3 5’ GCAAATGGCGCGCTCTTG 3’ 
R67T forward 5’ GAGACCGACGCAAATG 3’ 
R67 reverse 5’ ATCGCTCATCGTCTTAAAT 3’ 
R67A forward 5’ GAGGCGGACGCAAATG 3’ 
R79S forward 5’ AGATGATCAGAGCCTTGGCAAAT 3’ 
R79S reverse 1* 5’ GGCAACACCACGCCATTTGC 3’ 
R79A forward 2 5’ CCAGATGATCAGGCGCTTGGCAA 3’ 
R79A reverse4** 5’ CAAGAGCGCGCCATTTGC 3’ 
A3.3 Expression and purification of monoPGT targets 
PGT genes were either previously synthesized and cloned into pE-SUMO 
vector, or synthesized and cloned into pTB146 SUMO expression vector by 
GENEWIZ (Table A3.2). BL21 (DE3) pRIL or pRARE cells were transformed with 
the expression vector containing the PGT of interest, plated on LB/Agar plates (35 
µg/mL chloramphenicol and either 50 µg/mL KAN (pE-SUMO) or 100 µg/mL 
carbenicillin (pTB146), and grown overnight at 37 ° C. Individual colonies were 
picked to inoculate starter cultures of Luria broth (LB) containing the antibiotics 
identified above.  
The following day, 500 mL cultures ( in 2 L flasks) of autoinduction media 
were inoculated with 3-5 mL of the starter culture and grown either for 37 °C for 4 
hours, followed by 18 °C overnight or at 25 °C for 24 h, shaking at 200 RPM. Cells 
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were harvested via centrifugation at 5,000 RPM for 15 minutes. Harvested cell 
pellets were stored at -80 °C until needed.  
All PGT enzymes and variants were purified via the following protocol at 4 
°C. Pellet was resuspended in lysis buffer (5 mL/g cell pellet) containing 50 mM 
HEPES pH 7.5, 150 mM NaCl, 5 mM MgCl2, and 1 mM DTT with one protease 
inhibitor tablet (PIERCE), lysozyme (20 mgs) and DNase (6 mgs) for 30 min. Cells 
were lysed via microfluidization at 18, 000 PSI and spun down at 9300 RPM for 
45 minutes (Beckman Ultracentrifuge, Ti 70) to remove cellular debris. The 
supernatant was transferred to a new tube and spun down again (36,100 RPM, 65 
minutes, Ti70) to pellet the cell envelope fraction (CEF). The CEF pellet is then 
resuspended in roughly 25-30 mL CEF solubilization buffer  (50 mM HEPES pH 
7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, and 1 % w/v n-dodecyl-β-D-maltoside 
(DDM)) using a 14 mL dounce homogenizer. The solubilized CEF fraction was then 
rotated overnight. 
The solubilized CEF fraction was spun down at 40,500 RPM for 65 min 
(Ti70) to remove insoluble particulates/aggregates. The sample was then purified 
via NiNTA gravity column.  A gravity column was packed with 2 mL NiNTA slurry 
and equilibrated with 5 CV His equilibration buffer ( 50 mM HEPES pH 7.5, 150 
mM NaCl, 5 mM MgCl2, 1 mM DTT, 0.03% DDM, 5 % glycerol, 20 mM Imidazole 
pH 7.5). A 50 % resin slurry was then generated in equilibration buffer,  added to 
the CEF fraction, and rotated for 1 h. Following batch binding, the sample was 
added back to the gravity column and allowed for resin to settle (~10-15 min). The 
220 
flowthrough fraction was collected. Column was subsequently washed with 4-5 CV 
His equilibration followed by 4-5 CV wash buffer (50 mM HEPES pH 7.5, 150 mM 
NaCl, 5 mM MgCl2, 1 mM DTT, 0.03% DDM, 5 % glycerol, 45 mM Imidazole pH 
7.5). Protein was eluted with 4-5 CV elution buffer (50 mM HEPES pH 7.5, 150 
mM NaCl, 5 mM MgCl2, 1 mM DTT, 0.03% DDM, 5 % glycerol, 500 mM Imidazole 
pH 7.5). The peak fractions were immediately desalted using GE Desalting 
columns (5 mL prepacked) equilibrated with desalting buffer (50 mM HEPES pH 
7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 0.03% DDM, 5 % glycerol).  
Desalting fractions were then incubated with 0.14 equivalents of SUMO 
protease (Saccharomyces cerevisiae) rotating at 17°C for 4-6 h, followed by NiNTA 
gravity purification as described above. However, the flow-through fractions were 
collected and pooled. Samples were characterized for purity via SDS-PAGE and 
fractions greater than 90% purity were pooled and concentrated, flash frozen, and 
stored at -80 °C. 
Figure A3.1. SDS-PAGE analysis of PGT targets. All samples are showing the 
final purification step, after SUMO cleavage. Hpu: H. pullorum, Cb: C. botulinum; Fn: 
F. nucleatum. Panels D-G are purifications of C. concisus PglC variants
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A3.4 Crystallization efforts 
A3.4.1 Sparse matrix screening of monoPGT target enzmyes identified hits for 
further optimization 
Efforts focused on crystallizing Fusobacterium nucleatum (UniProt ID: 
Q8R6F8) Clostridium botulinum (UniProt ID: C5UXG8), and Helicobacter 
pullorum (UniProt ID: E1B268) PGTs. Initial sparse matrix screening yielded a 
few hits for F. nucleatum and H. pullorum, summarized in Table A3.3. H. 
pullorum and C. botulinum PGT trays were set up at 5 mg/mL and F. nucleatum 
PGT at 20 mg/mL protein all with either 1 mM UDP or 1 mM UndP. Additionally, 
C. botulinum and H. pullorum PGTs were sent to HWI for initial crystallization 
screening of 1,536 conditions at 5 mg/mL protein cocrystallized with 1 mM UDP. 
Initial hits for C. botulinum PGT and H. pullorum PGT are summarized in Table 
A3.3. The UV-VIS images did not provide anything noteworthy, however- the 
conditions with crystalline material were further optimized in house via sitting or 











Table A3.3. Top crystallization hits from sparse matrix screening for C. 










0.1-0.4 M magnesium chloride 






HWI 238 0.1 M ammonium sulfate, 0.1 M Tris pH 







0.1-0.4 M magnesium chloride 









0.2 M lithium sulfate monohydrate, 0.1 







0.05 M calcium chloride dihydrate, 0.1 




HWI 754 0.05 M sodium chloride, 0.1 M TRIS 8.5, 




1169 0.1 M Magnesium chloride hexahydrate, 





HWI 458 0.1 M potassium chloride, 0.1 M HEPES 







Index E9 0.05 M ammonium sulfate, 0.05 M 
BisTris pH 6.5, 30% v/v pentaerythritol 







0.2 M lithium sulfate, 0.1 M trisodium 
citrate pH 5.5, 26% PEG 200 
 
*note the image for F. nucleatum PGT is not from the initial condition, but from an 
optimized tray grown in 0.2 M lithium sulfate, 0.1 M trisodium citrate pH 5.3, 43% 
PEG 200. 
 
A3.4.2 Optimization of H. pullorum, C. botulinum, and F. nucleatum PGTs 
The conditions presented in Table A3.3 were further optimized in 24-well 
grid screen formats, both sitting and hanging drop format. Optimization of 
H.pullorum PGT condition Index E9 yielded the most reproducible crystals with a 
plate morphology. Low resolution diffraction (disordered) was observed screening 
samples optimized from hits: HWI458 and Index E9. This base condition was 
further optimized by using Hampton Research Additive screen, applying 96 unique 
additives to the base condition. The following conditions yielded hits with 
improved crystal morphologies than the base condition and were able to be 
reproduced: 1.5% diammonium hexane, 0.01 M manganese chloride, 0.02 M L-
proline, 0.1 M guanidine HCl, 0.15 M sodium thiocyanate. A summary of all 
additive hits is provided in Table A3.4 Additives diammonium hexane, 
manganese chloride and L-proline were able to be reproduced in optimization grid 
screen. The most promising additive is 1,6-diaminohexane. Crystals are three-
dimensional with striations which imply that it is likely that it is a large, uniform 
stack of plates. Screened crystals diffracted only to low resolution and with a 
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disordered lattice. Therefore, further optimization of this condition is underway 
using microseeding. Additionally, increasing the concertation of protein yielded 
larger, more ordered samples, so combining microseeding with increased protein 
concentration may yield crystals with a higher limit of diffraction. Dioxane could 
also be utilized as a nucleation poison to try to prevent stacks of plates from 
forming.  
Table A3.4 Additive screen hits for H. pullorum and F. nucleatum PGT 
 
Protein Base condition 
Additive 
Hit Condition Morphology 
F. nucleatum PEGRx E2 A2 0.01 M cadmium chloride hydrate 3D 
F. nucleatum PEGRx E2 A8 0.01 M strontium chloride hexahydrate 3D 
F. nucleatum PEGRx E2 A9 0.01 M yttrium (III) chloride hexahydrate 3D 
F. nucleatum PEGRx E2 B3 0.1 M ammonium sulfate 3D 
F. nucleatum PEGRx E2 C2 0.01 M L-proline 3D 
F. nucleatum PEGRx E2 C12 0.01 M taurine 3D 
F. nucleatum PEGRx E2 D11 0.01 M TCEP hydrochloride 3D 
F. nucleatum PEGRx E2 E3 3% w/v dextran sulfate (Mr 5,000) 3D 
F. nucleatum PEGRx E2 E9 3% w/v sorbitol 3D 
F. nucleatum PEGRx E2 E11 3% w/v D-(+)-trehalose dihydrate 3D 
F. nucleatum PEGRx E2 E12 3% w/v D-(+)-galactose 3D 
F. nucleatum PEGRx E2 C4 3% vv dimethyl sulfoxide needle/plate 
F. nucleatum PEGRx E2 E4 4% v/v pentaerythritol ethoxylate (3/4 EO/OH) needle/plate 
F. nucleatum PEGRx E2 F2 3% v/v glycerol needle/plate 
H. pullorum HWI 458 A11 0.01 M iron (III) chloride hexahydrate 3D 
H. pullorum HWI 458 B9 0.2 M sodium thiocyanate 3D 
H. pullorum HWI 458 D3 0.01 M spermine tetrahydrochloride 3D 
H. pullorum HWI 458 E3 3% w/v dextran sulfate (Mr 5,000) 3D 
H. pullorum HWI 458 E8 3% w/v xylitol 3D 
H. pullorum HWI 458 B12 0.1 M cesium chloride needle/plate 
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H. pullorum HWI 458 E1 0.01 M EDTA dihydrate needle/plate 
H. pullorum Index E9 A6 0.01 M magnesium chloride hexahydrate 3D 
H. pullorum Index E9 A7 0.01 M manganese (II) chloride tetrahydrate 3D 
H. pullorum Index E9 B6 0.2 M sodium chloride 3D 
H. pullorum Index E9 C2 0.01 M L-proline 3D 
H. pullorum Index E9 C8 3% w/v 1,6-diaminohexane 3D 
H. pullorum Index E9 C9 3% w/v 1,8-diaminooctane 3D 
H. pullorum Index E9 D2 0.02 M spermidine 3D 
H. pullorum Index E9 D7 0.1 M guanidine hydrochloride 3D 
H. pullorum Index E9 E7 3% w/v sucrose 3D 
H. pullorum Index E9 H5 4% v/v foramide 3D 
H. pullorum Index E9 H10 0.7% v/v 1-butanol 3D 
H. pullorum Index E9 A2 0.01 M cadmium chloride hydrate needle/plate 
H. pullorum Index E9 E3 3% w/v dextran sulfate (Mr 5,000) needle/plate 
 
 
F. nucleatum PGT crystals grow either as small prisms (<0.05 mm on one 
edge) or rectangular plates (~0.05-0.1 mm on one edge) which have diffracted to 
the highest resolution out of all PGT targets thus far, to approximately 7 Å (Table 
A3.5) optimized from condition PEGRx E2. Further optimizations using the 
additive screen yielded the following additives as optimal for improved crystal 
morphology: 0.01 M L-proline, x% glycerol, 3% dextran sulfate sodium salt (Mr= 
5,000). All additive hits are summarized in Table A3.4.  
C. botulinum PGT crystals grew in a hexagonal morphology, although they 
were gelatinous and quickly dissolved upon opening of the drop. Out of the C. 
botulinum crystals, one screened has diffracted thus far, to ~12 Å (Table A3.5). 
Based on the poor stability in air, these crystals are prime candidates for in situ 
crystallization.  
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A3.4.3 In-situ crystallization of monoPGT target enzymes 
Using the top condition for each of the three PGT targets (H. pullorum, F. 
nucleatum, and C. botulinum), in situ crystal trays (MiTeGen) were set up in 
sitting-drop format (drop volume: 0.5 µL, reservoir volume: 40 µL). The in situ 
format will allow for screening for diffraction without the need to open the drop 
and expose samples to air. Given that these crystals are relatively unstable, and 
dissolving upon air exposure is common, this setup may allow for better 
diffraction. Crystallization of F. nucleatum and H. pullorum PGT used the base 
conditions described in Table A3.4. For F. nucleatum, additive hits included: 6% 
glycerol, 3% sorbitol, 6% dextran, and 0.015 M L-proline. H. pullorum additive 
conditions include: 1,6-diammonium hexane (3% and 1.5 %), 0.01 M manganese 
(II) chloride, 0.01 M L-proline. Notably, H. pullorum crystals are currently the
most reproducible, and introduction of microseeding and increasing protein 










































































































































































































































































































































































































































































































































































































































































































































































































































































A3.4.4 Crystallization of “ANGEL” loop variants 
Sparse-matrix screening of the four designed variants of C. concisus PglC 
(E72V/R67T, E72V/R79S, E72A/R67A, and E72A/R79A) yielded the hits in 
PEG/Ion and PEGRx screens (summarized in Table A3.6). Initial screening of 
crystals did not yield any diffraction. However, optimization of these conditions in 
24-well hanging drop format is underway. Additionally, optimizations of the
condition used to grow the crystals used to obtain the  C. concisus PglC structure 
(0.1 M  BisTris pH 6.0, 0.4 M magnesium chloride, and 23% PEG 3,350) yielded 
small triangular crystals (~ 0.05 mm on one edge). Conditions containing nitrate 
salts yielded large spherulites, some with distinct edges. However, when opening 
the drop, the crystal decay was apparent. One round of optimization was conducted 
due to time constraints, so these conditions can be further optimized with varying 
protein concentration, temperature, precipitant, and also microseeding.  
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Table A3.6. Summary of ANGEL loop variant crystallization 
 
C. concisus PglC 
variant 
Hit Condition Image 
E72V/R67T (5 



















20% PEG 3,350 
 
E72A/R67A (5 





0.15 M BisTris 
pH 6 



















































In-depth kinetic and crystallographic studies of HADSF members have 
revealed the importance of the general base aspartate (Dn+2) in the phosphoryl 
transfer mechanism(53). Variants in which Dn+2 is mutated to alanine result in 
complete loss of activity(53). Both wild type and Dn+212A variants of BT4131 were 
crystallized in the presence of vanadate, a phosphate mimic. In the wild type-
vanadate complex, trigonal bipyramidal geometry is observed, with the apical 
positions occupied by the oxygen of aspartate and a water molecule. This complex 
mimics the hydrolysis of a phosphoaspartyl intermediate. However, in the Dn+2A-
vanadate complex, a distorted tetrahedral geometry is observed, in which Dn8 
contributes one coordinate bond to the vanadium(53), but there is no coordinating 
water. This change in geometry in the Dn+2A active site supports the model that 
hydrolysis of phosphoaspartate is dependent on Dn+2 activating a water molecule. 
These structural and kinetic analyses support the overall mechanism of catalysis, 
but direct evidence of the protonation of Dn+2 is necessary to confirm its role as a 
general base.  
We chose to use KDN9PP as the model for the HADSF as it crystallizes well 
and provides high- resolution data. Additionally, the enzyme oligomeric state 
enforces a cap-closed form such that the access to bulk solvent will not differ 
between complexes. Furthermore, several liganded X-ray structures of KDN9PP 
have been determined previously(83, 84, 285). Bryan et al. determined unliganded 
KDN9PP neutron structures, identifying that the Dn+2 aspartate is 
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deprotonated(286). My work contributed towards determining the neutron 
structure of KDN9PP mimicking the Michaelis complex using vanadate and N-
acetyl neuraminate (Neu5Ac), an alternate substrate with a catalytic efficiency five-
fold lower than that of the natural substrate (6 x 103 M-1s-1 vs 3 x 104 M-1s-1 for 
KDN9P)(83). We propose that Dn+2 will be protonated in the Neu5Ac/vanadate 
KDN9PP complex. However, if the residue is deprotonated, using neutron 
crystallography should still aid in developing an alternate hypothesis for leaving 
group protonation, perhaps through a hydrogen bond network.   
A4.2 Materials and Methods 
A4.2.1 Expression and Purification of KDN9PP 
The expression vector pET2a containing KDN9PP was generated as 
described previously.(285)  BL21 pLysS cells were transformed with pET2a-
KDN9PP vector and grown overnight at 37 °C. Individual colonies were used to 
inoculate LB media (35 µg/mL chloramphenicol and 100 µg/mL ampicillin). 
Cultures (1 L) were grown at 37 °C shaking (200 RPM) until OD600 reached 0.6-
0.8. Expression was induced with 1 mM IPTG and cells were incubated at 16 °C 
overnight (shaking at 200 RPM). Cells were harvested after 18-20 h via 
centrifugation at 5,000 RPM for 15 minutes. Pelleted cells from 2 L of media were 
stored at -80 °C until needed.  
The cell pellet was homogenized in 10 mL cold lysis buffer (50 mM HEPES 
7.5, 100 mM NaCl, 1 mM DTT) per gram of cell pellet via stirring at 4 °C for thirty 
minutes. Cells were lysed via microfluidization at 18,000 PSI and cellular debris 
were pelleted via centrifugation (100,000 x g, 35 minutes). Ammonium sulfate (50 
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% w/v) was added to the supernatant and stirred for 30 minutes at 4 °C followed 
by centrifugation at 100,000 x g (30 minutes). The supernatant was then subjected 
to a final concentration of 90 % w/v ammonium sulfate and pelleted as described 
for the 50 % cut. The subsequent pellet was resuspended in buffer A (50 mM 
HEPES 7.5, 16% w/v ammonium sulfate) and purified on a fast protein liquid 
chromatography (FPLC) system using hydrophobic interaction chromatography 
(HiTrap Butyl HP 5 mL). Protein was subjected to a 10 CV linear gradient from 0-
100 % buffer B (50 mM HEPES pH 7.5). Fractions were characterized via SDS-
PAGE and dynamic light scattering (DLS). Samples greater than 90% purity and 
homogeneity as determined via SDS-PAGE and dynamic light scattering (DLS) 
were pooled and concentrated to 20 mg/mL (buffer exchanged to 10 mM HEPES 
pH 7.0), flash frozen, and stored at -80 °C. Total yield 21 mgs/ g cell pellet.  
A4.2.2 Perdeuteration test expressions 
Cultures grown in LB media (100 µg/mL carbenicillin) harboring pET2a-
KDN9PP plasmid were used to inoculate minimal media containing deuterated 
glycerol in D2O. Cells were grown at 37 °C shaking until OD600 reached 
approximately 0.6 (~24 h). Cells were induced with 1 mM IPTG and continued to 
grow at 37 °C shaking, aliquots were taken at time points post induction (4 h, 16 h, 




Figure A4.1. SDS-PAGE analysis of KDN9PP expression in M9 deuterated 
media. Samples were normalized to the OD600 of the uninduced sample (OD600=0.6). 
Samples from Lane 1-5: uninduced, 4 h post induction, 16 h post induction, 20 h post 
induction, 24 h post induction.   
 
A4.2.3 Crystallization efforts 
Crystallization efforts focused on optimization of previously determined 
conditions (20 % PEG 3,350, x M magnesium chloride, 0.1 M MES pH 6.5, and 
200 mM sodium acetate) using 20 mg/mL KDN9PP cocrystallized with 10-100 
mM transition-state mimics (Neu5Ac or KDN, vanadate) in traditional 24-well grid 
trays (500 µL reservoir, 10-20 µL drop) and sandwich box trays (50.0 mL 
reservoir, 50-200 µL drop).(83, 84, 286, 287) Alternatively, soaking experiments 
were also tested using up to 100 mM Neu5Ac/KDN with 50 mM vanadate. Both 
soaking and crystallization optimizations aimed to reduce the concentration of 
acetate, to prevent competition in the active site. The concentration of sodium 
acetate was reduced from 200 mM to 20 mM for crystallization, followed by 
soaking crystals in 50 mM vanadate and 100 mM Neu5Ac with 27% PEG3350, 75 
mM magnesium chloride, 0.1 M MES pH 6.5, in the absence of acetate. After 
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confirmation of Neu5Ac occupancy, large crystals (1-4 mm3) were soaked in 50 mM 
sodium orthovanadate and 100 mM Neu5Ac for 2 weeks, followed by 
hydrogen/deuterium exchange in soaking solution described above in D2O in a 
quartz capillary for 1 week prior to data collection. 
A4.2.4 Data collection, structure determination, and refinement 
Crystallization conditions were screened using Boston University Chemical 
Instrumentation Center’s Bruker Bruker AXS X8 Proteum-R instrument, 
including a kappa four circle goniometer, MICROSTAR rotating anode X-ray 
source equipped with a PLATINUM135 CCD area detector and APS NECAT 24ID 
C and E to confirm successful occupation of ligands in the active site(s) as well as 
confirming high diffraction quality (≤ 1.5 Å resolution) prior to screening on a 
neutron beam. Crystal diffracted to 1.8 Å at room temperature. Large crystals (~1.0 
x 0.75 x 0.5 mm3) were screened at the High Flux Isotope Reactor at Oak Ridge 
National Lab (Beamline: IMAGINE). Continued optimization (most probably of 
the hydrogen/deuterium exchange procedure) is necessary and screening H/D 
exchanged and capillary-mounted crystals using X-ray diffraction is necessary to 
identify the source of the loss of diffraction.  
A4.3 Results and Discussion 
I have successfully grown crystals of sufficient size for neutron 
crystallography (1-4 mm3). Using smaller crystals (0.125-0.2 mm3) grown in the 
same condition, I conducted soaking experiments to confirm the presence of the 
ligand complex in the active site using X-ray crystallography. After initial efforts to 
soak 10 mM vanadate and Neu5Ac, data sets showed only vanadate was bound. 
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Upon further analysis, I identified that the acetate from the crystallization milieu 
was bound where the carboxyl moiety for the sialic acid would bind (overlay with 
PDB IDs: 3E81 and 4HGO, Figure A4.2). To remove acetate, I followed a two-
pronged approach: (1) optimize crystallization in the absence of acetate and (2) 
soak crystals in the absence of acetate with increased precipitant (PEG3350). After 
multiple rounds of optimization, occupancy of Neu5Ac was observed in all four 
active sites in the asymmetric unit. The concentration of sodium acetate was 
reduced from 200 mM to 20 mM during crystallization, followed by soaking 
crystals in 50 mM vanadate and 100 mM Neu5Ac with 27% PEG3350, 75 mM 
magnesium chloride, 0.1 M MES pH 6.5, in the absence of acetate.  
 
Figure A4.2 Fo-Fc map of KDN9PP confirming acetate bound in active site. 
 A. Omit map contoured to 3.5 σ and overlaid with PDB ID:3E81 confirms that acetate 
is bound at the carboxyl moiety of Neu5Ac. B. Omit map contoured to 3.5 σ for 
Neu5Ac.  
 Unfortunately, large crystals did not diffract when screened on IMAGINE 
(HFIR, Oak Ridge National Laboratory). Possible explanations include disruption 
of water network during H/D exchange in the presence of the transition state 
mimic, collapsing the crystal packing. To investigate this further, crystals were 
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grown in perdeuterated mother liquor, specifically- solutions were made in D2O 
and soaking experiments were conducted using crystallization reagents diluted in 
D2O. Notably, crystals still diffracted. However, it appears that higher 
concentrations of vanadate (≥ 50 mM with D2O present) substantially decreased 
the diffraction quality.  
A4.4 Conclusions and future directions 
KDN9PP crystallization efforts confirmed reproducibility of large single 
crystals of high diffraction quality (≤ 1.5 Å resolution) with full occupancy of 
transition-state mimic complex Neu5Ac/vanadate. Additionally, perdeuteration of 
KDN9PP is also possible to increase the total signal to noise in data collection.  
KDN9PP/Neu5Ac/vanadate complex crystals have not diffracted using a 
neutron beam thus far. Follow up experiments including optimization of the H/D 
exchange are necessary to confirm quality and reproducibility of crystals. Initial 
test expressions using BL21 pLySs cells harboring pET2a-KDN9PP cultured in 
deuterated M9 minimal media confirm that KDN9PP is overexpressed. Therefore, 
large scale growth in a fermenter is possible to produce perdeuterated KDN9PP 
which can then be purified under hydrogenated conditions. Protein stability and 
binding of product/vanadate will be necessary to lay the groundwork success of 
crystallization efforts with perdeuterated KDN9PP as well. 
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APPENDIX A5: Sequence information 
 
Table A5.1 UniProt IDs included in phylogenetic reconstruction. UniProt IDs 
are listed starting with the starred branch and following in a clockwise manner. 
 
 












A0A167G8C9 Ulvibacter sp. 
LPB0005 
Sugar transferase small 
A0A2E0W3V7 Ignavibacteriae 
bacterium 



































































Sugar transferase involved in LPS 







Sugar transferase regulatory 
A0A1M3LES6 Micrococcales 
bacterium 73-13 
Glutamate synthase subunit alpha uncharacterized 
A0A1G8UVZ4 Pedobacter sp. 
ok626 
Sugar transferase involved in LPS 
















A0A0P0NFR9 Pedobacter sp. 
PACM 27299 
Glycosyl transferase small 
A0A0A2DUD0 Porphyromonas sp. 
COT-239 OH1446 



































Bacterial sugar transferase (CapM) small 
A0A1G7HH12 Halorientalis 
regularis 
Sugar transferase involved in LPS 
























Sugar transferase large 
A0A0C2URJ0 Sulfurovum sp. 
AS07-7 
Sugar transferase uncharacterized 
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A0A0Q5UNY3 Sphingomonas sp. 
Leaf198 









Sugar transferase large 
A0A1Z4RGQ1 Calothrix sp. NIES-
4101 
Sugar transferase large 
A0A081NKA5 Endozoicomonas 
numazuensis 
Sugar transferase small 
A0A0S2K1K2 Pseudoalteromonas 
phenolica 












A0A081GQD0 Cyanobium sp. 
CACIAM 14 
Anti-sigma-factor antagonist 











































A0A0S3U064 Leptolyngbya sp. 
NIES-3755 
Sugar transferase large 
A0A0C2QYQ1 Jeotgalibacillus 
campisalis 
Multidrug MFS transporter small 
A0A060M6D2 Bacillus lehensis G1 Galactosyl transferase CpsE small 
A0A0K9GF90 Bacillus sp. FJAT-
27916 
Multidrug MFS transporter small 
A0A075LME8 Terribacillus 
goriensis 




sinduriensis BLB-1 = 
JCM 15800 


















A0A0P1IMQ4 Thalassobius activus Putative sugar transferase EpsL small 
A0A0C1GQU2 Ruegeria sp. ANG-R Sugar transferase small 
A0A0J5T177 Puniceibacterium 
sp. IMCC21224 
Glycosyl transferase small 
A0A0H4KXY5 Marinovum algicola 
DG 898 








A0A0C2UHH6 Bacillus badius Protein-export membrane protein 
SecG 
small 








protein ExoY (Sugar transferase) 
small 





















P26406 Salmonella enterica Undecaprenyl-phosphate galactose 
phosphotransferase (WbaP) 
large 





















A0A073IUV1 Synergistes jonesii Bac_transf domain-containing 
protein 
large 










Sugar transferase involved in LPS 
biosynthesis (Colanic, teichoic acid) 
large 
A0A146AWZ9 Bordetella ansorpii Exopolysaccharide biosynthesis 
glycosyl transferase 
small 
A0A0N1F5M8 Bosea vaviloviae Bac_transf domain-containing 
protein 
large 










Sugar transferase small 
A0A090VNM3 Algibacter lectus UDP-N-
acetylgalactosaminyltransferase 
small 






jenkinsii Ben 74 
Putative phosphotransferase 
involved in extracellular matrix 
synthesis 
small 


















A0A158M4S6 Bordetella holmesii 
CDC-H585-BH 
Sugar transferase small 








Sugar transferase small 
A0A031I293 Sphingomonas sp. 
RIT328 
Sugar transferase small 
A0A1C5T7N5 uncultured Blautia 
sp. 
Putative colanic biosynthesis UDP-




































A0A0K1Q5Q4 Labilithrix luteola Lipid carrier: UDP-N-
acetylgalactosaminyltransferase 
small 













Sugar transferase small 
A0A081N3Q4 Endozoicomonas 
numazuensis 
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